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X-linked lymphoproliferative (XLP) disease is a severe primary immunodeficiency. 
Immunodysregulatory phenomena are observed following EBV  infection suggesting 
that defects  exist in these  effector populations.  The  gene defective in XLP  is  SAP 
(SLAM-associated  protein),  an  intracellular  adaptor  protein  that  mediates  signals 
through  SLAM  and  other  immunoglobulin  superfamily  receptors  including  2B4. 
Cytotoxic T cells (CTLs) and natural killer (NK) cells play a major role in the normal 
immune response to  Epstein-Barr virus  (EBV)  infection.  EBV  specific  T  cell  lines 
(EBV-T  cell  lines)  were  generated  from  normal  individuals  and  XLP  patients  and 
examined for CTL function in response to different stimuli.  It has been  shown that 
XLP patients can generate EBV-T cell lines that are phenotypically similar to those 
from  unaffected  individuals.  XLP  patient  derived  EBV-T  cell  lines  showed  a 
significant decrease in interferon-gamma (IFN-y) production in response to 2B4 and 
autologous EBV transformed lymphoblastoid cell  line (LCL)  stimulation but not in 
response  to  SLAM.  Furthermore,  XLP  EBV-T  cell  lines  demonstrated  markedly 
decreased cytotoxic activity against autologous LCLs. By retroviral gene transfer of 
the  SAP  gene  into  XLP  patient  derived  EBV-T  cell  lines,  reconstitution  of IFN-y 
production  and cytotoxic  activity has been  shown,  confirming the defects  are  SAP 
dependent.  These studies demonstrate that in XLP the lack of SAP  affects  specific 
signalling pathways resulting in severe disruption of CTL function.
In  addition,  SLAM  and  2B4  expression  on  immune  cell  lineages  has  been 
investigated, the results suggest a wider range of 2B4 expression and deserve further 
investigation in relation to XLP molecular and cellular pathogenesis.
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IntroductionChapter 1 Introduction
1.1  Definition of X-linked lymphoproliferative  (XLP)
X-linked lymphoproliferative (XLP) disease is one  of the X linked primary
immune  deficiencies.  It  is  characterised  primarily by  an  inappropriate  response  to 
Epstein-Barr virus (EBV) infection, which is often fatal and has excessive damaging 
effects on the immune system of affected individuals. Since XLP was identified as a 
new immune deficiency disorder in 1975, there have been many efforts to understand 
its  molecular  and  cellular  pathogenesis  and  investigate  why  there  is  extreme 
susceptibility to EBV. The following chapter focuses on the clinical, molecular and 
cellular pathogenesis of XLP and the use of gene therapy as a potential investigational 
and therapeutic tool in this disease.
1.2  History of XLP
The  history  of  XLP  begins  with  the  description  of  EBV. Following  the
recognition of Burkitts lymphoma (BL) by Denis Burkitt in  1958, Epstein and Barr 
subsequently reported the identification of EBV, in  1964, by electron microscopy of 
cultured BL  cells (reviewed by Epstein,  1999).  Henle later established that EBV is 
cause  of infectious mononucleosis  (IM)  (Henle  et al,  1968).  The  earliest  report  of 
XLP in medical literature is an abstract describing two brothers who had sequentially 
experienced  IM,  acquired  hypogammaglobinemia  (AH)  and  non-Hodgkin’s 
lymphoma (NHL) by Hambleton et al in 1969 but it was rejected by a referee who did 
not  accept  that  EBV  could  cause  IM,  AH  and  NHL  (Hambleton  et  al,  1969). 
However, at the same time, on April 10, 1969 Purtilo and his colleague Vawter, from 
University of Nebraska Medical Centre, performed an autopsy on an 8-year old boy, a 
member  of the  Duncan  family who  had  died  30  days  after  the  onset  of IM  with
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fulminant  hepatitis  and  bone  marrow  failure.  This  condition was  excluded  from  a 
variety  of  ill-defined  entities  such  as  familial  lymphohistiocytosis,  acute 
lymphoblastic lymphoma and others.  Later on they found that a 2  and half-year old 
male  sibling  had  died  of acute  lymphoblastic  leukemia  earlier.  At  the  same  time 
Purtilo  noticed  a  report  on  high  frequency  of  NHL  in  children  with  inherited 
immunodeficiency disease by Gatti et al (Gatti et al,  1971). On further investigation 
of the Duncan family, Vawter found the death of a third boy and was informed by his 
mother that three nephews in her family had also died (Purtilo et al,  1991). One of AH 
after IM, another of NHL involving the ileocecal region without a history of IM, and a 
third  of NHL  in  central  nervous  system  in  his  half-brother  following  a  protracted 
period of IM. In 1974 Bar et al also reported fatal IM in a family (Bar et al,  1974). In 
1975, Provisor et al reported three males  in one  family who  had  an  illness with a 
presentation of EM. The two surviving males had agammaglobulinemia complications 
(Provisor  et  al,  1975).  They  confirmed  that  acquired  agammaglobulinemia  is  a 
clinical  feature  in  three  related  male  children  after  a  life-threatening  illness  with 
clinical and laboratory features of EM. In a report published in the Lancet by Purtilo et 
al  in  1975  this  immune  deficiency  related  to  EBV  was  identified  as  a  new 
terminology in medicine and became recognised in the medical community. Based on 
his observations, the inheritance pattern, the clinical and histopathological  findings, 
Purtilo  named  this  new  disease  X-linked  recessive  combined  variable 
immunodeficiency or Duncan’s disease (Purtilo et al,  1975). In their initial report the 
authors  suggested  that  EBV  or  other  viral  agents  may  have  triggered  the  fatal 
proliferation of lymphocytes and postulated that immunological shut-off mechanisms 
for controlling the proliferation of lymphocytes, especially B cells, were inadequate.
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For the past 30 years efforts have been contributed by clinicians and scientists 
to  address the clinical  symptoms  and pathogenesis of XLP.  The  gene  for XLP  has 
been  identified  offering  improved  diagnostic  tests  and  a  greater  awareness  of the 
clinical  spectrum  of  the  condition.  Furthermore,  as  the  molecular  and  cellular 
pathogenesis  of the  condition  begins  to  unravel,  the  initial  suggestions  of Purtilo 
continue to hold true (Purtilo,  1976).
1.3  Clinical manifestations
Although the identification of the defective gene in XLP has provided better 
diagnostic  tests,  it  has  also  revealed  that  the  clinical  diversity  of this  condition  is 
greater than was suggested by primary reports. To track and characterise this disease 
Purtilo established a registry in  1980, which serves as a world wide resource for the 
diagnosis,  treatment,  and research  of this  condition  (Purtilo  et al,  1991).  Although 
Purtilo died in 1992, the XLP registry continues and up until 1995, 272 cases among 
80 kindreds had been identified. It has been noticed that some cases of XLP can occur 
without EBV infection (Seemayer et al,  1995). According to this database, and recent 
individual  case  reports,  the  phenotypes  of XLP  can  be  classified  into  three  main 
subgroups and rare presentations as shown in Table 1.1 (Gaspar et al, 2002; Seemayer 
et al,  1995; Sumegi et al, 2000).
1.3.1  Fulminant infectious mononucleosis (FIM)
This  forms  the most common  and most  dramatic  manifestation of XLP.  The 
median age at onset of disease is 2.5  years. Importantly, this clinical phenotype also 
has  the  worst prognosis  with  over  90%  mortality.  The phenotype  is  insidious  and 
follows a progression of fever, malaise, pharyngitis, and generalised lymphocytosis.
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Table 1.1 Clinical phenotypes of X-linked lymphoproliferative syndrome 
Phenotype  Prevalence (%)  Mean  age  of  onset  Survival
(years)  rate (%)
Fulminant infectious mononucleosis  50  5  4
B-cell lymphoma  30  6  35
Dysgammaglobulinaeniw  30  9  55
Rare presentations  3  6-8  29-50
Vasculitis,  aplastic  anemia,  pulmonary 
lymphoid granulomatosis
Based on data from:  Seemayer et al,  1995; Sumegi et al,  2000; Gaspar et al, 
2002
Multi  organ  failure  is  a  general  feature.  Hepatic  coma,  respiratory  distress 
syndrome,  and  renal  failure  accompanying  bone  marrow  failure  progress  despite 
supportive  care.  The  lymphoid  tissues  undergo  biphasic  changes:  hyperplasia 
develops first and persists for 2-3 weeks and is followed by hypoplasia (depletion). 
The vital organ damage is caused by infiltration of atypical lymphocytes, NK cells, 
EB nuclear antigen positive  (EBNA+)  B  cells,  macrophages,  and  an accompanying 
dysregulated cytokine  release.  The  extensive  destruction of liver and bone marrow 
often leads to a fulminant hepatitis concurrent with virus-associated haemophagocytic 
syndrome (VAHS). In early VAHS moderate pancytopenia and a myeloid hyperplastic 
marrow  occur,  follow by the  appearance  of numerous  activated  macrophages  with 
erythrophagocytosis  and  nucleophagocytosis.  The  condition  evolves  with  lymphoid 
infiltration associated with necrosis and hemorrhage can occur.  The final step is adult 
respiratory distress  syndrome  and  hepatic  coma  as VAHS  persists.  Whereas VAHS 
occurs  in  approximately  90%  of  cases  with  FIM,  a  few  patients  (5%)  manifest
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hypolasia or aplasia of the bone marrow, which should not be confused with VAHS. 
In nearly 30% of those with aplastic anemia, EBV genome is present in bone marrow 
cells  (Baranski et al,  1988). The aplastic anemia in XLP is characterised by marked 
depletion  of haematopoietic  cells,  which  are replaced with  fat.  Infiltration  in  other 
tissues  has  also  been  described  with  splenic  (white  pulp  necrosis),  cerebral 
(perivascular mononuclear cell infiltrates), heart (mononuclear cell myocarditis) and 
renal (mild interstitial nephritis) involvement.
The mortality associated with FIM is high and the registry data compiled in 
1995 shows a 4% survival rate. With the use of etoposide and cyclosporine to control 
histiocytic and T-cell proliferation and activation, the outcome for this manifestation 
may have improved, but the condition still remains extremely difficult to treat.
1.3.2  Dysgammaglobulinaemia
In  one  third  of  boys  with  XLP,  EBV  infection  is  not  fatal  as  in  FIM 
presentations,  but is  followed by abnormalities  of immunoglobulin (Ig) production. 
This ranges from decreased levels of IgG to panhypogammaglobulinemia (Purtilo et 
al,  1982).  It  also  has  been  reported  that  prior  to  EBV  infection,  one  third  have 
hypogammaglobulinemia  (Purtilo  et  al,  1991).  In  more  severe  cases,  humoral 
dysfunction may accompany cellular T and natural killer (NK) defects (Sullivan et al, 
1980).  The  abnormalities  may  arise  from  the  extensive  necrosis  and  lymphoid 
depletion throughout the lymphoreticular system that follows acute EBV infection in 
these  individuals  (Purtilo  et  al,  1975).  Also  it  has  been  suggested  that  the  Ig 
abnormalities  could be  secondary to  T helper cell  dysfunction  (Crotty et al,  2003; 
Welsh  et al,  2003).  The  identification  of SAP  as the  defective  gene  in  XLP now
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allows unambiguous diagnosis of the condition. As a result, some patients previously 
labelled  as  having  common  variable  immunodeficiency  (CVID),  a  primary 
immunodeficiency  with  unknown  molecular  basis,  have  been  shown  to  have 
mutations in the SAP gene (Morra et al,  2001; Nistala et al,  2001). Although it has 
been suggested that all male CVID patients should be screened for SAP mutations, a 
recent  study  based  on  screening  of  a  large  cohort  of  men  with 
hypogammaglobulinemia and CVID  showed only 0.6% of them  carried  a germline 
SAP mutation (Eastwood et al, 2004). Therefore, it is unlikely that the true incidence 
of XLP in the CVID population  is  significant  and there  is  not any benefit of SAP 
mutation  analysis  of all  cases  of CVID  unless  they present  with  other  suggestive 
clinical features. The registry data suggests that this manifestation of XLP has the best 
prognosis, with greater than 50% survival.
1.3.3  Malignant lymphoma
The  malignancies  observed  in  XLP  are  mostly  non-Hodgkin  B  cell 
lymphomas and have occurred in approximately one third of affected individuals with 
XLP. The most common lymphoproliferative types are extranodal, usually BL of the 
ileocecal  region  (Harrington  et al,  1987).  Also  lymphomas  commonly  involve  the 
central nervous system, hepatic and renal systems. Almost all the lymphomas were of 
B-cell origin but tumours with a T-cell phenotype have also been described (Gaspar et 
al, 2002). The median age of affected boys is 4-6 years of age (Sumegi et al,  2000). 
The lymphomas can be histologically classified as Burkitt’s lymphomas (53% of all 
B-cell lymphomas), immunoblastic lymphomas (12% of all cases),  small cleaved or 
mixed  cell  lymphomas  (12%)  and  unclassifiable  lymphomas  (5%  of  all  cases) 
(Harrington et al,  1987). The features of lymphomas in XLP are similar to those seen
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in  other  primary  immunodeficiencies  with  extra-nodal  involvement,  high-grade 
histology,  and evidence  of clonality and  gene rearrangements.  The  survival  figures 
following the development of lymphoma are poor with 35%  survival  (Purtilo et al, 
1991).  Remission has often been achieved with  lymphoma chemotherapy protocols 
but there is a high rate of relapse or development of the other manifestations of XLP. 
There is also a risk of fatal IM many years after successful treatment.
1.3.4  Uncommon clinical presentations of XLP
In addition to the above three manifestations, which represent the main clinical 
features of XLP patients, the literature also describes a number of other presentations. 
Lymphoid vasculitis is another uncommon but well-described complication of XLP. It 
affects all medium and small vessels, involving retinal, cerebral, renal, pancreatic and 
coronary vessels.  Histological  evidence  demonstrates  arterial  wall  destruction  with 
aneurysmal dilatation. T-cell pulmonary lymphomatoid granulomatosis was the initial 
presentation with the lymphoproliferation characterised by predominant activation of 
CD4+  cells  in  some  cases  (Purtilo  et al,  1991;  Dutz  et al,  2001;  Kanegane  et al, 
2005).
Aplastic  anemia can  also be the  initial presentation rather than  arising  as  a 
complication  of fulminant  infectious  mononucleosis  with  haemophagocytosis.  The 
registry reports a number of individuals who present initially with aplastic anaemia 
(3% of all cases) (Seemayer et al,  1995). As numbers are small, there is very little 
detail on the pathogenesis of this phenotype.
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Therefore, it is likely that the phenotype is determined by a number of factors, 
including  the  genetic  elements,  and  environmental  and  infectious  factors  on  a 
background of disease modifier genes.
FIM  presentations  of  XLP  are  often  accompanied  by  various  degrees  of 
haemophagocytosis.  However,  haemophagocytic  lymphohistiocytosis  (HLH)  as  a 
disease entity is well recognized with established diagnostic clinical  and laboratory 
criteria,  and  exists  in both  familial  and  sporadic  forms.  In  a  certain  proportion  of 
patients,  HLH  is  caused  by mutations  in  the  gene  encoding perforin  (Stepp  et al,
1999).  Arico et al reported 16% of male patients with a HLH diagnosis carried SAP 
mutation  and  half of them had  a positive  family history  (Arico  et  al,  2001).  This 
suggests that XLP should be considered in all males presenting with HLH.
1.3.5  XLP without EBV infection
XLP presents many diagnostic difficulties not just as a result of the variety of 
clinical presentations. From the early descriptions, EBV has always been reported to 
be the viral trigger for the different XLP phenotypes. However, almost  10% of XLP 
cases  have  shown  clinical  signs  of  immune  deficiency  prior  to  EBV  infection 
(Sumegi et al,  2000). It has been reported that some affected boys with B-cell non- 
Hodgkin’s lymphoma were confirmed to have mutations in the SAP gene (Brandau et 
al,  1999;  Strahm  et al,  2000).  Efforts  to  detect  EBV  in  individuals  failed despite 
using  serological  and  genetic  investigations  (Brandau et al,  1999;  Gilmour et al, 
2000;  Nistala  et  al,  2001).  It  suggests  that  the  XLP  defect  is  not  a  specific 
susceptibility  to  EBV  but  a  more  general  dysregulation  of cellular  responses  to 
infection. Certainly, other viruses either alone or in combination may trigger abnormal
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immune  responses.  The  reports  of  hypogammaglobulinemia  following  measles 
infection  (Mawhinney  et  al,  1971;  Purtilo  et  al,  1977)  also  raises  the  intriguing 
possibility that there may be specific vulnerability to this virus as well.
A major milestone  in  the  history of XLP was  identification  of the  affected 
gene. After long investigation of the partial deletion of chromosome X among XLP 
kindreds  and  using  restriction  fragment  length  polymorphism  (RFLP)  linkage 
analysis,  Skare et al showed that  the XLP  locus  was  located between  DXS42  and 
DXS73  (Skare et al,  1989).  Soon Skare’s laboratory established the gene locus and 
refined its location to a 2.5-Mb region in Xq25 (Skare et al,  1993). Finally in  1998, 
three independent groups identified the mutated gene in XLP, through positional or 
functional cloning (Coffey et al,  1998; Sayos et al,  1998; Nichols et al,  1998). This 
gene  was  designated  as  SAP  [SLAM  (signal  lymphocyte  activation  molecule) 
Associated Protein] /SH2DA1  (SH2 domain protein 1A). Here we use the term SAP, 
indicating protein expression and SAP to define the gene. The SAP cDNA is 2,530 bp 
long and contains an open reading frame (ORF) of 462 bp, with an initiation codon 79 
bp from the start of the ORF. It contains four exons that code for a small  128 amino 
acid polypeptide with a molecular weight of 15 kD size consisting of a 5-amino acid 
N-terminal sequence, an SH2 domain, and a 25- amino acid C-terminal tail (Fig 1.1). 
The promoter and regulatory regions for the control of SAP expression have not yet 
been defined, however,  the sequences upstream  of exon  1   include putative binding 
sites for transcription factors important for T-lymphocyte development and function,
1.4 The genetic cause of XLP
1.4.1 Discovery of XLP gene
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Figure 1.1 SAP gene and protein structure
A) The SAP gene consists of four exons and encodes a cytoplasmic  protein of 
128  amino  acids.  B) The protein consists of a very short N-terminal,  a single  SH2 
domain and a small C-terminal tail. SAP protein binds to phosphorylated residues on 
the  cytoplasmic  tails  of SLAM-related  receptors  via  its  SH2  domain.  C)  Crystal 
structure of SAP and location of missense mutations identified in XLP patients. SAP 
has the overall characteristics of an SH2 domain fold, which includes a central sheet 
with helices packed against either side (C is taken from Poy et al,  1999).
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including c-est-1  and interferon (IFN) regulatory factor (IRF)-l  (Coffey et al,  1998; 
Wu etal, 2000).
No hydrophobic signal sequence was found to be present, suggesting that SAP 
is localized in the cytoplasm. Northern blot analysis with probes generated from the
cDNA showed expression of an approximately 2.5-kb mRNA at high levels in thymus 
and lung, with a lower level of expression in spleen and liver.  SAP expression was 
also  detected  by  RT-PCR  in  all  lymphocyte  populations  (B  and  T  cells)  assayed 
(Coffey et al,  1998; Nichols et al,  1998). Although SAP expression has been reported 
in  EBV-  carrying  lymphoblastoid  cells,  it is  not  expressed  in  all  EBV-transformed 
lymphoblastoid  cell  lines  (EBV-BLCL)  or  EBV-negative  Burkitt  lymphoma  (BL) 
lines as will be discussed later (see p.32) (Nagy et al, 2000).
1.4.2  SAP and EAT-2 are members of a gene family
A gene bank search for the other genes encoding proteins with a single SH2 
domain revealed EAT-2 gene (EWS-activated transcript-2) that is located on the long 
arm of chromosome 1   (lq23) approximately 700 kb from the SLAM gene in humans 
(Thompson et al,  1996). The human and mouse EAT-2 genes consist of four exons 
and encode a 132- amino acid protein that, like SAP, consists of a single SH2 domain 
followed by a short C-terminal sequence. The mouse EAT-2 gene was first identified 
as  a  transcript  induced  in  transformed  mouse  fibroblast  by  EWS/FLI1  oncogene. 
Using  PCR  and  cell  separation  techniques,  EAT-2  was  found  to  be  expressed  in 
macrophages and B cells but not in thymus-derived lymphocytes (Morra et al, 2001).
As  the  exon-intron  structures  of the  SAP and  EAT-2  genes  are  identical,  it 
appears that the  SAP and EAT-2  genes represent two identified members of a new
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family of genes, which are able to act as adaptor proteins and modulate cell signalling 
pathways.
1.4.3  SAP  and  EAT-2  expression  in  immune  cell
lineages
SAP  expression  is  different  in  immune  cell  lineages  as  well  as  human  and 
murine.  SAP is  expressed  in T  cells,  including CD8,  CD4  single positive T  cells 
(Sayos et al,  1998; Wu et al, 2000). Its expression is prevalent in Thl  cells, but Th2 
cells also contain the transcript (Sayos et al,  2000).  It has been shown that SAP in 
human T cells is up regulated at the RNA and protein level upon specific and non­
specific  stimulation  (Nichols  et  al,  1998;  Nagy  et  al,  2000;  2002).  However,  its 
expression in T cells is downregulated upon activation in murine cells (Mora et al,
2001).  The  rapid  down-regulation  is  the  result  of the  presence  of the  AUUUA 
sequence in the 3’ UT region of both the long and the short mRNA species (Sayos et 
al,  2000).  It may suggest that SAP expression is regulated differently in human and 
murine systems.
The studies in human has shown that SAP is expressed at low levels in resting 
NK cells but its expression increases upon activation in vivo and in vitro (Nagy et al,
2002).  Interestingly NK leukaemia lines express SAP like their normal counterparts 
(Nagy et al,  2000). However, the kinetics of SAP expression in cultured murine NK 
cells differed from murine T cells because of higher expression levels after activation 
(Sayos et al, 2000).
SAP is not expressed in all B cell subsets although its expression at the RNA 
level has been demonstrated by some groups (Yin et al,  2003).  It has recently been
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shown  that  SAP  is  expressed  by  murine  memory  B  cells  (Feldhahn  et  al,  2002). 
Significantly, the gene is not expressed in EBV transformed lymphoblastoid cell lines, 
and only a small number of B cell tumours express SAP (Nagy et al, 2000). The EBV- 
carrying cell panel contained type I BL lines such as Rael, Akata and Mutu I clones 
148  and  216  were  SAP  positive.  In  contrast,  the  BL  lines  with  type  III  latency 
phenotype (Raji, Daudi, P3HR1 and Namalwa) and EBV-negative lines (BL41, BL49, 
BL28,  DG75,  BL2,  CA  46  and  Ramos)  were  SAP  negative  (Nagy  et  al,  2000). 
Intriguingly, transformation of Mutu phenotype from type I (expressing only EBNA- 
1) to the type III (expressing all 6 EBNAs and 3 latent membrane proteins (LMPs)) is 
accompanied by the down regulation of SAP and the appearance of SLAM on the cell 
surface (Nagy et al, 2000).
Table  1.2  SAP  and  EAT-2  expression  in  different  human  immune 
cell lineages
Cell lineages SAP expression EAT-2 expression
CD4 T cells r+ -
CD8 T cells + -
NK cells 1  + +
LAK +/? -/?
NKT | +/? -/?
Monocytes - +
DCs i -/? ?
Macrophages - +
B cells ] -/? +
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SAP  expression  has  not  been  reported  in  other  periphery  immune  cells 
including monocytes, dendritic cells (DCs), and macrophages.
In contrast to SAP, the kinetics of EAT-2 expression has not been fully studied 
(Table  1.2). Like SAP, EAT-2 is expressed in immune cells, including macrophages, 
DCs, B cells (Morra et al,  2001). However, it is not found in T cells.  Interestingly, 
only in NK cells are SAP and EAT-2 co-expressed (Bouchon et al,  2001). This may 
imply a complex competitive function for these two SH2 domain adapter molecules.
1.5  SAP mutations
Over 50  different mutations in the SAP gene have been identified  so  far in 
XLP patients (Sumegi et al,  2000), although this number may be much greater (Fig 
1.2). They range from large or small deletions resulting in complete loss of the gene 
or  non-sense,  splice-site  and  missense  mutations  that  lead  to  premature  arrest  of 
protein synthesis or to a non-functional SAP (Coffey et al,  1998; Nichols et al,  1998; 
Yin  et  al,  1999;  Sumegi  et  al,  2000).  Despite  the  wide  range  of SAP  mutations 
associated  with  XLP,  similar  to  the  experience  found  in  other  primary 
immunodeficiencies,  there  is  no  correlation between the  type  of mutation  and  the 
severity of the disease and the clinical phenotypes (Brandau et al,  1999; Sumegi et al,
2000).  Indeed,  within the  same  family,  the  same mutation has resulted in different 
clinical presentations, which implies that other factors, genetic or environmental, are 
important for determining the manifestations of the disease (Arkwright et al,  1998; 
Morra et al, 2001).
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1.6  Structure of SAP and molecular association
SAP protein has  a unique  structure  containing  only  a  single  Src  homology 
(SH)-2 domain and a short C-terminal tail.  Sayos et al identified SAP using a yeast 
two-hybrid  system with the  77-amino-acid human  signalling  lymphocyte-activation 
molecule  (SLAM)  cytoplasmic  domain  as  bait  and  a  human  T-cell  library.  It  was 
postulated  that  the  novel  protein  might  be  involved  in  protein  tyrosine 
phosphorylation-mediated signal transduction events. Further experiments, including 
random  peptide  library  screening,  showed  that  the  SAP (and  EAT-2)  SH2  domain 
preferentially  recognizes  the  motif  TipYxxV/I  (where  T  is  threonine,  pY  is 
phosphotyrosine, V is Valine,  I is isoleucine and x is any other residue) (Poy et al, 
1999).  SH2 domain structure is highly conserved and forms a large antiparallel /3 - 
sheet  with  two  flanking  a-helices,  which  form  a  binding  pocket  for  specific 
phosphorylated tyrosine residues (Lichtarge et al,  1996).
Crystallography and nuclear magnetic resonance (NMR) studies revealed that 
the SAP SH2 domain interacts with its ligands via an unusual mode of binding (Poy et 
al,  1999; Hwang et al,  2002). In addition to the classical “two pronged” interaction 
between an SH2 domain and its ligand peptide, a third contact point between the SH2 
domain and residues located N-terminal to phosphorylated tyrosine is formed (Scott et 
al,  2000). The existence of this additional contact significantly enhances the affinity 
of the SAP SH2 domain for its ligand (Kd  *120-150 nM; compared to Kd  *500 nM 
for  conventional  SH2  domains).  A  similar  binding  mechanism  exists  for  EAT-2 
(Morra et al, 2001).
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Figure 1.2 Common mutation sites in SAP gene
The mutations vary from deletions, non-sense, splice-site and missense mutations that 
lead  to  premature  arrest  of protein  synthesis  or  to  a  non-functional  SAP.  Most 
mutations are located in the SH2 p sheets. (Taken from Sumegi et al, 2000).
SAP  has  another  unique  feature  limited  only  to  SLAM  binding  and  not  to  other 
members  of the  SLAM  family, which is binding to  a  14 amino  acid peptide in the 
proximity  of  Y281  in  the  cytoplasmic  tail  of  SLAM  in  the  absence  of 
phosphorylation.  Although  the  functional  significance  and  structural  basis  of this 
feature  are  not  known,  it  may  further  enhance  the  interaction  between  SAP  and 
SLAM, as opposed to binding to other SLAM family members.
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1.6.1  SAP interacts with SLAM family
SAP  was  initially  identified  as  a  ligand  for  SLAM,  a  CD2-subset  of  the 
immunoglobulin superfamily of cell surface receptors. The SLAM family of immune 
cell receptors comprises at least six members named SLAM (CD 150), 2B4 (CD244), 
Ly-9  (CD229),  CD84,  NTBA and  CRACC  (summarized  in  Table  1.3).  These  cell 
surface  receptors  are  glycoproteins  of  60-100  kD,  with  3-8  potential  N-linked 
glycosylation sites and share a common overall structure. In all cases except Ly-9, the 
extracellular region contains two Ig-like domains; one membrane-distal variable (V) 
non-disulfide domain and a membrane-proximal truncated Ig constant-2 (C2) domain 
containing  two  intrachain  disulfide  bonds.  This  configuration  of  Ig  domains  is 
duplicated in Ly-9 (Tangye et al,  2000).  The cytoplasmic domains contain three or 
more unique tyrosine-based motifs TxPYxxV/I (Figure 1.3). The genes encoding the 
human SLAM family are localized to chromosome 1 at bands lq21-24.
In immune cells, SAP was shown to associate with SLAM, 2B4 and NTB-A 
(Latour et al, 2003). While it remains to be proven if SAP interacts with other SLAM- 
related  receptors  in  immune  cells,  an  interaction with  CD84  and  Ly-9  as  well  as 
binding  of EAT-2  to  various  SLAM-related receptors was  seen  in transfected cells 
(Sayos et al, 2001).
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Table 1.3 Members of the SLAM family
M itorie  Names  Associates  Expression  Ligand  Function
with
CD84 Ly9B SAP, EAT-2, 
SHP2, SHIP1
B, T cells, 
monocytes, platelets
CD84 Control of TCR-induced 
IFN-production
CPI50 SLAM SAP, EAT-2,
SHP2,SHIP1,
Fyn
Memory/effector T 
cells, activated B, 
monocytes & 
dendritic cells
CD150 Cytokine production, 
Thl/Th2 polarization, 
B&T cell proliferation
CD229 LY9 SAP, EAT-2, 
SHP2, AP2
B and T cells CD229 Unknown
CD244 2B4 SAP, EAT-2,
SHP1,SH2
andLAT
NK, CD8, 
monocytes, and 
Basophils
CD48 NK and CD8 cell 
cytotoxicity, NK co­
stimulatory molecule
CSi CRACC,
Novel-LY9
SAP NK, B and T cells 
and DC
CSI SAP-independent NK- 
cell cytotoxicity
NTBA SF2000,
LY108
SAP, 
SHP1 & 
SHP2
NK, B and T cells Unknown NK-cell cytotoxicity
BLAME Unknown Macrophages & DC Unknown Unknown
CD84-H1 SF2001,
CD2F10
Unknown DCs, B, T cells, 
macrophages
Unknown Unknown
Modified from: Engel et al, 2003
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Figure 1.3 The structure of SLAM-related family receptors
The structure of SLAM,  2B4 and Ly-9 are shown. The cell surface receptors of the 
SLAM-related family are a subset of the CD2 family of glycoprotein (60-100 kD) cell 
surface molecules, which share common structures. The extracellular domains of CD2 
are compromised of a N-terminal non-disulfide bonded Ig variable (V) domain and 
membrane-proximal truncated Ig constant-2 (C2), which in Ly-9 is duplicated.  The 
cytoplasmic part contains two or more tyrosine-based motifs (pY). The tyrosine-based 
motifs  interact typically with SAP SH2  domain and probably with other molecules 
containing SH2 domain.
38Chapter 1  Introduction
1.6.2  Function of SLAM family in immune response
SLAM-related receptors play multiple roles in normal immune homeostasis. 
The functions of these receptors could explain how the absence of SAP may cause 
diverse pathological phenotypes. The SLAM family has been recognised as important 
co-stimulatory molecules expressed on immune cells and are important in providing 
the  second  signal of a two-signal paradigm of immune cell activation (Figure  1.4). 
SLAM-related family receptors are expressed differentially on lymphocyte lineages as 
described in Table 1.3. They are upregulated upon activation with various stimuli such 
as EBV infection, cytokines (Cocks et al,  1995; Nagy et al, 2000; Engel et al,  2003; 
Latour et al, 2003 & 2004).
SLAM is one of the family members, which has been extensively studied in 
relation  to  XLP  pathogenesis.  SLAM  is  upregulated  on  T  and  B  cells  following 
antigen  receptor  activation  and  similarly  on  dendritic  and  B  cells  through  CD40 
stimulation  (Cocks  et  al,  1995;  Punnonen  et  al,  1997;  Castro  et  al,  1999).  Its 
expression  is  also  induced  after  activation  of macrophages  with  LPS  and  IFN-y 
(Howie et al, 2002).
Through its extracellular domain, SLAM has homotypic interaction ability to 
bind to SLAM on other cell lineages (Mavaddat et al, 2000). In the presence of SAP, 
these  engagements  conduct  SLAM  mediated  signal  transduction,  which  appears  to 
modulate the cytokine response. SLAM activation on human and murine T cells using 
soluble anti-SLAM antibodies leads to selective production of Thl cytokines, such as 
IFN-y  and  tumour  necrosis  factor  (TNFa).  No  effect  on  the  production  of Th2 
cytokines  such  as  IL-4  is  observed  (Carballido  et al,  1997).  Cytokine modulation 
requires pre-activation of T cells.  In human preactivated T cells, SLAM activation
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Figure 1.4 A model of SAP and SLAM function in T cell function
The binding of the SLAM-family receptors to their ligands induces the phosphorylation 
of their cytoplasmic tails, allowing the subsequent binding of SAP or SHP-2 through a 
tyrosine-containing motif located in their cytoplasmic regions. It has been suggested that 
SAP  prevents  SHP-2  binding.  This  prevents  phosphatase  activity  at  the  SLAM 
cytoplasmic  tail  and  thus  prolongs  phosphorylation  after  SLAM  stimulation.  SLAM 
activation also increases Dokl and Dok2 phosphorylation and NFk p levels. It leads to a 
Thl upregulation in T cells.
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induces proliferation in a CD28 independent manner that is resistant to Cyclosporin A 
(Cocks et al,  1995). This result has not been reported in murine cells.
Recent  results  based  on  transfected  murine  T  cell  lines  and  SAF1 ' T  cells 
suggest an inhibitory function of SAP  following SLAM engagement rather than an 
enhancement  effect  (Latour  et  al,  2001;  Howie  et  al,  2002;  Latour  et  al,  2003). 
Conversely, anti-SLAM antibodies block the inhibitory effect of SLAM interaction in 
these experiments. However, it is not clear why in response to co-stimulation of TCR 
and SLAM, SAP'1 ' T cells still produce higher IFN-7 levels than when compared to T 
cells  stimulated  only  through  TCR  (Howie  et  al,  2002).  The  paradox  of  these 
conflicting data needs to be further investigated especially in human T cells.
Curiously,  anti-SLAM  antibodies  fail to enhance human B  cell proliferation 
but augment the susceptibility of some B cell lines to Fas (CD95) induced apoptosis 
(Liu  et  al,  1998;  Mikhalap  et  al,  1999).  Some  groups  have  reported  B  cell 
proliferation and Ig production following SLAM and anti-CD40 activation of B cell 
lines, but not in primary B cells (Punnonen et al,  1997).
Although SLAM is expressed on activated DCs and macrophages, its function 
has not been fully understood.  It may play a major role in antigen presentation and 
immune  response  after  viral  infection.  However,  data  from  SLAM  deficient 
macrophages has revealed that it may be involved in IL-12, TNF-a, nitric oxide (NO) 
and IL-6 production (Wang et al, 2004).
While  SLAM  activation  seems  to  modulate  Thl  responses,  engagement  of 
2B4  on  NK  cells  affects  both  cytokine  production  and  degranulation-mediated 
cytotoxicity (Gami-Wagner et al,  1993; Valiante et al,  1993). Interaction of CD48, a 
member of CD2 Ig superfamily with high level expression on monocytes, DCs, NK, T 
and  B  cells,  and  EBV-BLCL,  with  2B4  induces  the  secretion  of IFN-y and  IL-2
41Chapter 1  Introduction
(Latchman et al,  1998; Tangye et al, 2000; Chuang et al, 2001). 2B4, CSI and NTBA 
regulate  NK-cell  cytotoxicity  (Garni-Wagner  et  al,  1993;  Bottino  et  al,  2001; 
Kumaresan et al, 2002; Falco et al, 2004).
In the absence of SAP, 2B4 and NTBA inhibit, rather than activate, NK-cell 
cytotoxicity (Parolini et al,  2000; Bottino et al,  2001).  In contrast,  CSI  function is 
SAP-independent  in  NK  cells.  CSI  might  activate  NK  cell  mediated  cytotoxicity 
through  an  extracellular  signal-regulated  kinase  (ERK)-mediated  pathway.  This 
suggests that SLAM family receptors are likely to signal through both SAP-dependent 
and  SAP  independent  pathways.  However,  there  is  little  known  about  function 
downstream of other SLAM family receptors, such as NTBA, Ly-9, CD84. Certainly 
further  examination  of their  structure  and  function,  is  required  to  understand  the 
pathogenesis of XLP and its phenotypic diversity.
1.7  Role of SAP in immune cell signalling
It has been suggested that SAP is a true adapter required for signalling through 
SLAM-related family receptors. In transiently transfected COS cells, SAP can prevent 
the  SH2  domain-containing  protein  tyrosine  phosphatase  (PTP)  SHP-2  binding  to 
SLAM  or 2B4  (Sayos et al,  1998)  (Figure  1.4).  By blocking SHP-2 binding or by 
displacement  of SHP-2,  SAP  may modulate  phosphatase  activity  of T  cells  upon 
SLAM activation. This is mediated by the SH2 region of SAP and the first of three 
tyrosines in the cytoplasmic domain of SLAM (Y281 in humans, Y288 in mice).
It has been also reported that SAP binds specifically to Dok (p62) to block its 
binding to SHP-2, and thereby SAP by maintaining tyrosine phosphorylation of Dok 
prolongs  the  inhibition  induced  by  Dok  to  the  Ras  pathway  (Sylla  et  al,  2000). 
However, the inhibitory role of SAP has not been shown in primary cells and with
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other members of the SLAM family. Therefore the phosphatase blocking function for 
SAP  may  only be  an  observation  in  in  vitro  models  and  it  may not  hold  true  in 
primary cells.
The  simplicity  of SAP  composition  was  an  obstacle  to  explain  its  adapter 
functions and ability to recruit other proteins. However, this recruitment function has 
been  recently  documented  in transfected  T  cell  lines  as well  as  in  ex  vivo  normal 
mouse  T  cells.  It  reflects  the  formation  of  trimolecular  complex  involving 
phosphorylated  SLAM,  SAP  and  Src-related  protein  tyrosine  kinase  (PTK)  FynT 
(Latour  et  al,  2001).  The  capacity  of SAP  to  recruit  and  activate  FynT  is  highly 
specific and does not extend to other Src-PTK family members. The crystal structure 
of the  tertiary  complex  reveals  that  SAP  binds  the  FynT  SH3  domain  through  an 
unusual  surface-surface  interaction  that  does  not  involve  classical  SH3  or  SH2 
binding interactions.  The interaction is mediated by a novel  surface in  SAP’s  SH2 
domain that is centred around arginine 78, between the sixth @  sheet and the second a 
helix and with SH3 domain of FynT via a nonproline-based motif (Chan et al, 2003). 
It  has  been  suggested  that  the  interaction  of SAP  with the  Fyn-SH3  domain  may 
change  the  auto-inhibited  conformation  of Fyn  into  a  stabilised,  open  and  active 
conformation (Figure 1.5). This facilitates the coupling of Fyn to SLAM (Chan et al,
2003).  By recruiting FynT to  SLAM,  SAP promotes the phosphorylation of several 
downstream  intermediates  and  delivers  an  inhibitory  signal  associated  with  the 
selective  attenuation  of IFN-y secretion by activated  T  lymphocytes  (Latour et al,
2001). In addition, following SLAM engagement, SHIP and adaptor molecules Dokl 
and  Dok2  are  also  phosphorylated  (Figure  1.4).  A  series  of experiments  in  Fyn- 
deficient  mice  showed  lack  of  FynT  had  inhibitory  effects  on  the  tyrosine 
phosphorylation  of SLAM.  Moreover,  disruption  of the  SAP/FynT  association  by
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mutation of SAP Arg 78 in transfected cell lines has similar effects on SLAM tyrosine 
phosphorylation as did SLAM stimulation in FynT deficient mice T cells.
Although it remains unclear whether the association of SAP and FynT is true 
in primary human  T  and NK cells,  co-expression of FynT  and  SAP  in other cells 
expressing SLAM family receptors supports the SAP adaptor model.
In NK cells,  stimulation of 2B4 triggers an activation signal that implicates 
phospholipase Cy (PLC-y), Vav, the p85 subunit of phosphatidylinositol (PI)-3 kinase 
and linker for activation of T cells (LAT)  (Bottino et al,  2000).  The association of 
LAT and 2B4 in membrane microdomains in lipid rafts, may be applicable to other 
members of SLAM family.
The  LAT  and  2B4  interaction  occurs  through  a  dicysteine  motif  (CXC) 
located  at  the  junction  of the  transmembrane  and  cystoplasmic  regions  of 2B4. 
Consistent with the involvement of PLC-y in this pathway, ligation of 2B4 can also 
induce intracellular Ca2+  fluxes  and PI turnover (Valiante et al,  1993).  It has been 
shown this  cascade depends on  SAP  interaction with at least two  of five tyrosines 
regions  in  cytoplasmic  part  of 2B4.  Thus,  in  contrast  to  SLAM  activation,  SAP 
mediated signals downstream of 2B4 in NK cells are different, which may support its 
different effects in these cell populations.
In contrast, EAT-2 is unable to bind the FynT SH3 domain because of the lack 
of the  arginine  78-based  motif (Latour  et  al,  2003).  This  suggests  an  alternative 
function for EAT-2 or the possibility of EAT-2 binding to other Src-related kinases 
such as c-Fgr, Hck and Lyn.
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Figure 1.5 A model of Fyn activation and recruitment by SAP
The binding of SAP to the SH3 domain of the tyrosine kinase FynT via an unusual 
surface-surface interaction and recruitment of this complex through SAP SH2 domain 
by SLAM changes the inactive conformation of FynT into an active open and stable 
conformation.  Subsequently,  receptor-associated  Fyn  T  can  phosphorylate  tyrosine 
residues in the cytoplasmic tail of the receptor or neighbouring receptor molecules. 
This creates docking sites for SH2 domain containing proteins such as SHP2 (SH-2 
domain-phosphatase) or SHIP (SH-2 domain-inositol polyphosphate 5’ phosphatase). 
Taken from Engel et al, 2003.
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1.8  EBV infection and related disorders
As  mentioned previously,  EBV plays  a trigger role in the majority of XLP 
patients.  It  is  therefore  important  to  review  EBV  and  its  heterogeneous  related 
disorders in order to obtain a greater understanding of the pathogenesis of XLP.
EBV is one of the most successful viruses, which ubiquitously infects humans 
and  persists  for  the  lifetime  of the  individual.  EBV  is  classified  as  an  enveloped 
gamma-herpesvirus  and contains double stranded linear DNA of 170-175 kb in the 
nucleocapsid  (Bomkamm  et  al,  2001).  It  is  well  known  as  the  causative  agent  of 
infectious  mononucleosis  (IM)  and  post-transplant  lymphoproliferative  disorder 
(PTLD)  (Cohen,  2003).  Also,  it  has  been  demonstrated  that  several  types  of 
malignancy,  including  Burkitt  lymphoma,  nasopharyngeal  carcinoma  (NPC), 
Hodgkin’s disease and gastric cancer, are EBV-associated cancers. Recently, chronic 
active  EBV  infection  (CAEBV),  EBV-associated  haemophagocytic 
lymphohistiocytosis  (EBV-HLH),  and  mosquito  allergy  with  granular 
lymphoproliferative disorder (GLPD) and CAEBV-like serological abnormality have 
been considered as neoplastic diseases related to EBV (Ohga et al, 2002). Moreover, 
lymphoproliferative  disorders  in  patients  with  autoimmune  lymphoproliferative 
syndrome (ALPS), which is a disorder of defective induction of apoptosis through the 
Fas- Fas ligand pathway of cell death, might be associated with infections by viruses 
such as  EBV  during  early infancy (Dianzani  et al,  1997;  Wang et al,  1999).  XLP 
disease is also well known genetic disorder for its recognition as a profound defective 
immune  response  to  EBV.  The  EBV  related  immunopathological  disorders  are 
summarised in Table 1.4.
46Chapter 1 Introduction
Table  1.4  Characterisation  of  EBV-related  immunopathological 
disorders
CAEBV  GLPD  XLP  ALPS
Hereditary Unknown Unknown X-Linked AD(AR)
Sex M&F M&F M M&F
Gene localization Unknown Unknown Xq25 10q23
Responsible Gene Unknown Unknown SAP/SH2D1A Fas/F  asL/caspase 
10
Clinical Phenotype LPD LPD FIM/LPD/
AGL
LPD
VAHS + + ++ +
Lymphoadenopathy +/Malignant,
Benign
+/Malignant/
Benign
+/Malignant ++/Benign,
malignant
Immunoglobulin High High Low High
Autoimmune +
- - ++
BBV-antibodies High High Low Normal-High
EBV-genome High High High Normal-high
Adapted  from  Hiroshi,  2002.  The  abbreviations  are  standing  for:  Autoimmune 
Lymphoproliferative  syndrome  (ALPS),  Chronic  Active  EBV  infection 
(CAEBV),  Granular  Lymphoproliferative  Disorders  (GLPD),  Virus-associated 
haemophagocytosis syndrome (VAHS), X-linked Lymphoproliferative Syndrome 
(XLP).
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Although  the  pathogenesis  of EBV  and  its  related  disorders  are  not  fully 
understood,  the  ability of EBV  to modulate the  immune response may explain the 
pathogenesis and phenotypes of different EBV related disorders. Immune responses to 
EBV cover a wide range from very mild responses in asymptomatic infection to an 
exaggerated  response  in  IM  and  potentially  lethal  complications  in  PTLD  and 
particular  susceptibility  in  XLP  patients  (Figure  1.6).  Thus before  discussing XLP 
pathogenesis in detail,  a brief description of recent data on the immune response to 
EBV and its ability to modulate the immune response would be useful to understand 
XLP and diversity of its phenotypes in EBV positive patients.
In most human populations, primary EBV infection occurs during the first few 
years of life.  EBV enters the oropharynx and adjacent structures,  and preferentially 
infects B cells via the C3d complement receptor, CD21. Other co-receptors for virus 
entry have been reported although CD21 route remains the main pathway.
Primary infection  during  early childhood is mostly asymptomatic  or mildly 
symptomatic, and that during adolescence causes acute IM in 30-50% of cases (Ohga 
et al, 2002). It is not clear whether the severity of age related presentation is related to 
virus load or to age related differences in host immunity. Acute IM patients present 
with  fever,  painful  lymphoadenopathy,  sore  throat  with  pharyngotonsillitis, 
hepatosplenomegaly, and skin eruption. During this period the EBV-infected B cells 
increase  to  1-20%  of circulating  B  cells.  This  is  followed by  a  vigorous  immune 
response consisting of a brisk rise in NK cells, CD8 T cells, IFN-7 production, and 
antibody-dependent cell mediated cytotoxicity (ADCC) (Rickinson et al,  1997). The 
results of CD8 T cell response are an atypical lymphocytosis, which can be as many 
as  60%  of  the  peripheral  mononuclear  cells  population.  CD8  T  cells  show  the 
selective expansion of V/37 and V/36 in some IM patients (Smith et al,  1993).
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Figure 1.6 The immune response to EBV infection and disturbance of 
immune function leading to LPD disorders
Primary  infection  with  EBV  induces  non-specific  (NK,  IFN-y)  (indicated  as  red 
colour  and  specific  including  humoral  (indicated  as  yellow  colour)  and  cellular 
(indicated as green colour) mainly cellular immune responses. EBV- infected cells can 
escape from immune surveillance with EBV genomic invasive machinery. The EBV 
maintains  its  escape  with  invading  immune  response  leading  to  aberrant  cytokine 
production.  As  a  result  EBV  induces  B  cell  clonal  formation  and  finally 
LPD/Lymphoma disorders.
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However, T cells specific for lytic epitopes account for up to 44% of the CD8 T cell 
pool, while CTL specific for the immunodominant proteins of latent proteins reached 
only 1-2% (Hislop et al, 2002).
EBV  infection  causes  B  cell  proliferation  and  humoral  immune  responses, 
particularly IgM secretion, in the early stages (Papesch and Watkins, 2001). IgG anti- 
EBV early antigen (EA) and IgM antibody against EBV viral capsid antigen (VCA) 
are frequently detectable at 4 weeks and reach their maximum at 6-8 weeks. This is 
followed by a late  anti-EBV nuclear protein (EBNA)  IgG response, which remains 
with  IgG  anti-VC  A  at  a  high  level  for  many  years.  The  pattern  of  serological 
responses  to  EBV  infection  may  be  misleading  in  immunosuppressed  patients. 
However, the dominant immune response in EBV infection is cellular, which in itself 
sometimes  has  a  suppressive  effect  on  Ig  secretion  and  B  cell  lymphocyte 
proliferation.
The  EBV  genome  encodes  more than  100 proteins  (Epstein,  2001).  In this 
context  EBV  is  capable  of modulating  the  immune  response  by  encoding  novel 
homologs  of cytokines.  BCRF1  is  one  of the  early  lytic  genes,  which  exhibits  a 
human  IL-10  function  and  negatively  regulates  IL-12  to  inhibit  IFN-y production 
(Hiroshi, 2002). The overall biological effects of these proteins remain elusive.
EBV  infected  B  cells  also  show  the  immortalisation  ability  of the  EBV 
genome.  Following  the  initial  replicative  (lytic)  infection,  the  EBV  genome 
circularises to be maintained as a multicopy plasmid in the B cell nucleus. There are 
12 genes which encode different proteins involved in the latency programs of EBV. 
The  6  nuclear  antigens  EBNA1,  2,  3  (A,  B),  5  (LP),  3C  and  3  latent  membrane 
proteins (LMP)l, LMP2A,  LMP2B are the most important in maintenance of latency 
(Papesch and Watkins, 2001). Different EBV related tumours express some of these
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antigens dependent on the type of latency (Type I,II,III).  In persistent infection, the 
major  latent  epitopes  targeted  by  CTLs  are  EBNA3A,  EBNA3B,  EBNA3C 
(Rickinson et al,  1997).  It has been suggested that EBV- specific  CD4 T cells may 
play a  significant role  in primary infection  and  in  the maintenance  of functionally 
competent  CD8  memory  (Zajac  et al,  1998; Amyes  et al,  2003).  More  recently  a 
cytotoxic function of EBV- specific CD4 T cells has been reported particularly against 
EBNA1 proteins (Steigerwald-Mullen et al, 2000; Munz et al, 2000).
However,  despite  exciting progress  in understanding the  role  of EBV-CTLs 
and  Thl/Th2  polarization  of  the  cytokine  balance  during  EBV  infection,  many 
fundamental aspects in the pathogenesis of EBV related disorders remain unknown. 
Thus verification of cellular pathogenesis of XLP may shed some light not only on the 
EBV  immune  response,  but  also  on  the  development  of  lymphoid  malignancies, 
therapeutic and preventive strategies for the EBV-associated diseases.
1.9  Immunoserological studies in XLP
1.9.1  Immunoserological defects in XLP patients
Although most patients with XLP  are healthy prior to EBV infection,  it has 
been suspected that there may be subtle immunological abnormalities.  A number of 
studies have been undertaken on XLP boys who had been  identified  as  a result of 
previous family history and by inheritance of the abnormal X-chromosome by linkage 
analysis,  but  the  data  is  inconclusive.  A  report  from  Purtilo  et  al  showed 
approximately 5% of boys with XLP prior to EBV infection, had developed measles 
pneumonitis, with a few cases infection of Neiseria meningitis and also disseminated 
vaccinia  following  smallpox  vaccination  (Purtilo  et  al,  1991).  Defects  in 
immunoglobulin  isotype  switching  (IgM  to  IgG)  have  been  identified,  using
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vaccination with the neoantigen cjD/Xl 74 (Purtilo et al,  1989). In the largest study to 
date, 32 boys were identified as having XLP, all of whom were serologically negative 
for EBV  at  the  time  of analysis  (Seemayer  et  al,  1995).  Of these,  only  five  were 
healthy  with  a  normal  immunological  profile.  Of  the  remaining  27,  17  had 
dysgammaglobulinaemia with elevated levels of IgA and IgM and /or variable defects 
in IgG, IgGl or IgG3 production. However, in the majority of cases these findings did 
not have any significant clinical presentation.
1.9.2  Immunoserological defects in XLP female carriers
Carrier females in XLP are in general asymptomatic but analysis of humoral 
responses  to  EBV  suggests  a  number  of abnormalities.  This  includes  a  fourfold 
elevation  in  IgG  anti-VCA  titres,  and  persistence  of  IgM  and  IgA  anti-VCA 
antibodies, both of which are not normally found after seroconversion (Sakamoto et 
al,  1982).  IgG  antibodies  against  the  Epstein-Barr-virus  early  antigen  (EA)  were 
present in over half the carrier group but in only 19% of the control population. It has 
been suggested that these findings are indicative of continued viral replication or an 
attempt to compensate for a partial T-cell defect but the absence of other clinical and 
immunological problems in carrier females makes this unlikely. However, the recent 
data on murine models along with genetic epidemiological studies suggests that SAP 
deficiency  is  a  recessive  phenotype,  therefore  one  normal  SAP  allele  could  keep 
immunological balance in carriers (Crotty et al, 2003; Yin et al, 2003).
1.10  Molecular and cellular pathogenesis of XLP
The hallmark of XLP is a dysregulated, ineffective host response against EBV 
and other virulent pathogens. Although the exact pathogenesis of XLP is unknown, it
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has been suggested that the inability of the immune system of XLP patients to control 
EBV-infected B lymphocytes is likely to be due to defects of Th cells, CTLs, and NK 
cells.  SAP  is  a component of the  signalling mechanism used by the  SLAM  family 
receptors  and  represents  a  new  paradigm  in  signal  transduction  defects  associated 
with primary immunodeficiencies  (PIDs).  In  contrast to  other signalling  molecules 
involved  in  PIDs,  such  as  yc,  JAK-3,  and  ZAP70  in  severe  combined 
immunodeficiency and Btk in X-linked agammaglobulinemia which, are non adaptor 
components  in  immune  cell  signalling,  SAP  exhibits  a  modulator  role  in  signal 
duration  and  intensity.  Lack  of  SAP  function  leads  to  a  series  of  molecular 
dysfunctions in immune cells causing diverse phenotypes.
However,  a series of studies  in humans  and more recently in SAP deficient 
murine models has clarified some of the molecular and cellular abnormalities in XLP. 
The  data  from  human  and  murine  models  are,  in  some  aspects,  contradictory  and 
deserve further analysis. Thus the pathogenesis of XLP is discussed in two sections as 
below.
1.10.1  XLP Pathogenesis based on human findings
In the first description of XLP pathogenesis reported by Purtilo,  an intrinsic 
defect  in  B  cells was  suggested to play the main role in XLP  (Purtilo,  1976).  The 
clinical  and  pathological  findings  reported  by  Purtilo  showed  that  affected  boys 
suffered  from  chronic  bacterial  infections  and  low  serum  Ig  level  before  and  after 
EBV  infection.  Therefore,  it  was  suggested  that  the  dysgammaglobulinemia  was 
caused by an arrest in B cell maturation to plasma cells.  In addition, he observed a 
vulnerability of XLP boys to rubeola (measles) and vaccination, and concluded that T 
cell anergy due to the B cell defect impaired the control of B cells and was a major
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part of XLP pathology. Whereas, SAP is not expressed in the majority of B cells, an 
intrinsic B cell deficiency is unlikely and the humoral immunodeficiency is likely due 
to dysregulation of T helper cell function (Lai et al,  1987). It is well documented that 
CD4  T  cells  play  an  important  role  in  providing  appropriate  B  cell  help  through 
costimulatory  signals  such  as  CD40L,  CXCR5  expression  and  cytokine  secretion, 
which may highlight SAP function in CD4 T cells in parallel with existing pathways 
to initiate B cells response to EBV infection (Breitfeld et al, 2000). It holds true when 
XLP  males  with  immunoglobulin  class  and  subclass  deficiencies  prior  to  EBV 
infection are considered (Grierson et al,  1991). However, this remains elusive in XLP 
pathogenesis.  Also  development  of  B-cell  lymphoproliferative  disease  in  XLP 
initially led to the proposal that B cells in XLP patients may be less susceptible to T 
cell-mediated killing (Ando et al,  1986). However, the lack of SAP expression in B 
cells  particularly  EBV-transformed  B  cells  and  evidence  that  XLP-derived  B  cells 
resemble normal LCLs in vitro, with respect to induction of EBV-specific cytotoxic T 
cells  (CTL),  the  ability to  present  EBV  viral  antigens,  and  susceptibility  to  EBV- 
specific and MHC-restricted CTL-mediated killing, suggest that the cellular defect is 
not B-cell specific (Jager et al,  1998).
Large numbers of responding NK cells and CD4+ and CD8+ T lymphocytes 
are typically involved in the normal response to primary EBV infection. Furthermore, 
the  large  number  of activated  effector  T  cells  are  associated  with  the  release  of 
cytokines  and  inflammatory  mediators  that  ordinarily  lead  to  IM.  Although  XLP 
patients prior to EBV infection show a normal peripheral lymphocyte count, except a 
reverse  CD4/CD8  ratio,  it  has  been  reported  that  B  and  T  cells  (mainly  CD8) 
excessively  proliferate  and  infiltrate  the  organs  during  their  acute  phase  of EBV 
infection (Seeley et al,  1981; Lindsten et al,  1982; Sullivan et al,  1983 & 1989).  This
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suggests that EBV infection is the significant trigger for the phenotypic expression of 
XLP syndrome due to the excessive T cell activation and cytokine imbalance. Also it 
has been reported that EBV genomes were detected in peripheral blood lymphocytes 
and organs of affected males suggesting that failure of cytotoxic activity may be part 
of the pathology in XLP  (Purtilo et al,  1991).  As  SLAM  is  expressed  on T  and  B 
lymphocytes, it is postulated that homotypic binding, promotes T cell costimulation, 
proliferation, and production of Thl  cytokines. During EBV infection, SLAM-SLAM 
and MHC II molecule-TCR interactions at the interface between EBV-infected B cells 
and CD4 T cells,  or CD48-2B4 interaction between EBV-infected B  cells  and NK 
cells,  may  promote  the  development  of EBV-specific  Thl  responses.  Studies  on 
specific T-cell immunity to EBV are contradictory. Firstly, Purtilo and his colleague 
suggested  that  T  suppressor  lymphocytes  (CD8)  might  play  a  role  in  impaired 
immune  surveillance  against  EBV  (Purtilo,  1976).  EBV-specific  memory  T-cell 
activity,  as measured by inhibition of autologous EBV-LCLs outgrowth (regression 
assay), was defective in seven out of ten of XLP patients studied in comparison to 
female carriers and healthy individuals (Harada et al,  1982). Sullivan et al (1983) also 
demonstrated failure of T cell cytotoxic activity against a variety of targets related to 
EBV.  In  contrast  Rousset  et  al  (1986)  reported  two  XLP  patients  with 
hypogammaglobulinaemia exhibited  normal  EBV-specific  HLA-restricted  cytotoxic 
activity, although he was not able to show the cytotoxic activity of the EBV specific T 
cell clone level in those patients. Later, Okano et al (1990) reported a 19 year-old boy 
with XLP and IM with defective killing activity of PBL against his LCL during the 
course of the disease.  In another study, it was shown that the cytokines produced by 
T cells from ten XLP patients failed to inhibit B-LCL growth (Yasuda et al,  1991). 
For  the  first  time,  Yasuda  tried  to  explore  the  underlying  mechanisms  of T  cell
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cytotoxic dysfimtion in XLP by investigation of Thl  cytokines.  In Yasuda’s  study, 
IFN-7  production  was  normal  upon  allogenic  LCL  stimulation  in  XLP  patients. 
However,  T  cells  from  XLP  patients  exhibit  a  significant  decrease  in  IFN-7 
production in response to stimulation by autologous EBV-LCLs (Yasuda et al,  1991). 
Furthermore,  the  production  of IL-2  by  T  cells  upon  PHA  or  autologous  B-LCL 
stimulation  showed  no  difference  between  XLP  patients  and  those  in  the  normal 
control group. Okano et al reported a 20-month- old XLP boy with FIM who showed 
detectable IFN-7 in his serum and PBL culture supernatant, which decreased during 
the acute phase of EBV infection. Exogenous IFN-7 administration caused transitional 
improvement of his clinical condition with decreasing numbers of EBV positive cells 
(Okano et al,  1989 & 1990 a and b).
More  recently,  it  was  shown  that  Herpesvirus-saimiri-transformed  CD4+  T 
cells from XLP patients exhibited severe defects in cytokine secretion (Nakamura et 
al, 2001). Stimulation with anti-SLAM caused no significant IFN-7 secretion and also 
activation of the TCR resulted in little or no up-regulation of IFN-7 or interleukin 2 
(IL-2)  in  comparison  with  controls.  Similar  results  were  observed  in  mixed 
lymphocyte reactions (MLRs) (Nakamura et al,  2001). Moreover, molecular studies 
of XLP  transformed  CD4  T  cells  showed  an  enhanced  level  of basal  and  TCR- 
induced tyrosine phosphorylation of CD3£ ZAP70, and Cbl.  Other key partners of 
TCR  downstream  kinase  families  including  mitogen-activated  protein  kinase 
(MAPKs),  external  signal-regulated  kinase  (ERKs),  c-Jun  NH2-terminal  kinase 
(JNKs)  and  also  pleotropic  proteins  (Akt,  GSK)  showed  an  increase  in 
phosphorylation  upon  TCR  activation  in  XLP  CD4  T  cells,  but  the  level  of 
phosphorylation declined faster in comparison with phosphorylation in normal CD4 T 
cells. It suggests that SAP is important in TCR down stream signalling pathways and
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may control cytokine production not only through SLAM  family receptors but also 
via the  TCR pathway.  More recently it was  shown that  SAP  deficient T  cell  lines 
generated by  stimulation  of T  cells  with  allogeneic  B-LCL  demonstrated  impaired 
TCR-CD3 signalling (Sanzone et al,  2003). In support of the above results, the SAP 
deficient  lines  showed  an  enhanced  phospholipase  C  7I  (PLC  7I)  phosphorylation 
and  calcium  response,  but  phosphorylation  of  VAV  and  downstream  signal 
transduction events such as MAPKs were diminished (Sanzone et al, 2003). This also 
leads  to  diminished  IL-2  production  upon  TCR  activation  in  XLP  T  cell  lines. 
Furthermore, it is well known that LAT (linker for activation of T cells) is a central 
adaptor for transduction in proximal CD3 signalling associated with PLC7, VAV and 
other kinase proteins  (Zhang et al,  1998).  Also  LAT  is  associated with  2B4  via a 
dicysteine motif in NK cells, and the presence of SAP is important in LAT function as 
a central adaptor (Latour and Veillette, 2003).  It is likely that SAP deficiency could 
provoke selective alterations in the phosphorylation of distinct LAT tyrosine residues 
either  through  SLAM  family  receptors  or  via  alternative  mechanisms  causing 
imbalanced  signalling  in  T  cells  from  XLP  patients.  However,  although  the  above 
information  provides  a  better  understanding  of  T  cell  dysfunction  in  XLP,  the 
molecular  basis  of TCR  mediated  T  cell  defects,  particularly  in  association  with 
SLAM family receptors remains largely elusive and needs further investigation.
Studies on NK cells from XLP patients were more conclusive than T cells, 
and it has been suggested that the failure of cytotoxicity is 2B4-mediated,  although 
other SLAM family receptors expressed on NK cells have not been excluded. NK cell 
activity was one of multiple XLP  immune defects described (Sullivan et al,  1980). 
Sullivan et al in their report published in Science (1980) demonstrated XLP-NK cells 
from  12  patients  aged  5-19  years  old  exhibit  significantly  lower  killing  activity
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against K562 target cells in comparison to controls  (10 out of 12) but in 2 XLP cases 
prior to EBV infection the NK killing activity was intact. In contrast, 10 XLP carriers, 
10  patients  with  IM,  and  33  normal  individuals  presented  a  high  NK  cytotoxic 
activity.  In a second study by the same group, NK cytotoxic activity against K562 
target  cells  in  2  XLP  patients  was  normal  but  abnormal  in  a  third  XLP  patient 
(Masucci  et  al,  1981).  However,  it  was  later  shown  that  NK  cell  killing  activity 
against K562 or Daudi (a Burkitt’s lymphoma cell line) cell lines is abnormal in XLP 
patients (Harda et al,  1982; Argov et al,  1986; Benoit et al, 2000; Tangye et al, 2000). 
Moreover the  effect of exogenous  EFN-7 to  improve NK cell  cytotoxic  function  is 
controversial, and differential effects have been reported (Masucci et al,  1981; Argov 
et al,  1986; Okano et al,  1989&  1990). Argov et al (1986) also showed that NK cell 
function mediated by antibody-dependent cellular cytotoxicity (ADCC)  is  intact  in 
XLP patients. Thus, when XLP NK cells were stimulated with receptors that do not 
bind  SAP  such  as  CD2,  CD 16  or  NCRs,  cytotoxicity  was  comparable  to  normal 
controls, suggesting only specific pathways are affected in these patients (Argov et al, 
1986; Parolini et al, 2000; Tangye et al, 2000). 2B4-CD48 interaction augments non- 
MHC restricted cytotoxicity by NK cells (Nakajima et al, 2000).  As K562 cell lines 
are  CD48  and  HLA negative,  the recent  data casts  doubt  over the NK cell  killing 
failure reported previously. The more recent studies investigated cytotoxic function at 
a molecular level to solve this paradox.  The 2B4-mediated cytotoxic activity in NK 
cells  is  Ras/Raf  dependent  and  involves  multiple  MAPK  signalling  pathways 
including ERK1/2 and p38 (Chuang et al,  2001). 2B4 activates NK cells via a LAT- 
dependent  signalling  pathway,  in  which  the  binding  of  LAT  and  2B4  is  SAP 
dependent and 2B4- mediated cytotoxicity is dependent on SAP interaction with 2B4 
(Tangye et al,  2000; Chuang et al, 2001). Therefore, as CD48 is highly expressed on
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EBV-LCLs it was speculated that the NK cell defect in XLP is limited to 2B4/CD48- 
specific  NK-cell  killing  activity.  In  addition,  inducing  expression  of CD48  on  a 
transfected  K562  HLA  negative  leukaemia  cell  line  enhanced  killing  activity  of 
normal NK cells. XLP-NK cells showed decreased killing of CD48-expressing target 
cells  in  comparison  with  normal  controls  (Parolini  et  al,  2000).  Disruption  of the 
association between 2B4 and CD48, using a 2B4 masking antibody, restored normal 
cytolytic function, suggesting that this defect arises from the delivery of an inhibitory 
signal through the 2B4 /CD48 interaction (Parolini et al, 2000; Tangye et al, 2000).
However,  it  remains  undefined  how  the  lack  of  SAP  affects  cytokine 
production, particularly IFN-y, and also CS1 and NTBA function in XLP patients and 
their specific role in pathogenesis. In this regard, a subpopulation of killer cells called 
lymphokine-activated  killer cell  (LAK)  are  defective  against  Raji  cell  line  (a NK- 
resistance cell line) in XLP, and again the pathology of the defect has not been fully 
explored (Benoit et al, 2000).
1.10.2  XLP pathogenesis based on murine model findings
The first animal experiments for XLP were performed in a severe combined 
immunodeficiency (SCID) mouse model by Purtilo and his colleagues (Purtilo et al, 
1991).  The engraftment of PBL  from  9  XLP patients  showed no  graft-versus-host 
disease (GVHD), suggesting T cell defects. In contrast, in a control group the majority 
of engrafted mice developed GVHD.  After almost a decade, the discovery of the SAP 
gene made it possible to generate an XLP murine model. Three groups have generated 
S!4P-deficient mice models by targeting different exons of the SAP gene (exons 1,2 or
3)  in mice (Czar et al, 2001; Wu et al, 2001; Yin et al, 2003).  Wu et al deleted exon 
1   whereas Czar et al and Yin et al developed their model by targeting exon 2 and 3,
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respectively.  In murine SAP knockout models, lymphocyte development is normal as 
previously reported in humans (Czar et al,  2001;  Wu et al,  2001; Yin et al,  2003). 
Expression  of cell  surface  markers  for  lymphocyte  sub-population  were  normal  in 
knockout SAP murine models  (Czar et al,  2001;  Wu et al,  2001;  Yin et al,  2003). 
Before exposure to any kind of infection the only immunological abnormality in the 
mice model was a lower level of all IgG subclasses (Yin et al,  2003) and low level 
IgE reported in two models (Czar et al,  2001; Yin et al,  2003). However, the SAP- 
deficient models  showed  a number of different post  infection pathological  immune 
responses. Challenging of the mice with LCMV (lymphocyte choriomeningitis virus: 
a  virus  that  elicits  similar  responses  to  infection  with  EBV),  or  murine 
gammaherpesvirus-68  (a herpesvirus of wild rodents which genetically is related to 
human  herpesvirus-8  and  human  EBV)  or  Toxoplasma  resulted  in  impaired  Th2 
differentiation and Thl/Th2 skewing.
The SAP deficient mouse models present a relatively intact immune response 
to  clear  acute  infection  but  progress  into  immune  dysregulation  with  pathological 
presentations. However, infection with a more virulent clone of LCMV (clone 13) or 
a hepatotropic strain of LCMV (LCMV-WE) causes increased morbidity (Czar et al, 
2001)  or  mortality  (Wu  et  al,  2001)  in  these  models.  Conversely,  infection  with 
gammaherpesvirus-68 in the SAP deficient mice does not increase in any morbidity or 
mortality (Yin et al, 2003).
Moreover, all three models showed an increased number of activated T cells, 
mainly  CD8  T  cells,  presenting  with  higher  IFN-7 production  after  1-2  weeks  in 
comparison with the wild type mice. The CD8 T cells in response to LCMV-specific 
peptides produce excessive IFN-7 and TNFa production in comparison to  a normal 
control. Also the number of antigen-specific CD8 T cells for LCMV antigens stained
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with the MHC-class I Ag-specific tetramers, was significantly higher than the control 
group  after LCMV infection (Czar et al,  2001).  The overall proliferation of CD8  T 
cells in response to gammaherpesvirus-68 infection shows subsets expressing the V/34 
T cell receptor,  a characteristic  feature after murine gammaherpesvirus-68  infection 
(Yin et al,  2003).  These data may confirm the  function of CD8  and cytotoxicity of 
CD8-CTLs  are  intact  in  SAP  defective  murine  models.  The  organ  lymphocyte 
infiltration is mainly of T cells and may be caused by over responsiveness of T cells. 
The  higher  proliferation  of SAP  defective  murine  T  cells  in  response  to  TCR  or 
SLAM stimulation is reported before infection.
CD4 T cells of SAP deficient mice show an enhanced IFN-7, TNF-a and IL-2 
production  in  response  to  infection  but  the  total  number  of  CD4  T  cells  was 
comparable between wild type and SAP deficient mice, except in the Wu et al (2001) 
report in which the number of CD4 T cells was slightly higher than wild type mice 
(Czar et al,  2001; Wu et al, 2001; Crotty et al,  2003; Yin et al, 2003). In addition, it 
has been reported that T helper CD4 cells have impaired production of IL-4,  IL-10, 
IL-13 in SAP deficient mice, which would be corrected with Th2 polarization (Wu et 
al,  2001).  However,  the  murine  SAP  defective  T  cells,  before  infection,  upon 
stimulation of TCR or SLAM also show a consistently high IFN-7 and low production 
of IL-4,  IL-10,  IL-13,  suggesting  fundamental  immune response impairment.  It has 
been well documented that the rapid production of IL-4 by CD4 T and NKT cells in 
response to Lieshmania major (L-M) causes persistence of infection and susceptibility 
of mice (Launois et al,  1997). The SAP knockout murine model showed a Th2 defect 
in response to L-M infection similar to that shown in response to  LCMV infection, 
supporting the idea that the regulation of IL-4 production is SAP dependent (Czar et 
al, 2001).
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Furthermore,  the  SAP-  deficient  mouse  model  following  infection  with 
LCMV, T gondii,  L.M, or challenged with ovalbumin (OVA) shows a lower level of 
IgE and IgG production particularly after the acute phase (Czar et al, 2001; Wu et al, 
2001;  Crotty  et  al,  2003;  Yin  et  al,  2003).  Although  the  presence  of 
dysgammglobulinemia before infection reported by some groups suggests an intrinsic 
B  cell  dysfunction in addition to impaired T helper cell  function,  the recent results 
using an  adoptive transfer system have  emphasised the role of SAP  in  CD4  T cell 
function for late B-cell help and development of long-term humoral immunity (Crotty 
et al,  2003).  The  number of antibody-secreting  cells  (ASCs)  and  IgG  serum  level 
(IgGl, IgG2a, IgG2b) are increased after infection but decrease after two weeks in the 
SAP deficient murine model, confirming SAP is not important for early B cell help 
and  class  switching.  In  vitro  studies  show  murine  SAF  B  cells  proliferate  and 
differentiate into ASCs normally.  The normal expression of CD40L and CXCR5 on 
SAF CD4 T cells confirm that the interaction and migration of T helper cells as an 
important  part  of B  cell  help  is  intact  in  XLP.  The  reconstitution  of SAF  B  cell 
function after adoptive normal CD4 T cells transfer in vivo underlines the crucial role 
of Th2 cytokine polarization in XLP (Figure 1.7).
Several groups have studied the biochemical immunopathological response in 
SAP  deficient  murine  models.  Upon  SLAM  stimulation  the  SAF  T  cells  show 
defective phosphorylation of SHIP, the adaptor molecules Dok2, Dokl  and She, and 
RasGTPase-activating protein RasGAP that leads Thl/Th2  imbalance (Latour et al, 
2001; Chan et al,  2003).  This pathway is regulated by SAP dependent coupling of 
Fyn to SLAM. Although, the same dysregulation has been shown in Fyn- deficient T 
cells, it was not addressed how the absence of SAP causes the aberrant TCR signal. 
To address this question, Howie et al suggested that the recruitment of SLAM and
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Figure  1.7  SAP  function  via  CD4  T  cells  and  its  potential  role  in 
pathways of B cell differentiation
In germinal  centres,  SAP-expressing CD4+  T cells may promote the  formation and/or 
survival of B cells which after completing affinity maturation become memory B cells 
and long-lived plasma cells. In a murine model it has been shown that SAP expression is 
necessary for the long-term humoral immune response (adapted from Welsh et al, 2003).
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SAP  to  the  site  of TCR  engagement  may  explain  how  SLAM  influences  TCR- 
mediated signals (Howie et al, 2002). More recently it has been shown that a defect of 
IL-4 production in SAP- deficient murine cells is caused by impaired TCR-mediated 
induction of the GATA-3 pathway (Cannons et al, 2004). In contrast to humans, study 
of TCR signalling revealed normal  Ca2+  mobalization  and  ERK  activation  in  SAP- 
deficient  murine  cells,  but  decreased  PKC-0  recruitment,  Bel-10  phosphorylation, 
I/cB-a degradation,  and  nuclear NFxBl/p50  levels.  Interesting,  Fyn-  deficient  cells 
also show the same TCR signalling dysregulation. However, the Fyn deficient model 
was  able  to  address  the  down-regulation  of  IL-4  but  not  the  increased  IFN-7 
production precisely.
Furthermore, although these studies suggest that SAP deficiency can directly 
affect signalling downstream of the TCR in conjunction with the SLAM receptor in 
CD4 T helper cells, there is not any evidence in this model that is extendable to other 
lymphocyte  populations  or  to  other  SLAM  family  receptors  affected  by  SAP 
regulatory function in the immune response.
1.11  Diagnosis and treatment of XLP
Molecular  analysis  of the  SAP  gene  and  protein  expression  are  the  latest 
methods,  which  are  used  by  a  number  of different  centres,  for  diagnosis  of XLP. 
Mutation analysis with direct sequencing of the four exons using intronic primers is 
performed to give high sensitivity results. However, the genetic test for XLP shows a 
low detection rate of between 54 and 64% (Yin et al,  1999) even in cases with a X 
linked  pedigree  and  particularly  in  cases  with  sporadic  presentation.  The  linkage 
studies on XLP probands mapped the XLP gene to the Xq25 region, suggesting that 
another gene abnormality is unlikely. Thus mutations in SAP promoter or regulatory
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regions should be sought at least in a majority of cases with a negative test of SAP 
mutation analysis. More recently, a SAP protein assay has shown a higher detection 
rate  even  without  a positive  genetic  test,  which  again  suggests  the  defect  in  some 
cases may lie in regulatory or promoter of SAP expression region rather than in the 
gene (Gilmour et al, 2000). However, the genetic test for SAP in affected males with 
an  X-linked  pedigree  and  definite  XLP  presentation  is  highly  sensitive  with  97% 
(Sumegi  et al,  2000).  The  defect  in  cases with  sporadic  or atypical presentation  is 
elusive.  To  improve  the  diagnosis  of  XLP  cases  and  prevent  misdiagnosis,  the 
European  Society  for Immunodeficencies  (ESID)  and the Pan American  Group  for 
Immunodeficencies  (PAGID)  has  recommended  guidelines  for  XLP  diagnosis 
(Conley  et  al,  1999).  The  criteria  are  based  on  SAP  mutations,  common  and 
uncommon phenotypes,  EBV infection,  and the presence of affected maternal male 
relatives with a history of similar disease. According to these criteria there are three 
groups of cases including definite, probable, and possible criteria, where the chance of 
having  XLP  is  different  in  each  group.  Still  there  are  some  cases  with  a negative 
genetic test and lack of SAP protein expression but with a similar XLP phenotype, 
known  as  XLP  like  disease,  which  still  remain  undefined.  However,  a  better 
understanding of the underlying XLP molecular pathology will  allow the design of 
more  definite  guidelines.  The  new  technology  such  as  microarrays  or  proteomics 
arrays would provide this along side better and more comprehensive diagnostic tools 
in XLP.
After diagnosis of XLP, the most striking challenge is treatment of XLP cases 
particularly those with a poor prognostic phenotype.  At present, the only definite and 
preventive  cure  for  XLP  and  the  EBV  and  non-EBV  complications  is  allogeneic 
hematopoietic stem cell transplantation (HSCT) either using bone marrow, peripheral
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blood, or umbilical cord blood stem cell (Gross et al,  1996).  However,  it is mostly 
unsuccessful in affected males with an age of more than  15 years and also with pre- 
HSCT  infective  complications.  Other  therapeutic  strategies  developed  for  treating 
manifestations  of XLP  such  as  using  antiviral  drugs,  high-dose  immunoglobulin, 
immunosuppressive  agents,  and  IFN-7  have  been  largely  unsuccessful,  and  are 
palliative at best. The lack of success of conventional treatments for XLP makes the 
development of a gene therapy strategy for XLP an attractive proposition.  There is 
great potential  to  use  gene  manipulation  either  as  investigation  tool  or  therapeutic 
strategy  in  XLP.  The  following  section  will  discuss  the  gene  therapy  approach  in 
general  and  specifically  on  advantages  of  retroviral  gene  therapy  in  primary 
immunodeficiencies.
1.12  Gene therapy and viral vectors
Somatic gene therapy is defined as the delivery of new genetic material into a 
patient’s somatic cells for the treatment of disease and is made possible through the 
development of viral and non-viral gene transfer vectors. Primary immunodeficiency 
(PID) disorders are good candidate disorders for this type of therapy and have played 
a major role in the development of techniques  for human gene therapy. A series of 
encouraging results obtained in chronic granulomatous disease (CGD) patients (Grez 
et  al,  2000)  and  patients  affected  with  the  X-linked  and  ADA  forms  of  severe 
combined  immunodeficiency SCID  (XSCID  & ADA-SCID) have  shown promising 
progress in recent years in the primary immune deficiency field (Blaese et al,  1995; 
Fischer et al,  2001; Aiuti  et al,  2002;  Gaspar et al,  2004;  Muul  et al,  2003).  The 
technical progress will be critical for future development of gene therapy approaches 
for other forms of PIDs.
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Since the cloning of the gene responsible for XLP, it has been confirmed as 
one of the monogenic X-linked primary immunodeficiency diseases, which with our 
developing  knowledge  of  its  molecular  and  cellular  pathogenesis  makes  it  an 
interesting  disorder  to  develop  for  gene  therapy.  Distribution  of  SAP  expression 
mainly in T and NK cells strongly suggest that gene therapy would be very possible 
since, both T and NK cells are readily accessible and particularly since T cells can be 
efficiently transduced. Gene reconstitution in XLP could be a strong tool to study the 
cell mediated immune response in XLP and also it might offer a new approach  for 
treatment of this fatal genetic disorder.
To  successfully  achieve  gene  therapy  for  XLP,  it  is  crucial  to  develop  an 
optimal vector. An ideal vector should; (1) allow efficient and selective transduction 
of the target cell of interest, (2) be maintained and (3) expressed at levels necessary 
for  achieving  therapeutic  effects,  and,  last  but  not  least,  (4)  be  safe  in  terms  of 
avoiding unwanted side effects in the host. Viruses are considered as a good tool for 
gene transfer as they have evolved to deliver their genome efficiently to target cells 
with  subsequent  high  level-gene  expression.  Vector  systems  for  therapeutic  gene 
transfer have been developed from different virus groups, each system having specific 
advantages and drawbacks. Viruses are obligate parasites and cannot replicate without 
the help of host cells. Thus they are, by nature, adapted to efficiently transmit genetic 
information to cells. Among the viruses many different strategies have evolved that 
allow them to  enter cells,  and the  form of their genetic information to  some extent 
determines the  latter mechanisms  used  for replication  and production of new virus 
particles or virons.
Retroviruses are particularly of interest in this respect, because although they 
carry an RNA genome, this genome is transcribed into a double-strand DNA in the
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infected cell, which can then efficiently integrated into the host cell DNA (reviewed 
by  Coffin  et  al,  1997).  Once  integrated,  the  virus  DNA,  known  as  a  provirus,  is 
transcribed like any other cellular gene and the virus-specific DNA is used to produce 
viral proteins and new genomic RNA, both of which are assembled into new virons. 
The integrated provirus is a stable part of the cell genome for life of the cell and is 
passed on to  all daughter cells that arise  from the original  infected cell.  This  latter 
property of retroviruses  makes them  ideal  candidates  as  gene  delivery vehicles,  or 
vectors,  that give long-term gene expression.  The ability to  integrate up to  9 kb  of 
foreign DNA into the host genome and the lack of immunogenicity has made the use 
of retroviral vectors very popular. So far retroviral vectors have been used in human 
gene therapy in different areas such as: adoptive immunotherapy, tumor vaccination, 
suicide gene transfer, and modified stem cell therapy (Rooney et al,  1995; Plavec et 
al,  1996; Qasim et al, 2002; Gaspar et al, 2003).
Retroviruses  are  classified  based  on  genome  structure  into  seven  groups, 
which  are  summarized  in  Table  1.5.  Until  recently,  most  retroviral  vector  systems 
used  for  human  gene  therapy  based  on  murine  leukemia  viruses  (MLVs).  These 
belong to the mammalian C-type retroviruses and are further classified according to 
the species distribution of their receptors (Coffin et al,  1997). To understand retroviral 
vector architecture the following section is dedicated to structure of simple retrovirus 
type C such as MLV.
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Table 1.5 Retrovirus genera
G ain s Example viruses
Avian leukosis sarcoma
Mammalian C type
Rous sarcoma virus (RSV)
Murine leukaemia virus (MLV), several strains: such as 
Moloney, Harvey Abelson 
Feline Leukemia virus (FeL V)
Gibbon ape leukemia virus (GALV)
D-type viruses 
B-type viruses 
HTLV-BLV group 
Lentivirus 
Spumavirus
Mason-Pfizer monkey virus (MPMV)
Mouse mammary tumor virus (MMTV)
Human T cell leukemia virus (HTLV)-1 and 2
Human immunodeficiency virus (HIV)-land 2
Human foamy virus (HFV)
Adapted from:  Coffin et al,  1997
1.12.1  Characterising of common structure of retroviruses
The  common  structure  of retroviruses  is based  on two parts;  cis-active  and 
trans- active (Figure  1.8),  which control all crucial elements for the replicative life­
cycle of retroviruses (Campbell et al,  1997; Coffin et al,  1997; Pages et al, 2004).
The trans-active part of a retrovirus is the polycistronic RNA, which encodes 
more than one gene, and which with alternative splicing mechanisms produces two or 
more  gene  products.  The  trans-active  elements  of retroviruses  carry  at  least  three
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major  genes  including:  1)  gag  encoding  the  internal  structure  protein  of  all 
retroviruses which provide the matrix  protein  and package the two  retroviral  RNA 
genome into a viral nucleocapsid. 2) pol encodes several enzymes necessary for virus 
replication including DNA polymerase, ribonuclease H (RNase H), integrase which is 
specific  for  each  virus,  and  the  viral  protease  which  cleaves  the  gag  and  pol 
precursors into the individual proteins.  3) env which encodes glycosylated envelope 
that by its specific interaction with ligand on target cells control virus entry into host 
cells.
The cis-acting elements regulate viral gene expression and all steps necessary 
for viral  life cycle (reviewed by:  Belshe,  1991;  Campbell et al,  1997;  Coffin et al, 
1997;  Hu et al,  2000). The cis-acting elements in pro  virus  are  flanked by the  long 
terminal  repeats  (LTRs),  carrying the terminal  attachment  (att)  site.  The  att  site  or 
inverted repeat (IR) is a short sequence (3-25bp) that forms a perfect inverted repeat 
at the ends of the LTR and provides recognition sites for integrase which has specific 
sequences in each retrovirus subtypes. Generating the linear duplication of the LTR in 
both  5’  and  3’  in  retroviral  DNA  is  necessary  to  establish  suitable  substrates  for 
integration and to regenerate regulatory sequences (the promoter and polyadenylation 
site) that are lost when the provirus is transcribed into genomic RNA.
The  LTR  is  composed  of three  parts  the  U3,  R,  U5,  sites.  The  U3  region 
carries the viral enhancer and promoter elements. Transcription of viral genomic RNA 
begins at the 5’ LTR and is controlled by U3 activity and in the 3’ LTR, initiation of 
transcription  is  suppressed by 5’  LTR interference  and polyadenylation  signal  in R 
region of 3’ LTR.
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Figure 1.8 Schematic of the proviral form of a replication-competent 
simple C-type retrovirus
The combination of cis and trans components in a simple C-type retrovirus. (Adapted 
from Baum et al,  1999).
Components active in trans:
Gag : MA (matrix, p i5), pi2, CA( caspid, p30), NC (nucleocapsid, plO)
Pol: protease (PR), reverse transcriptase/RnaseH (RT), integrase (IN)
Env: SU (surface protein, gp70), TM (transmembrane protein, pl5SE) 
Components active in cis:
att: integration signal  vp: dimerization and packaging  signal
E P: enhancer/ promoter  PP: polypurine tract
PBS: tRNA-primer binding site  Pa: poly adenylation signal
SD, SA: splice donor, splice acceptor
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The  R  is  an  identical  repeated  (R)  redundant  and  short  sequence  (15-250 
nucleotides) present at 5’ and 3’ ends of the RNA genome which play an important 
role  during  reverse  transcription  with  providing  the  complementary  sequence  of 
minus-  strand  strong-  stop  DNA copy  from  R  region.  The  U5  or  Unique  5’  is  a 
sequence (70-250 nucleotides) positioned between R and primer binding site (PBS). 
The U5 is present once in genomic RNA and twice in the LTR of the provirus, which 
is crucial for reverse transcription and terminus with att site. The 5’ LTR immediately 
is followed with untranslated leader sequence upstream of gag which is 18 nucleotides 
long and beginning with a 5’ TGG that forms the primer binding site (PBS). The PBS 
is perfectly complementary to the 3’ terminus of a specific host tRNA species. The 
PBS  provides  the  binding  site  for  a  tRNA  that  acts  as  the  primer  for  reverse 
transcriptase to initiate synthesis of the minus strand of viral DNA. Leader sequences 
downstream of the PBS contain the splice donor site for generating the subgenomic 
RNAs, as well as the packaging signal sequences. These sequences are termed “Psi” 
(vj/)  or alternatively “E”.  They  are required  as  a dimerization  signal,  which  directs 
incorporation of the two viral RNA genomes into virons and thus are necessary for 
reverse transcription (Rein, 1994; Berkowitz et al,  1996). Optimal packaging can also 
require additional sequences, such as the first 400 nucleotides of gag in MLV-based 
vectors (Bender et al,  1987).
1.12.2  Virus life cycle
Knowledge  of  retrovirus  structure  helps  us  to  better  understand  the 
sophisticated  virus  life  cycle  in  host  cells  and  physiological  aspects  of retroviral 
vectors  function  and  architecture.  The  life-cycle  of a  retrovirus  consists  of three 
essential major parts: 1) virus entry, 2) reverse transcription, 3) integration
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Provirus  1:DNA
5’LTR
Retroviral genome: RNA
5’LTR
R U5
PBS
Transcription
Provirus  2: DNA
5’LTR
3’LTR
IJ3 R ITS in R 175
PBS "PP
3’LTR
PP
U3 R Poly (A)
Reverse tr inscription
3’LTR
U3 R U5
PBS PP U3 R U5
Figure 1.9 Transcription and reverse transcription steps of MLV
Provirus 1  is transcripted into the retroviral genome flanked by the R sequences. Two 
genomes are packaged into each virion and released from the cell. After infection of 
the target cell the genomic RNA is reverse transcribed into provirus 2. (Adapted from 
Baum et al,  1999).
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Figure 1.10 Life cycle of a replication-competent retrovirus
1)  virion binding; 2) virion penetration and uncoating; 3) reverse transcription of RNA 
genome  into  proviral  DNA  (for  detail  see  Figure  1.9);  4)  nuclear  transport  of 
preintegration complex  and integration of provirus;  5) transcription of genomic and 
subgenomic mRNA and translation of viral gene products; 6) nucleocapsid assembly, 
budding, and maturation of virion. (Adapted from Baum et al,  1999).
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(Figure  1.9).  Following fusion of viral and cellular membranes, the nucleocapsid is 
released into the cytoplasm (Coffin et al,  1997). The next stage is a multi step reverse 
transcription  process,  which  provides  the  DNA  (provirus)  format  of the  retroviral 
RNA genome (Figure 1.10). The nucleocapsid protein (NC) increases the efficiency of 
reverse  transcription  and  remains  with  the  viral  genome  during  the  reverse 
transcription process.  Retroviral DNA synthesis is absolutely dependent on the two 
distinct enzymatic  activities of RT:  a DNA polymerase that can use  either RNA or 
DNA as a template, and a nuclease, termed ribonuclease H (RNase H), that is specific 
for the RNA strand of RNA: DNA duplexes.
After reverse transcription, the nucleocapsid proteins remain tightly associated 
with proviral DNA. This complex carries all factors necessary for integration of the 
viral DNA into the genome of the host cell (Coffin et al,  1997).  For some types of 
retroviruses such as MLVs, this complex cannot pass through the nuclear pores, and 
nuclear  transport  requires  mitosis  with  breakdown  of the  nuclear  membrane.  In 
lentiviruses, such as HIV, this step is not cell division dependent and probably the vpr 
protein (a protein, found in virons, that causes infected cells to arrest in G2) with virus 
matrix facilitates passing the complex through nucleus pores (Federico, 1999).
1.12.3  Retroviral vector architecture
Based  on  retroviral  physiology  and  the  flexible  structure  of their  genome, 
retroviral vector systems can provide promising gene delivery systems with a large 
capacity and stable expression.  To consider safety issues  for design of a replication 
deficient retroviral vector, the virus production machinary is split into two parts:  1) 
packaging cell line (Figure 1.11) and 2) vector containing transgenic cDNA.
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Figure 1.11 Principles of retroviral packaging cell systems
The  retroviral  plasmid,  carrying  a  target  gene  of interest,  is  transfected  into  the 
packaging cells using standard chemical approaches (NX Ecotrpic). In the second step 
replication-incompetent  retroviral  particles  are  used  to  infect  amphotropic  PG13 
packaging cell  lines.  The  gag-pol  and  env  components  are  supplied  independently. 
Vector  RNA  combines  with  the  products  of  gag-pol  and  env  genes  to  produce 
infectious virus. When the virus infects a target cell, the cycle of replication is aborted 
once  the  proviral  DNA  integrates  in  the  host  genome  as  the  viral  structural  and 
envelope proteins are missing. (Adapted from Lemoine and Cooper, 1996).
76Chapter 1   Introduction
A modem, safety-modified packaging cell line contains at least two expression 
constructs  for  viral  genes,  one  encoding  for  gag-pol  and  one  for  envelope  genes 
(Miller,  1990; Cosset et al,  1995). Although, these mRNAs are designed without the 
packaging signal for safety purposes the packaging cells encode all trans-acting viral 
elements required for particle assembly, release, maturation, and transduction of the 
target cell (Miller, 1990).
The  vector  contains  those  cis-active  elements  required  for  a  single 
transduction: cap site and poly (A) signal for the genomic message, packaging signal 
for  incorporation  into  particles,  BPS,  PP  and  R-U5  sequences  for  reverse 
transcription, and att sites  for integration (Baum et al,  1999).  Moreover,  it contains 
the  transgene  cassette(s)  of  interest  including  enhancer/promoter  sequences  for 
initiation of transcription.
1.12.4  SFFV hybrid retroviral vector
Moloney murine leukemia virus (Mo-MuLV) is commonly used as a retroviral 
vector (Gunxburg et al,  1996). To achieve high and constant expression by retroviral 
vectors,  modification  and  hybridization  of the  retroviral  backbone  has  been  a  key 
issue in vector development. The spleen focus-forming vims (SFFV) hybrid is based 
on Mo-MuLV vector. It has been engineered from at least four retrovirus derivatives 
(Baum et al,  1995; Hoatlin et al,  1998). Lastly, the polycythemic strain of SFFVp has 
been  modified  from  Friend  mink  cell  focus-forming vims  (FMCF)  as  a mutant  of 
replication-defective vector (Baum et al,  1995). The SFFVp contains the most potent 
retroviral  enhancer configuration  for  gene  expression  in  myeloerythroid progenitor 
cells. This currently represents the best backbone for strong transgene expression in 
hematopoietic  cells.  This hybrid has  good  activity in activated T cells and B  cells,
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which has extra advantage to high lymphotropic vector based on Mo-MuLV (Couture 
et al, 1994; Baum et al,  1999; Qaseem et al, 2002).
To  get  an  advantage  from  SFFVp  hybrid  vector  and  its  wide  host  cells 
expression and long- term expression, we used FMEV (FMCF-MESV; murine ES cell 
virus)  backbone  modified  in  5'LTR  from  PCMV  (PCC4  cell  passaged  murine 
sarcoma  virus)  a  myeloproliferative  sarcoma  virus  (MPSV)  subtype  (Baum  et  al, 
1999).  5'LTR  from  PCMV  provides  high  expression  in  packaging  cell  lines  as  a 
benefit  of  its  active  expression  in  embryonic  carcinoma  cells  and  further  has 
advantage  from  the  SFFVp  3’  LTR which  controls  recombinant virus  incompetent 
replication expression activity (Baum et al,  1995).
The vector backbone construct contains packaging signals from LX based Mo- 
MuLV vector (including 400bp of gag sequence with disrupting AUG) (Miler et al, 
1989; Hawley et al,  1994; Baum et al,  1999). To enhance efficiency of this vector to 
transduce  haemopoietic  progenitors  and  mainly  lymphocytes,  a  GALV  pseudotype 
vector has been used.  Pseudotype retroviral vectors are generated by co-expression of 
vector RNA  containing the packaging  signal,  with retroviral  Gag and Pol,  and the 
unrelated glycoprotein (Miller et al,  1991; Bauer et al,  1995; Bunnell et al,  1995).
1.12.5  Third generation of lentivirus vectors
The lentiviruses are members of complex retroviruses, which have provided 
very efficient vectors  for gene delivery.  The  ability of lentiviruses to  integrate into 
non-dividing cells relies on nuclear localization signals present in the preintegration 
complex  that  allow  their  entry  into  the  nucleus  without  the  need  for  nuclear 
membrane  fragmentation  (Bukrinsky  et  al,  1993).  Recent  third-generation  HIV-1 
based vectors and self-inactivating (SIN) vectors represent highly efficient and more
78Chapter 1   Introduction
advanced  viral  vehicles  (Miyoshi  et  al,  1998).  The  HIV  genome  codes  for  three 
structural (gag, pol, and env) and six regulatory (Vif, Vpr, Vpu, Tat, Rev and Nef) 
proteins (Trono,  1995). The first generation HIV vector kept all elements and lacked 
packaging signal and env but in the second generation vectors, developed to be safer, 
more  elements;  Vif,  Vpr,  Vpu,  and  Nef were  deleted  in  the  packaging  construct 
(Luciw, 1999). However, the second generation vectors kept cis-active elements in the 
transfer  construct  vector  and  rev-responsive  element  (RRE)  and  tat  in  packaging 
vector  construct  (Zufferey  et  al,  1997).  It  has  been  shown  that  the  rev  protein  is 
strictly required for efficient viral production and with tat it is necessary for stable 
viral transcription (Emerman et al,  1989). However, further improvements to generate 
safer lentiviral vectors have been achieved by third generation based self-inactivating 
HIV1  virus  (Miyoshi  et  al,  1998;  Bai  et  al,  2003).  SIN  vectors  are  obtained  by 
deleting all genes unnecessary for viral replication from 3’ LTR of the transfer vector, 
corresponding to most of the U3  in  3’  LTR.  In other word,  SIN vectors  lack  any 
LTR-driven transcription activity in target cells  and no  significant decreases  in the 
viral titers were observed. In viruses generated from SIN transfer vectors, inactivation 
of 5’  LTR prevents promoter interference  with  only external  promoter  such  CMV 
located downstream of 5’  LTR (Kim et al,  1998). To enhance the efficiency of SIN 
lentivirus vectors in our lab the SIN transfer vector has been modified by addition of a 
central polypurine tract (cPPT) and termination sequence upstream of external SFFV 
promoter  and  also  insertion  of  the  Woodchuck  hepatitis  virus  post-transcription 
regulatory element (WPRE) in the 3’ untranslated region (Demaison et al, 2002). The 
cPPT  and  termination  sequence  in  this  lentiviral  vector  facilitates  reverse 
transcription, nuclear entry, transduction and also gene expression (Dardalhon et al, 
2001; Manganini et al,  2002). It seems gene expression by this vector is boosted due
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to addition of the WPRE and cPPT elements (Demaison et al,  2002).  Efficiency of 
this vector particularly in non-dividing cells and haematopoietic cells, may make it a 
very useful tool for gene delivery into T cells.
1.13  Project plan
The project had developed in regard to study cellular pathogenesis of the XLP. 
The aims of this study were refined based on the study results and the data published 
in  the  literature.  The  main  target  was  to  use  an  in  vitro  model  to  confirm  and 
investigate the cellular functionality of XLP cytotoxic T cells. Therefore to develop 
an in vitro model for this study we were able to achieve following aims:
1) The generation of retroviral and lentiviral vectors for the transfer of SAP 
gene into XLP T cells.
2) Developing transduction protocols for gene transfer into EBV-T cells using 
retroviral and lentiviral vectors.
3) Generating EBV-T cell  lines  from XLP patients and normal controls and 
reconstitution of cell lines with retroviral vector encoding SAP from both groups
4) Immunophenotyping of EBV-T cell lines and immune cell lineages
5) Assessment that the function of immune cells in XLP is SAP dependent for 
cytokine production and cytotoxicity.
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2.1 Reagents and buffers
All general chemicals were supplied by Sigma unless otherwise stated.
2.1.1
Bis-tris
Reagents
Bovine Serum Albumin (BSA) 
Dimethyl Sulfoxide (DMSO) 
Ethylenediamineteraacetic acid (EDTA) 
Ethidium bromide 
Paraformaldyde (PFA)
Phosphate Buffered Saline (PBS)
NaOH
Sucrose
Tryptone peptone 
Yeast extract 
Bacto tryptone 
Phytohaemaglutinin (PHA)
Phorbol 12-myristate 13-acetate (PMA) 
Ficoll-Paque Plus 
Cyclosporin (CSA)
Acyclovir
Primers
(New England Biolabs)
(Gibco)
(Difco)
(Difco)
(Difco)
(Pharmacia Biotech)
(Sandoz pharmaceuticals, UK) 
(Faulding  Pharmaceutical  Pic, 
UK)
(Sigma Genosys Ltd)
HyperLadder I lkb
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Agarose
Taq DNA polymerase, dNTPs buffer
Resriction enzymes
Shrimp alkaline phosphtase
T4 DNA Ligase, buffer
Dulbecco’s modified Eagle medium (DMEM)
RPMI1640
Fetal calf serum (FCS)
Glutameax
Trypsin/EDTA solution 
L-glutamine 
Penicillin-Streptomycin 
X-Vivo10
Recombinant  Retronectin
Recombinant IL-2 
Emeryville, CA)
ElectroMAX DH10B Cells
(Gibco BRL)
(Qiagen)
(Promega)
(Promega)
(GibcoBRL)
(GibcoBRL)
(Myoclone Superplus) 
(GibcoBRL)
(Gibco BRL)
(Gibco BRL)
(Gibco BRL)
(Bipwhittaker)
(Takara  Biomedicals,  Shiga, 
Japan)
(Proleukin,  Chiron,
(Gibco BRL)
2.1.2  Buffers
4% PFA/3% (w/v) Glucose: 4g of PFA was weighted out in a fume cupboard 
and added to PBS warmed to 60°C. Concentrated NaOH was added to aid dissolution. 
3g sucrose was added and the solution was made to pH 7.4 using concentrated HC1 
and to 100 ml with PBS. Stocks were divided into 5 ml aliquots and frozen for use.
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1%  (w/v) PFA: 4% PFA was made as above and diluted with PBS to make 
1% PFA.
1% (w/v) BSA:  lg bovine serum albumin (BSA) dissolved in 100 ml PBS.
1M Tris-HCl pH 8.0: 60.7 g Tris and 400 ml dH20, stirred to dissolve. Once 
dissolved concentrated HC1 was to achieve a pH of 8.0 and the solution was made up 
to 500ml with dH20.
TAE (x50): 0.2M Tris, 1M glacial acetic acid (BDH), EDTA, pH 8.0
L-Broth:  lOg Tryptone peptone (Difco), 5g yeast extract (Difco), lOg NaCl in 
500ml water.
CSA: For stock:  10 mg powder added to  10 ml absolute alcohol and filtered 
through  0.2  pm  filter.  To  make  working  solution:  (lOOpg/ml),  1ml  of stock  CSA 
added to 9ml RPMI and filtered through 0.2 pm filter.
Acyclovir:  Making  lOOpM  of  Acyclovir  in  RPMI  (The  molarity  of
Acyclovir is 1.1 M and molecular weight is 225g).
Western Blotting buffers:
PBS-Tween (PBS-T): 500ml PBS, 500 pL Tween-20.
2.5% milk-PBS-T (w/v): 1.25 g milk (Marvel), 50ml PBS-T
Stacking gel buffer: 30.35 g Tris was dissolved in 400 ml (IH2O and the pH 
was corrected to 6.8 with HC1. 2.5 ml 20% sodium dodecyl sulphate (SDS) was added 
and the solution was made up to 500ml with dH20.
Main gel buffer:  91.06g Tris was dissolved in 400ml dH20 and the pH  8.0 
with HCL.  2.5ml  20%  SDS  was  added  and the  solution was made up to  500ml  in 
dH20.
Running buffer: 3g Tris and  14.4 glycine were dissolved in 997.5 ml (IH2O. 
2.5ml 20% SDS was added and mixed.
84Chapter 2 Materials and Methods
Transfer buffer: AlOx stock was made by dissolving 29. lg Tris and  14.65g 
glycine in 450ml (IH2O.  The pH was corrected to 9.2, the solution was made up to 
500ml with dH20, and filter sterilized for storage.  10ml of the lOx stock were added 
to 70ml dH20 and 20ml methanol immediately before use.
NP40 lysis buffer:  1% (v/v) NP40 (Calbiochem), 20mM Tris-HCL pH 8.0, 
130mM  NaCL,  lOmM  NaF,  ImM  diothiotheitrol  (DTT),  20pM  leupeptin,  1% 
aprotinin, lOOpM Na3VC>4, ImM phenylmethylsulfonylfluoride (PMSF). The solution 
was filter sterilized before use.
2x SDS buffer: 75g Tris, 0.5mg bromphenol blue, 10ml glycerol, 20ml dH20 
and 5ml 20% SDS were mixed. The solution was corrected to pH 6.8 with HC1, made 
up to 50ml with (IH2O and filter sterilized before use.
SDS sample buffer:  3ml 2x SDS buffer, 60 pi p-mercaptoethanol.
2.1.3 Kits
Plasmid miniprep/maxiprep/megaprep kit (Qiagen)
ELISPOT Kit (Biosource)
CytoTox 96 (Non-Radioactive Cytotoxicity assay) (Promega)
2.1.4 Equipment
0.4 cm glass cuvette (Biorad)
Gene Pulser Electroporator (Biorad)
Qiaex gel extraction kit (Qiagen)
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Table 2.1 List of Antibodies that were used in this study 
labelled Antibodies
A stib o & y Label Species Isotype Company Use
pe, fit c, per Mouse IgGl Pharminogen F.C
AmMnoBCD4 PE, FITC, APC Mouse IgGl Pharminogen F.C
AHd-tame CDS PE, FITC, APC Mouse IgGl Pharminogen F.C
A li hnnwaCDllC PE Mouse IgG2b Pharminogen F.C
A nfrhuB iC P t4 PE Mouse IgG2a Bectoo Dickinson F.C
Am' b urnt CP16 FITC Mouse IgGl Pharminogen F.C
A*M amnCD19 FITC Mouse IgGl Pharminogen F.C
As&bnnNnCD25 PE Mouse IgGl Pharminogen F.C
AmMm CHO CD27 PE Mouse IgG2a Becton Dickinson F.C
AM M nmiCD2S PE, FITC Mouse IgGl Pharminogen F.C
A a^hm nC M SK A PE, FITC Mouse IgGl Pharminogen F.C
Anti-humt CD45RO PE, FITC Mouse IgGl Pharminogen F.C
Anti-human CD56 PE, APC Mouse IgGl Pharminogen F.C
Anti-human CD69 PE Mouse IgG2 Pharminogen F.C
Anti-human CD95 PE Mouse IgGl Pharminogen F.C
(F»)
M ta in C S lS O PE Mouse IgGl Pharminogen F.C
(SLAM)
Anti-human CD224 FITC, CY Mouse IgGi Pharminogen F.C
(2B4)
^tMnaaCGl5 PE Mouse IgG2b R&D Systems F.C
Anti-bumanCCL5 FITC Mouse IgG2 Pharminogen F.C
Anti-human OCR7 FITC Mouse IgGl R&D Systems F.C
Anti-human O0TCR |  FITC Mouse IgGl Dako F.C
Anti-human yBTCR PE Mouse IgGl Dako F.C
LNGFR PE Mouse IgGl Dako F.C
Anti-Rabbit I  HRP Goat Poly Sigma Western Blot
Abbreviations: F.C; Flow Cytometry
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Cont. Table 2.1 List of Antibodies that were used in this study 
Purified Antibodies
Antibody Purified Species Isotype Company Use
Aati-hirr— CD3 Purified Jsnssen-CHag Cell Activation
Anti-boom CD28 Purified Mouse IgGl Becton Dickinson Cell Activation
Anti human CD150 Purified Mouse IgGl BDPhaxMinogen Cell Activation
Anti-fcuiniaCD224 Purified Mouse IgG2 Immunotech- Cell Activation
Couher
Anti-SAP Purified Rabbit Cell Activation
AatM»mn OPN^y Purified Mouse IgGl MabtechAB ELISPOT
Antibumni OL-5 Purified Mouse IgGl Mabtech AB ELISPOT
AnHtonw IL-10 Purified Mouse IgGl Biosource ELISPOT
2 .2 Cloning
2.2.1  Plasmids
pGEM-T  containing human  SAP  cDNA:  Human  SAP  (SH2D1A)  cDNA 
(OMIM no:  AL023657) cloned into pGEM-T (Promega, Madison, USA) was a gift 
from Dr. Alison Coffey (The Sanger Center, Cambridge, UK).
pBS  (plasmid Bluescript):  contains the internal ribosomal  entry sequences 
(IRES)  from  Encephalomycarditis  virus  and  red  shifted  variant  of  the  green 
fluorescent protein (eGFP) or LNGFR.
SFFVp  retroviral  backbone  vector:  A  murine  replication  deficient 
oncoretroviral vector containing the U3  modified 3'  LTR from  SFFV,  5'LTR from 
PCMV (PCC4 cell passaged murine sarcoma virus) and PBS (Primer binding site) (a 
gift from Dr K Parsley, ICH).
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SIN HIVI backbone vector:  A HIV1 self inactivated (SIN) based vector was 
used which takes advantage of the U3 part of the spleen focus forming virus (SFFV) 
strain  P  long  terminal  repeat  sequence  (SFFV-U3LTR),  upstream  of  the  central 
polypurine tract cis-active sequence (cPPT) and central termination sequence (CTS) 
and also the non-translated Woodchuck hepatitis virus posttranscriptional regulatory 
element (WPRE) sequence down stream of 3’LTR of vector backbone. 
pMD.G. plasmid:  encoding VSV-G envelope protein
pCMVR8.91  packaging  plasmid:  providing  (gag-pol,  cPPT,  Rev,  and  tat 
elements.
2.2.2  Conventional gel electrophresis
DNA  fragments were  resolved by electrophoresis  through  1%  agarose  gels. 
Agarose was dissolved in  lx TAE buffer by boiling it in a microwave. The gel was 
allowed to cool to 60°C before ethidium bromide was added at 0.5pg/ml and the gel 
poured into a gel former with a comb fitted.  The gel was then immersed in  lxTAE 
buffer and liquid samples of DNA mixed with loading buffer (bromophenol blue in 
0.1  M EDTA,  20% Ficoll) were loaded into the wells.  DNA standard size markers 
were also run to enable accurate size determination of DNA fragments. The gel was 
then subjected to a voltage of 50-100V (up to  150mA) and the DNA was visualised 
by exposing it to ultra violet light.
2.2.3  Restriction endonuclease digestion of DNA
DNA (generally 0.2-2 pg) was cut in a 20 pi final volume of 1   x buffer (10 x 
supplied by manufacturer and diluted in sterile water). The amount of enzyme used 
varied depending of the concentration of the enzyme stock and the amount of DNA,
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but never exceeded 10% (v/v) of the total reaction volume. The endonuclease reaction 
was  carried  out  at the  manufacturer’s  recommended temperature  for  1-2  hours  the 
reaction  parameters  were  altered  accordingly.  If a  double  digest  was  required,  in 
which  the  two  enzymes  were  active  in  incompatible  buffers,  the  DNA  was  first 
digested  with  one  enzyme,  and  then  the  cut  DNA  cleaned  by PCR  DNA  Kit  and 
resuspended in the buffer compatible with the second enzyme.
2.2.4  Dephosphorylation of vector ends
In cases in which a digested vector had compatible termini,  the ends of the 
linear  molecule  were  dephosphorylated  to  prevent  vector  self-re-ligation.  Shrimp 
alkaline  phosphatase  (SAPh)  is  a  phosphomonoesterase  purified  from  shrimp 
intestinal mucosa that hydrolises  5’-phosphate  groups  in DNA  and was  used in all 
reactions. The enzymes was supplied as a 26 U/d_ 1  stock and was diluted in lx SAPh 
dilution buffer such that after dilution it contributed no more than  1/10th of the final 
restriction volume. The enzyme was generally added to restriction enzyme digests that 
had  been  inactivated,  by  heating  or  a  phenol/chloroform  extraction,  prior  to  gel 
purification and therefore did not require additional dephosphorylation buffer.
Dephosphorylation of 1   pmol of DNA 5’-protruding ends requires 0.01  U of 
SAPh  at  37  °C  for  30  minutes,  whilst  1  pmol  of DNA  5’-recessed  or blunt  ends 
required 1  U at 50 °C for 1  hour. If the reaction is allowed to proceed for too long, the 
SAPh damage the strand termini so the enzyme was inactivated by heating to 70 °C 
for 10 minutes, followed by a gel extraction.
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2.2.5 Ligation
The amount of DNA added to  ligation reactions varied depending upon the 
nature of the reaction. In general however, the ratio of vector: insert ranged from 1:1 
to 1:3. Ligations were carried out in a total volume of 10 /d. A 1:10 dilution of the T4 
DNA  ligase  enzyme  was  prepared  in  lx  ligase buffer  and  the  DNA,  dfLO,  ligase 
buffer  and  1   fi\  (lu)  of the  diluted  enzyme  were  mixed  together.  Ligations  were 
carried  out  16  °C  for  16  hours  or  37  °C  for  2  hours.  The  ligation  were  used  to 
transform competent bacteria immediately, or were stored at -20 °C for later use.
2.2.6  Ethanol precipitation
This  procedure  was  used  to  remove  salts  from  DNA  solutions  or  to 
concentrate DNA by precipitating it from solution. The volume of DNA solution was 
estimated and one-tenth the volume of 3 M sodium acetate (pH5.2) and two times the 
volume of 100% ethanol were added. The solution was mixed by inversion and placed 
at  -80°C  for  15  minutes  to  precipitate  the  DNA  that  was  then  pelleted  by 
centrifugation at 17,000 xg for 30 min at 4°C. The supernatant was then discarded and 
the pellet washed in 70% ethanol, with centrifugation for 10 min under the previous 
conditions.  The  ethanol  was  removed  and  the  pellet  was  briefly  air  dried  and 
resuspended in an appropriate volume of 10 mM Tris-HCI pH 8.0. Plasmid DNA was 
stored at -20°C.
Purification of DNA fragments from agarose using silica particles. Following 
electrophoresis of the DNA in an agarose gel the required band was excised using a 
clean scalpel blade under low intensity long-wave ultraviolet (UV)  light in order to
2.2.7 Gel purification of DNA
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minimise DNA degradation. Then DNA was extracted from the agarose using Qiaex 
II or QLAquick kits (Qiagen). Wash steps were performed under high salt conditions 
to eliminate the agarose and subsequently in an ethanol-based solution to  eliminate 
residual salt and dyes. The DNA was eluted from the silica gel particles/column under 
low salt conditions with TE or Tris buffer. The procedure was carried out according to 
the manufacturer’s instructions and the DNA eluted in a total volume of 30 pi TE pH
8.0  or 10 mM Tris-HCI pH 8.0.
2.2.8  Polymerase chain reaction (PCR)
PCR DNA amplification was generally performed in a total volume of 10 pi 
containing lOOng of DNA, each primer at 0.5 pM, dNTPs each at 200 pM, 2.5 U Taq 
polymerase  and  the  appropriate  buffer  (Qiagen).  The  appropriate  buffer  for  each 
primer pair was  defined by titration  of the concentration of MgCh  in the  supplied 
buffer. The cycle conditions were optimised.
Primers were designed with two Sal I sites (sequences shown with underline) 
within the forward and reverse primers (Sigma):
SAP-F: GCC CAA GAGTCGACCAGG CCA TGG
SAP-R: GTA CAA GGT GTT TTAGTC GAC TTC ATG GGG GCT TTC
A PCR reaction was prepared in total volume of 50 pi and the PCR cycle was 
set up as below:
1) 94 °C for 2min/l cycle
2) 50 °C for lmin and 72°C for 1  min and 94°C for lmin/5 cycles
3) 60°C for 1  min and 72°C for 1  min and 94°C for 1 min/30 cycles
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2.2.9  Transformation of plasmid DNA by electroporation
E  coli  DH5a  electrocompetent  cells  were  used  to  transform plasmid  DNA. 
Cells were stored in  10% glycerol in 50pl aliquots at 70°C. Ligation mix or plasmid 
preparation was dialysed on  10mm filter paper floating on dF^O for 20-25 minutes. 
10pl of the preparation was added to an aliquot of DH5a on ice in a 0.4 cm glass 
cuvette.  The  sample  was  immediately  electroporated  (Voltage  2.5kV,  Resistance 
200Q;  Capacitance 25pF) using a Gene Pulser.  The cells were then resuspended in 
940pl of LB medium and incubated in a shaking incubator at 37°C  for 60 minutes, 
after which they were plated onto LB-Ampicillin agar plates. Plates were incubated 
overnight at 37°C and colonies picked using sterile pipette tips, and used to inoculate 
3-5ml LB-Ampicillin cultures.
2.3  Tissue Culture
2.3.1  Peripheral blood mononuclear cells prep
Whole blood anticoagulated with EDTA was diluted  1:1  in Dulbecco’s PBS, 
layered over lymphoprep (Nycomed) and spun for 25 minutes at 2400 rpm (750g), no 
brake. Peripheral blood mononuclear (PBMCs) were collected from the interface and 
washed in HBSS at 1200 rpm (250g) x  10 minutes. A further 2 washes were carried 
out at 1100 rpm (150g) for 5 minutes to reduce platelet contamination. PBMCs were 
used for further experiments where used to generate different cell lines or were frozen 
according to instruction to be used in future work.
92Chapter 2  Materials and Methods
2.3.2  Cell counting
Cells  were  counted  using  a  Naubauer  haemocytometer  by  Trypan  blue 
exclusion and phase contrast microscopy.
2.3.3  Cell cryopreservation and thawing
A cryopreservation solution of 90% FCS and  10% DMSO was used for cells 
other than primary T  cells,  for which  human  AB  serum  was  used.  Cells  were  re­
suspended in DMEM or RPMI, cooled on ice and equal volume of cryopreservation 
solution  added  dropwise.  Aliquots  were  then  frozen  at  -70°C  using  a  cooling 
chamber, before transfer to liquid nitrogen.
Table 2.2 List of cell lines and suppliers
C ell L ine O rigin S upplier M edium
B95-8 EBV carrying marmoset ECACC, Salisbury, UK RPMI
HeLa Human cervical 
carcinoma
ECACC, Salisbury, UK DMEM
PG13 NIH 3T3 mouse fibroblast Gift from Pro. Collins, 
UCL. London, UK
DMEM
Phoenix 293T human embryonic 
kidney
Nolan Laboratories, 
Stanford, USA
DMEM
293T 293T human embryonic 
kidney
ECACC, Salisbury, UK DMEM
ECACC: European collection of cell culture, NIH: National Institute of Health, 
UCL: University College London
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Thawing of frozen cells was carried out by immediately placing cryovials in a 37°C 
water bath.  The  cells  were  transferred  slowly to  10 ml  of appropriate pre-warmed 
growth medium and pelleted by centrifugation. They were then resuspended in  1   ml 
of growth media and transferred to 4 ml of pre-warmed medium in a 25cm2 tissue 
culture flask.
2.3.4  DC preparation
PBMCs were resuspended in complete medium and plated at 3-6x106 cells per 
ml in 6 well tissue culture plates (Falcon). After 2 hours incubation at 37°C /5%Co2, 
non-adherent  cells  were  gently  washed  off.  The  adherent  fraction  was  cultured  in 
complete  medium  with  lOOng/ml,  recombinant  human  granulocyte-macrophage 
colony-stimulating  factor  (GM-CSF)  (Leucomax,  Sandoz/Schering  Plough)  and 
25ng/ml  recombinant  interleukin-4  (IL-4)  (gift  from  Dr  S.Bums,  ICH).  Cytokines 
were refreshed on day 3 or 4 of culture.
2.3.4.1  Harvest of DC
On  day  6-7  non-adherent,  immature  DC  were  removed,  layered  over 
Lymphoprep and spun at  1600rpm (400g)  for 25  minutes, brake off  Cells from the 
interface  were  washed  twice  in  HBSS  AT  1200rpm  (250g)  for  10  and  5  minutes, 
respectively. DC were purified to approximately 90% by immunodepletion using CD3 
and CD 19 Dynabeads (Dynal) to extract T and B lymphocytes.  DC and beads were 
incubated on a rotator at 4°C for 20-30 minutes before magnetic removal of beads.
Mature DCs were harvested on day 7 or 8 after 24hr incubation with LPS by 
the same method. Mature cells from large loosely adherent clumps were washed into 
suspension in the well for collection.
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2.3.4.2  Maturation of DC
Immature DC were matured by addition of 50ng/ml LPS (from E. coli 026.B6, 
Sigma) on day 6 of culture for a total of 24 hours.
2.3.5  Generation and culture LAK cell lines
Non-adherent PBMCs were plated at 2 xl06/ml in six-well tissue culture plates 
in complete RPMI 16 medium with 1000 IU/ml recombinant human (rIL-2) incubated 
at 37°C/5%  CO2.  The  supernatant  (non-adherent cells  and media)  was removed on 
day 3 and replaced with 2 ml of media and 500 IU/ml of rIL-2. Every 3 days, for 12 
days, media replaced accordingly. On day 14, adherent cells were harvested for use in 
the designed assays.
2.3.6  Preparation of concentrated EBV from B95-8 cell line 
culture
The B95-8 cell line was cultured in complete RPMI medium. The volume was 
expanded to  1000ml during two weeks according to the cells growth. The vented cap 
of flasks containing cell lines were sealed with parafilm for 7-10 days to let viruses go 
into  lytic  phase.  The  cell  culture was  centrifuged  at  2000rpm  for  10 minutes.  The 
supernatant was filtered into 0.8 p filter. The suspension was transferred into sterile 
Beckman  tubes  and  centrifuged  at  16,000rpm  for 2  hours  at  4°C.The  supernatants 
were removed gently and pellet resuspended in RPMI medium and aliquoted  100 pi 
per cryovial and stored at-70°C
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2.3.7  Generating  EBV-BLCLs  from  XLP  patients  and 
normal individuals
EBV-BLCL lines were produced by mixing 2xl06 PBMCs with  100-200  pi 
concentrated B95-8 virus and lOpl Cyclosporin A (CSA) in 1ml complete RPMI 20% 
medium.  The  PBMCs  were  incubated  at  37°C  for  1   hour then  were  diluted  (final 
concentration lxlO6 cells/ml) and dispensed in 48 well plates. They were fed weekly 
with completed RPMI and after two weeks were treated with acyclovir 100 pM twice 
per week. After 4weeks, the generated EBV-BLCL lines were transfered to 25ml flask 
and kept in RPMI 10% FCS (lxlO6 cells per ml) at 37°C incubator for further use.
2.3.8  Generation and culture of EBV-T cell lines
EBV  transformed  LCLs  were  generated  from  normal  donors  and  EBV 
seropositive XLP patients  (PI  and P2)  standard techniques.  EBV-T  cell  lines were 
generated by  stimulating  1   x  106/mL  PBMCs  cells  with  2.5  x  104/mL  autologous 
LCLs (40/1  cell ratio) using standard culture conditions. Cells were restimulated and 
re-cultured at a concentration of 1   x  106/mL as described in Chapter 4.  Cells were 
either prepared for gene transfer or kept in culture with re-stimulations weekly at an 
effectoritarget ratio of 4:1.  A total of 20 IU of IL-2 was added to the cultures for the 
first time at day 10 and twice weekly thereafter. All cell lines were cultured for up to 
8-10  weeks.  EBV-T  cell  lines  with  mainly  a  CD4+  phenotype  were  produced  by 
stimulation  with  PHA  (5  ng/ml)  and  IL-2  (20  IU/ml)  as  described  in  Chapter  4 
continued in the same conditions as described above.
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2.4  Generation of viral supernatant
Retroviral  vector  supernatants  were  generated  using  Phoenix  ecotropic  and 
PG13  amphotropic  packaging  cell  lines.  Single  cell  sorting  by  FACS  (Beckman 
Coulter  EPICS)  into  96  well  plates  was  used  to  select  clones  with  high  virus 
production. In the case of lentiviral vector supernatants, the virus was generated by a 
co-transfection  system  (using  293T  cell  line).  The  viral  titre  was  measured  by 
measuring the efficiency of transduction of HeLa cells by single exposure to a range 
of virus dilutions for 48 hours.
2.5  Gene transfer
Stimulated EBV T cells with different protocols (Protocol No  1-3, see Table 
4.1) were washed with Xvivo  10 and counted by staining and lxlO6 cells in XvivolO 
cultured for two hours at 37 C, 5% CO2.  In cases using retronectin, non tissue culture 
24 well plates were coated with  15  /d retronectin (lmg/ml) in  185  /d PBS per well 
(total volume 200 /d) overnight at 4°C or at least for two hours at room temperature. 
Then  plate  was  blocked  with  1%  human  serum  albumin  for  1  hour  at  room 
temperature and washed with PBS.  Coated plates were preloaded with at least  100- 
200 /d per well retrovirus supernatant or in case of lentivirus with  10-20 /d diluted 
with Xvivo  10 per well (to reach 200 /d total volume) and centrifuged at 2000 rpm 
(550g)  for  20  mins.  Cultured  cells  were  replated  into  coated  plates  in  Xvivo  10 
medium  at  present  rIL-2  and  virus  in  Xvivo  10  used  at  different  MOI  ratio  to 
transduce  cells.  When  using  polybrene,  cells  were  cultured  in  Xvivo  10  in  the 
presence  of polybrene  at  4  /zg/ml  and rIL-2  for  3-4  hours before  transduction  and 
virus  supernatant was then added.  In all  experiments,  cells were cultured at a final 
concentration of lxlO6 cells/ml.  Then cells were centrifuged at  1500 rpm (350g) at
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room temperature for 30 min and incubated at 37C, 5% CO2 overnight.  The next day 
half the medium  was  replaced with  fresh Xvivo  10  and  additional  rIL-2.  After 48 
hours of the first round of transduction, the second round infection was carried out 
with  the  addition  of viral  supernatant.  On  the  fourth  day,  cells  were  stained  and 
analyzed  for  CD3,  CD4,  CD8,  eGFP  expression  with  flow  cytometry  or  cultured 
further to generate EBV specific CTL clones.
2.6  LDH release cytotoxic assay
The cytoxicity of EBV-T cell lines was measured using LDH release assays 
(Promega). Briefly, autologous LCLs were used as target cells with EBV-T cell lines 
as  effector  cells  at  different  effector:target  cell  ratios.  All  targets  were  plated  in 
triplicate.  After  4h  incubation,  supernatants  were  harvested  and  the  specific 
cytotoxicity determined using a microplate ELISA reader (Dynatech). The percentage 
of specific  lysis  was  calculated  as  100%  *  (experimental  release  [-]  spontaneous 
release)/(maximum release  [-] spontaneous release). Maximum release was obtained 
by adding 100 pi of 5% Triton X-100 to the  100 pL medium containing target cells. 
Spontaneous release was consistently below  15% of maximum release in all assays. 
Ideally  a  specificity  control  should  be  have  done  using  autologous  PHA  blast  to 
measure probability of cytotoxic activity of EBV- T cell lines against self-antigens. 
This has not been done completely due the shortage of patient blood’s samples (data 
on some lines not shown in this thesis).
2.7  Antibody stimulation
For antibody stimulation of PBMCs and EBV-T cell lines, all antibodies (CD3 
or OKT3, CD28, a-SLAM, 2B4) used at concentrations of 5pg/ml (as soluble) or  1
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pg/ml  (pre-coated  non-tissue  culture  plates).  The  stimulated  cells  were  used  for 
ELISPOT assay or for SLAM-2B4 expression studies.
2.8  MHC class I blocking of target cells
W6/32 monoclonal antibody (a gift from Dr Bin Gao, ICH) was used to block 
MHC class I antigen presentation on LCLs. Cells were washed twice with PBS and 
then incubated with W6/32 mAb (1 /-ig/ml) on ice for 1 h. The cells were then washed 
and used in cytotoxicity assays.
2.9  ELISPOT assay
PBMCs and EBV-T cell lines were plated at 1   x  104/well for IFN-y detection
assay  and  lx  105   /well  for  IL-5  and  IL-10  detection  assays.  Responder  cell 
populations  were  seeded  across  a  range  of concentrations  to  achieve  10  to  100 
spots/well so as to facilitate accurate and reproducible counting. For LCL stimulators 
with  PBMC  responders,  the  concentration  used  was  5  x  103   LCLs  to  2  x  104 
PBMC/well; stimulators with EBV-T cell line responders, this was 5  *  103  LCLs to 2 
x  104 EBV-T cell lines/well.  For antibody stimulation of PBMCs and EBV-T cell 
lines,  all  antibody  concentrations  used  in  the  ELISPOT  assay  were  optimized  at 
5pg/ml  (CD3  or OKT3,  CD28,  a-SLAM,  2B4  and as a positive control PBMC  or 
EBV-T  cell  lines  stimulated  with  2.5  pg/ml  PMA,  or  Ags  (gift  from  Dr  L. 
Weddelouin, ICH), or LPS and 1  pg/ml ionomycin (Sigma). All cells were cultured in 
RPMI-FCS  10% supplemented to a final volume of 200 pL/well. After undisturbed 
incubation for 24 to 48 h at 37°C, with 5% CO2, plates were washed 4 times with PBS 
containing  0.05%  Tween  20  (PBS/0.05%  Tw).  Wells  were  incubated  with 
biotinylated  ‘detection’  antibody  against  IFN-y,  IL-5  or  IL-10.  The  plates  were
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washed  6  x  with  PBS/0.05%  Tw.  100  pi  of Avidin-Peroxidase-Complex  (AEC; 
prepared  according to  manufacturer’s  instructions;  Vector Laboratories)  was  added 
per well  for  1   h at room temperature. The plates were washed 3  x with PBS/0.05% 
Tw,  followed by 3  washes  with  PBS.  AEC  substrate  (Sigma,  St.  Louis,  MO)  was 
prepared  according  to  manufacturer’s  instructions  and  filtered  through  a  0.45  pM 
filter  prior  to  use.  100  pi  was  added  per  well.  After  4  minutes  the  reaction  was 
stopped with deionized water and the plates dried overnight prior membrane removal. 
The spot number was determined in an independent blinded fashion (Bioreader 3000; 
Bio-Sys). In each experiment, the result was expressed as spots/1000 cells (for IFN-y) 
or spots/10000 (for IL-5 and IL-10) and the results of three experiments were used to 
calculate means and standard deviations.
2.10  SAP immunoblotting
Cell  lines  from  patients  and  healthy  donors  used  to  produce  cell  lysates 
according  to  previous  protocols.  Briefly  cells  were  pelleted  by  centrifugation  x  5 
minutes at 2000 rpm (550g) in Eppendorf tubes, washed with PBS to remove medium 
and repelleted. Approximately lOOpl NP40 lysis buffer was added, on ice for every 1  
x  106 cells. After  10 minutes debris was pelleted by centrifugation for 5  minutes at
14,000  rpm, 4°C and supernatant was transferred to a fresh tube. To  lOOpl of lysate, 
100pl SDS sample buffer was added and the sample was then stored at -20°C.
2.10.1  Gel preparation
Glass  gel  plates  were  cleaned with  70%  ethanol,  dried  and assembled.  In a 
uinversal tube, 6ml 30% (w/v) acrylamide (Protogel from National Diagnostics), 5ml 
main gel buffer, 8.8ml water, 20pl tetramethylenediamine (TEMED) and 200jil 10%
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(w/v) ammonium persulphate (APS) were added together to make a 10% gel. The gel 
was poured into the assembled gel plates and overlaid with water. Once polymerized, 
the water was poured off.  A 4%  stacking gel was made by adding together  1.3  ml 
30%  acrylamide,  2.5ml  stacking  gel  buffer,  6.1ml water,  lOjul  TEMED  and  lOOpl 
10% APS and was poured on top of the main gel.  Combs were inserted and the gel 
was left to polymerase.  Once polymerized,  the gel  assembly was placed  into  a gel 
tank with approximately 500ml of running buffer in the top chamber and 500ml of 
running  buffer  into  the  bottom  chamber.  Cell  lysates  were  heated  to  100°C  for  3 
minutes,  spun  briefly  at  13,000  rpm  in  a  microcentrifuge  and  loaded  to  the  gel. 
Recombinant protein molecular weight markers (Amersham) were also loaded to the 
gel. The gel was run at between 100-200V.
2.10.2  Gel transfer
A sheet of nitrocellulose (MSI) and six pieces of Whatmann 3MM paper of a 
similar  size  to  the  gel  being transferred  were  soaked  in transfer buffer.  A transfer 
stack  was  assembled  as  follows:  3  pieces  Whatmann,  gel,  nitrocellulose,  3  pieces 
Whatmann. Air bubbles between layers were removed by rolling a pipette carefully 
on the stack. The gel was transferred using a semi-dry blotter (Biorad) at 12V for 20- 
30 minutes before the stack was dismantled and the membrane was either placed in 
2.5% milk-PBS-T for immunostaining or stored at 4°C wrapped in Saran Wrap.
2.10.3  Immunoblotting
The  membrane  was  blocked  in  1%  milk-PBS-T  for  1   hour  at  room 
temperature  and  then  incubated  for  2  hours  at  room  temperature  with  anti-SAP 
antibody generated against the C-terminal end of SAP protein at a final concentration
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of 1:1000. The membrane was washed with PBS-T and incubated with a horseradish 
peroxidase-conjugated  anti-rabbit  antibody  (Sigma)  for  30-45  minutes.  After  a 
further  5  washes  in  PBS-T  an  enhanced  chemiluminescence  (ECL;  Amersham 
Biosciences) was applied for 1 minute for detection. In the dark room film was placed 
in the cassette and exposed to the blot for 30 seconds. A longer or shorter exposure 
was occasionally required.
2.11  Flow cytometric analysis and FACS
To  prepare  samples  for  analysis,  a minimum  of 2xl04 cells/tube  in  a  small 
volume (<100pl) and appropriate amounts of antibody (see Table 2.1) were added to 
FACS tubes on ice and incubated in the dark for 15-30 minutes. Cells were washed 
with PBS, before cenrifugation at 1500 rpm (300g) for 5 minutes at 4°C. Supernatants 
were flicked off and pellets resuspended in 200pi  1% PFA.  Samples were stored at 
4°C in the dark till flow cytometric analysis. Flow cytometry of EBV-T cell lines was 
performed using an EPICS XL flow cytometer (Beckman Coulter, High Wycombe, 
UK)
Gene-modified  EBV-T  cell  lines  were  purified  using  an  EPICS  Altra 
fluorescence activated cell sorter (FACS) (Beckman Coulter, High Wycombe, UK). 
Cells were  stained with phycoerythrin (PE)  conjugated CD3  (BD Pharmingen,  San 
Diego, CA) and analyzed for PE-CD3 and eGFP expression. Dual-color positive cells 
(positive fraction) and single-color CD3 cells (negative fraction) were sorted to high 
purity (more than 99%).  One unsorted fraction was retained. The three cell fractions 
were subsequently used separately for cytotoxicity assays.
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2.12  Statistical analysis
The T test was used for statistical analysis, unless otherwise stated.
2.13  Ethical approved, consenting and materials of normal 
individuals and XLP patients
The  Institutional  Research  Ethics  Committee  approved  this  study  and 
informed written consent was obtained from all subjects before taking blood.  Anti­
coagulated whole blood was derived from three healthy donors (C) who were EBV 
seropositive and three XLP patients (PI, P2 and P3) for this study. The three patients 
were all from different kindreds and each had a different mutation in the SAP gene, 
which led to the absence of SAP expression (see Chapter 5, Table5.1).
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3.1  Introduction
Gene therapy was initially developed as a replacement strategy for treatment 
of monogenic diseases.  It is a new area in biology that has taken feasible advantages 
from  genomic  techniques,  particularly  in  developing  sophisticated  vectors  to 
introduce a transgene into the new host. Vector construction involves the generation 
of  a  plasmid  that  contains  all  of  the  elements  necessary  for  the  expression  of 
interested genes. Viral vectors are the most common vectors in the gene therapy field. 
They are genetically engineered to incorporate the transgene with the aim of selective 
expression in the target cell following transfection.
To  study  the  feasibility  of gene  therapy  for  XLP,  retroviral  and  lentiviral 
backbone vectors (discussed in Chapter 1) encoding SAP and a reporter gene or only 
a  reporter  gene  were  generated  in  this  study  (summarized  in  Figure  3.1).  The 
Encephalomyocarditis Virus  derived internal ribosomal  entry sequence  (IRES) was 
used  to  design  bicistronic  vectors.  An  enhanced  variant  of the  green  fluorescent 
protein  (eGFP)  from  the  jellyfish  Aequorea  victoria  was  used  as  a  reliable 
bioluminescent  reporter  for  retroviral  mediated  transduction  (Zhang  et  al,  1996). 
Expression of the molecule  is not thought to be toxic to  lymphocytes  or have any 
known influence on  function.  The truncated  form  low  affinity nerve  growth  factor 
receptor (ALNGFR)  was  also  chosen  as  the  alternative  cell  surface  marker in this 
study to investigate the effect of reporter protein on the expression of two transgenes 
from our bicistronic vectors.
Replication-incompetent  retroviral  particles  were  produced  using packaging 
cell  lines.  The  Phoenix-Ecotropic  (3>e)  cell  line  has  been  used  to  produce  SFFVp 
retrovirus encoding SAP and a reporter protein. The Phoenix cell packaging line is a
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bipartite packaging system, which minimises the potential for recombination overlap 
and for the creation of wild-type virus. The Phoenix ecotropic packaging cell line has 
been  generated  by  introducing  the  gag-pol  and  env  genes  under  non-Moloney 
promoters to reduce recombination potential in the two separate constructs, firstly the 
gag-pol with a hygromycin resistant gene selection and also a second vector encoding 
the env gene (ecotropic envelope) with diphtheria resistance as a co-selectable marker. 
These  packaging  lines  have  been  engineered  to  allow  monitoring  of  gag-pol 
production  through  linkage  to  a  CD8a surface  marker  downstream  of the  reading 
frame  of the  gag-pol  construct.  Phoenix  packaging  lines  are  capable  of carrying 
episomes  for long-term  stable production of retrovirus.  High efficiency transfection 
was achieved using polyethyleneimine (PEI) and the retroviral virions produced were 
harvested from the spematant of subconfluent cultures. The filtered supernatant from 
phoenix  ecotropic cells was used to  stably transduce the PG13  line.  PG13  cell line 
was  derived  from  TK-NIH/3T3  mice  fibroblast  cells  (Miller  et  al,  1991).  This 
packaging cell  line is based on gibbon ape Leukaemia Virus  (GALV) and provides 
retroviral vectors with GALV envelope. The GALV envelope has been reported to be 
more efficient for retroviral delivery to haematopoietic cells in humans (Von Kalle et 
al,  1994;  Bunnell  et  al,  1995).  The  GALV  receptor  (GALVR-1)  is  expressed  on 
lymphocytes at much greater levels than receptors for amphotropic viruses,  and the 
PG13 packaged vectors have been shown to transduce T cells at a higher efficiency 
than the previous generation of vectors (Lam et al,  1996).
The  lentiviral  virions  (VSV-G  pseudotype  vector)  were  produced  by  a 
transient co-transfection system using 293T cells line as discussed in section 3.8.2.  A 
reliable virus titre was achieved using this system.
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Then the SAP expression in transduced cells was assessed by immune blotting 
technique.
3.2  Preparation of SAP cDNA
The  SH2D1A cDNA is  2,530  bp  long  and  contains  an  open  reading  frame 
(ORF) of 462bp, with an initiation codon 79bp from the start of the ORF (Coffey et 
al,  1998) (SAP (SH2D1A) cDNA OMIM: AL023657). The SAP cDNA (670bp) was 
cloned into pGEM-T (Promega) vector, which was kindly provided by Dr. A Coffey 
(Sanger Center-UK)  (Figure 3.2 A).  To  avoid the poly A signal downstream of the 
SAP ORF  and to prepare  a reliable  site  for the next  step of cloning,  a PCR based 
mutagenesis site technique was used. By PCR, two Sal mutation sites upstream of the 
ORF and downstream before the poly A signal were designed.
The  PCR  product  was  run  on  a  1%  agarose  gel  and  the  SAP  band  was 
identified around 400 bp as expected (Figure 3.2 B).
3.3  Cloning of SAP in pBluescript (pBS) vector
pBluescript (pBS) (Stratagene) is a vector with multiple cloning site (MCS).
It  confers  ampicillin  resistance  on  the  host,  allowing  for  selection  of  bacteria 
transformed with plasmid. We used a pBS vector which already encoded the internal 
ribosomal  entry  sequences  (IRES)  from  Encephalomyocarditis  virus  and  enhanced 
green fluorescent protein (eGFP) downstream of the multiple cloning site (MCS). The 
Sail site of MCS of pBS was used in conjunction with the Sal 1 site of SAP.
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Figure 3.1 Summary of vectors used in this study
The  SFFVp  retroviral  vectors  are  shown  which  encoding  human  SAP  cDNA and 
reporter genes  eGFP or LNGFR (A-C).  The two  lentiviral vectors encoding human 
SAP  cDNA and  reporter  genes  eGFP  or only eGFP  are presented  (D,  E).  For the 
abbreviations refer to Chapter 1.
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Figure 3.2 Plasmid map of human SAP cDNA and PCR product
A) The pGEM-T (Promega) vector including the SAP cDNA (670bp). B) The SAP PCR 
products were run on an agarose gel.  Different SAP DNA concentrations were used for 
PCR reaction (0.1  pg, 0.2pg and 0.5pg for PCR reaction 1, 2, 3 respectively).  The PCR 
products were loaded to a 1% agarose gel (Lines 1, 2, 3 represent the PCR product from 
PCR reaction one, two and three, respectively). The PCR product band was identified as 
about 400 bp  as  SAP band in all lanes.  The PCR reaction 3 was selected  for the next 
cloning step.
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The SAP PCR product was cloned into the pBS vector at the Sal I site. After 
transforming bacteria using electroporation, 20-40 colonies were obtained. DNA from 
nine of these colonies was prepared and analysed with Nco I restriction endonuclease 
digestions as shown in Figure 3.3 A. Results from digest experiments (Figure 3.3 B) 
revealed that Clones 3, 6, 9 have a single SAP insert. The comparison of the plasmid 
map revealed that only Clone 3 contains SAP in the correct orientation.
3.4  Sequencing of SAP insert
To  show  correct  sequence  of cloned  SAP,  the  pBS  vector  containing  SAP- 
IRES-eGFP (Clone 3) was prepared for sequencing using standard M l3 primer. The 
DNA was precipitated and then sequenced by LARK Technologies Co. The provided 
sequence  for  forward  and  reverse  complement  of the  pBS  SAP  were  checked  by 
Vector  NTI  software  (InforMax)  to  compare  with  SAP  cDNA  map  (OMIM: 
AL023657) and no difference or mutation was identified.
3.5  Cloning SAP-IRES-eGFP in the retroviral SFFV 
backbone
We used a FMEV backbone modified in the 5'LTR from PCMV (PCC4 cell 
passaged  murine  sarcoma  virus),  a  MPSV  subtype  and  the  SFFVp  3’  LTR  and 
containing a packaging signal from LX based Mo-MuLV vector (including 400bp of 
gag sequence with disrupting AUG) (see Chapter 1). The backbone vector included a 
MCS for insertion of a transgene of approximately 5.8 Kb in size.
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Figure  3.3  Plasmid  map  and  restriction  digestion  analysis  of the  pBS 
SAP-IRES-eGFP
A) The map pBS  SAP-IRES-eGFP vector containing of the SAP cDNA with Sail sites. 
As indicated on the map, the Ncol site can be used for selecting right clone with correct 
SAP orientation.  Digestion of the vector containing the SAP in the correct orientation 
would release a band of 992 bp.  Plasmid DNA of harvested clones were digested with 
Ncol  restriction  enzyme.  Digested  DNA of 9  clones  was  run  on  a  1%  agarose  gel. 
According to the digest only clones 3, 6, 9 contained the SAP cDNA. Clone 3 contains 
the SAP insert in the correct orientation with size of 992 bp.
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To prepare the SFFV backbone vector for ligation, it was digested by EcoR 
I and Not I (not shown).  The insert was prepared by releasing the SAP-IRES-eGFP 
fragment from the pBS- SAP-IRES-eGFP vector (from the previous step, see section 
3.3) by EcoR I and Not I digestion and the isolated fragment was cleaned as discussed 
in  Chapter 2.  It  was  ligated  into  the prepared  SFFV backbone  vector (Figure  3.4).
After transforming bacteria with ligation reaction, growing colonies were screened for 
DNA plasmid  containing  the  insert.  Finally,  DNA  from  one  of the  correct  clones 
(clone 6) containing the SAP gene was prepared for viral vector production.
3.6  Cloning SAP-IRES- ALNGFR in SFFV backbone
To  generate  retrovirus  SFFV  vector  encoding  SAP  with  another  selectable 
marker protein, we used the retroviral SFFV vector containing the gene encoding the 
truncated form low affinity nerve growth factor receptor (ALNGFR) -IRES. SAP was 
released from pBS-SAP-IRES-eGFP using Sal I restriction enzyme. The insert (SAP) 
was  cloned in the  SFFV vector down-stream of IRES  sequences  in  Sal  I  site.  The 
plasmid DNA from 30 clones was digested with Nco I to check the SAP insert had the 
correct  orientation.  The  clones  containing  the  SAP-IRES  (1149  bp)  band  were 
identified according to the vector map (data not shown).
3.7  Generating retrovirus using packaging cell lines
To  produce  replication-incompetent  SFFV  retroviral  vector  encoding 
transgenic SAP and reporter proteins eGFP or ALNGFR, we used two steps,
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Figure  3.4  Plasmid  map  and  restriction  digestion  analysis  of 
retroviral SFFV-SAP-IRES-eGFP backbone vector
A) The map of retroviral  SFFVp backbone vector encoding SAP and eGFP.  B) Ten 
clones were investigated for Retroviral SFFV vector containing SAP-IRES.eGFP. The 
DNA was digested with EcoR I and Not I. The 1753 bp band of SAP-IRES-eGFP was 
identified  in  all  clones.  The  clone  6  was  selected  for  virus  production  in  all 
experiments.
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introducing vector genomes into packaging cell lines, by transfection and in the final 
step by retroviral transduction which gives the highest titer virus possible as described 
in Chapter 1.
The  Phoenix-Ecotropic  (< t> e)  cell  line  has  been  used  to  produce  SFFVp 
retrovirus encoding SAP and a reporter protein. The SFFV vector plasmid construct 
containing the SAP and eGFP or ALNGFR genes was prepared for transfection. DNA 
delivery  was  facilitated  using  polyethyleneimine  (PEI)  as  cationic  DNA  complex.
Cells were transfected with the PEI and DNA complexes. In the next step virus was 
harvested  as  described  in  Chapter  2  and  used  for  the  PG13  packaging  cell  line 
transduction.  We  used  the  PG13  cell  line  to  produce  permanent  SFFV  retrovirus 
vector containing SAP-IRES-eGFP or SAP-IRES-ALNGFR with GALV envelopes. In 
this  step  harvested  virus  from  the  previous  step  was  used  to  transduce  PG13 
packaging cell line. The expression was checked by flow cytometric analysis for both 
viral  vectors  (Figure  3.5).  Thus  introduction  of retroviral  vector  into  PG13  cells 
provides vector integration and permanent viral vector RNA expression and a constant 
source of replication- incompetent SFFV retroviral vector production.
3.7.1  Sorting  PG13  packaging  cell  bulk  culture  with 
high expression reporter gene to isolate single clone
The bulk culture of transduced packaging cell  line consists of heterogenous 
packaging cells with different viral production titre capability. To achieve the highest 
titre of virus, transduced packaging cells were sorted to single cell clones. FACS Cell 
sorting was used to select single cell clones of PG13 packaging cell lines transduced 
by SFFV-SAP retroviral vector. Transduced PG13 cell line for both viral vectors were
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Figure 3.5 Production of PG13 packaging cell lines
Analysing  transduced  PG13  packaging  cell  lines  with  flow  cytometry.  The 
supernatant  from  Phoenix  cells  was  used  for  PG13  transduction.  The  cells  were 
harvested 72 hours after transduction with (A) SFFV-SAP-IRES-eGFP (B) ALNGFR 
and  were  analysed  for  eGFP  or  ALNGFR  (using  anti-ALNGFR  PE  antibody) 
expression  based  on  fluoresence  intensity.  Histograms  from  a  representative 
experiment are displayed and were generated by gating on cells with a high forward 
and side scatter and then on eGFP or ALNGFR positive cells.
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prepared  in  suspension  in  FACS  buffer.  In  the  case  of SFFV-SAP/ALNGFR,  the 
sample was  stained using a-  ALNGFR antibody conjugated with PE.  The prepared 
cells were sorted by gating on the cell population expressing reporter protein and then 
selecting the 1  -2% of cells expressing reporter protein with highest mean fluorescence 
intensity (MFI)  into  a single cell per well  in 96 wells plate with complete DMEM 
medium. The clones were cultured for two weeks and growing clones transferred into 
24 well plates and the virus supernatant harvested. At this stage clones were screened 
for virus production.
3.7.2  Selection of a single clone with the highest virus titre 
production
Screening of clones was performed by fluorescence microscopy and titration 
of virus particles by measuring infection capability on the HeLa cell line. HeLa cells 
were  infected by  virus  supernatant  harvested  from  each  PG13  clone  at  a  different 
dilution.  A day  later,  half the  supernatant  from  each  well  was  replaced  with  fresh 
medium. The infected HeLa cells were prepared for flow cytometric analysis after 48 
hours  (Figure  3.6).  The  percentage  of positive  infected  cells  with  reporter protein 
eGFP or /ALNGFR was calculated using Expo analyze program.
The titre of the virus was determined according to the following formula:
(% of positive cells) x (dilution) x (number of infected cells)= Viral titer (Viral particles /ml)
100
The clones with virus titres of up to  106 for both vectors were selected and 
used for reconstitution studies.
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Figure 3.6 Titration of retrovirus particles produced by PG13 clones
HeLa cells were exposed to serial dilutions of virus supernatant in a final volume of 
lml (1:2,  1:20,  1:200). The infected HeLa cells were analysed by flow cytometry for 
reporter protein  expression  (eGFP/ALNGFR;  A  and  B  respectively).  Using  5pi  of 
supernatant (1:200) a transfer efficiency of 10-12% was observed and hence the titre 
of the viral preparation is estimated at 106/ml in this experiment.
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3.8  Generating lentivirus vector containing SAP
Vectors based on the lentivirus subclass of retroviridae are able to transduce a 
wide range of target cells, and may be a promising tool  for gene delivery into non­
dividing  cells.  The  latest  generation  of  HIV-1  based  vectors  called  SIN  (self 
inactivating)  HIV-1  vector  as  discussed  in  Chapter  1   were  used  in  this  study.  A 
pseudotyped lentiviral vector encoding SAP was produced by transient co-transfection 
of pHR’ SIN lentivirus vector and the envelope plasmid pMD.G  encoding vesicular 
stomatitis virus G envelope (VSV-G) protein and the packaging plasmid pCMVR8.91 
(providing gag-pol, cPPT, Rev, and tat elements) as discussed below.
3.8.1  Cloning  of  SAP  in  pHR’  SIN  SFFVp  lentivirus
backbone vector
Cloning  of SAP  in  the  cassette  pHR’  SIN  lentivirus  backbone  vector,  was 
achieved using a two step cloning procedure.
First the pBS  shuttle plamid encoding WPRE  (a gift  from Dr Kate Parsley,
ICH) was digested with BamH I and Not I enzymes and linear plasmid prepared for 
ligation  (data not  shown).  Then  SAP-IRES-eGFP  fragment was  selected  from pBS 
containing SAP-IRES-eGFP (from section 3.3) by digesting with BamH I and Not I 
and the relevant fragments were isolated from the gel (data not shown).  The vector 
and  insert were  used in a ligation reaction to  transform bacteria by electroporation 
(Chapter  2).  The  DNA  of transformed  clones  was  screened  for  SAP-IRES-eGFP 
insertion with multiple restriction endonuclease digestions (BamH  I and Not I)  and 
analysis  by  gel  electrophoresis  (data  not  shown).  The  clone  showing  the  correct 
restriction map was reserved for next stage in the cloning process.
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Figure 3.7 Plasmid map and restriction digestion analysis of pHR 
SINcPPT- SFFVp-SAP-IRES-eGFPS-WPRE (SIEW)
A)  The map of lentiviral SIN HIV1 vector (pHR SINcPPT-SIEW) with size of 10 Kb. B; 
DNA from selected clones was digested with Sal I or Kpn I. Digestion with Sal I (lane 1) 
released four bands 8.3 kb, 1.3 kb, 0.7 kb, and 400 bp and digestion with Kpn I (lane 2) 
released only two bands of 9 and 1.6 kb.
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To  construct  pHR’  SIN  SFFV  lentivirus  backbone  vector  encoding  SAP- 
reporter  eGFP protein under  SFFV U3  promoter,  the  cassette  of SAP-IRES-eGFP- 
WPRE was prepared from last step (pBS -SAP-IRES-eGFP-WPRE with ~ 6 kb size) 
with digestion of DNA (data not shown). The DNA fragment was cloned in the pHR’
SIN SFFV lentivirus backbone vector at BamH I and EcoR I  sites. The transformed 
E. coli colonies were selected and DNA was screened by digestion with Sal I or Kpn I 
restriction endonuclease as shown in Figure 3.7. The DNA from the clone with correct 
map was used to produce lentiviral vector.
3.8.2  Preparation of lentiviral vector particles
VSV-G  pseudotype  vector  was  produced  by  transient  transfection  of three 
plasmids  into  293T  cells:  the  pHR’  SIN  transfer  vector  plasmid,  multideleted 
packaging plasmid pCMVAR8.91, and pMD.G plasmid (Figure 3.8). The DNA plus 
PEI complexes were used to transfect 293T cells as described in Chapter 2. The vector 
particles  were  concentrated  20  to  100-fold  by  ultracentrifugation  (see  Chapter  2).
The virus particles was resuspended in serum free medium and kept at -80°C until 
use. The virus vectors were titrated as described before by infecting HeLa cells with 
serial  1:10  dilution  of  virus  and  analyzing  for  eGFP  expression  at  72  hours 
postinfection. The titre for harvested virus was calculated as explained and a final titre 
108  was achieved (Figure 3.9).
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Figure 3.8  Producing lentiviral particles using a co-transfection 
system
A)  The plasmid constructs essential for virus production
B)  The co-transfection system using 293 T cell line for virus harvesting
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Figure 3.9 Titration of lentivirus particles produced by 293 T cell 
lines
HeLa cells were exposed to serial dilutions of virus supernatant in a final volume of 
lml (1:106, 1:105, 1:104, 1:103  shown B-E respectively). The infected HeLa cells were 
analysed by flow cytometry for reporter protein (eGFP) expression by gating on cells 
with a high forward and side scatter (A) and then on eGFP positive cells (B-E). Using 
lpl of supernatant (1:103) a transfer efficiency of 75% and hence the titre of the viral 
preparation is 10 /ml in this experiment.
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3.9  Detection of SAP expression in HeLa transduced cell 
lines by retroviral and lentiviral vectors
The  use  of bicistronic  expression  vectors  has  improved  the  efficiency  of 
selection during transduction by ensuring that over 90%-95% of cells expressing the 
selectable marker also  express the gene of interest.  The retroviral  vectors  encoding 
IRES are well recognized for use in expressing two genes, under the control of one 
promoter.  The  IRES  element  is  able to  promote  internal  initiation  of translation  of 
RNA in a cap independent manner, which facilitates the expression of two or more 
proteins  from  a polycistronic  transcription unit in eukaryotes (Martinez-Salas et al, 
1996).
In order to investigate whether generated retroviral and lentiviral vectors could 
induce SAP expression in human cells along with the surface reporter protein,  SAP 
expression  was  detected  by  western  blotting.  The  HeLa  cells  were  infected  with 
harvested  retroviral  and  lentiviral  encoding  SAP  as  described  before.  To  measure 
transduction  efficiency  of a viral  vector,  the  ratio  of number of viral  particles  per 
millilitre to number of cells per millilitre or multiplicity of infection (MOI) is a widely 
used parameter in gene manipulation.  Retroviral and lentiviral vectors were used at 
MOI  20  and  10,  respectively.  As  a  control,  retroviral  and  lentiviral  constructs 
encoding  only  eGFP  protein  were  used  to  infect  HeLa  cells.  After  48-72  hours, 
transduction efficiency was measured by flow cytometric analysis of eGFP expression 
and  showed  up  to  50-60%  transduction.  The  lysates  from  transduced  and  non­
transduced HeLa cells were examined by western blotting,  for the presence of SAP 
(Figure 3.10).
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t
Figure  3.10  Detection  of  SAP  in  HeLa  transduced  cells  by 
immunoblotting
Immunoblot analysis using an anti-SAP antibody shows a 15kD protein expressed in 
transduced HeLa cells with retroviral vector encoding SAP-eGFP (A) and lentiviral 
vector encoding SAP/eGFP (C) not in cells transduced with retroviral encoding eGFP 
(B).
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Equivalent  amounts  of total  protein  from  106  cells  were  loaded  in  each  lane.  As 
shown,  only HeLa  cells  transduced  with  viral  vectors  encoding  SAP  showed  SAP 
expression.
3.10  Discussion
Retroviral  vectors  are  the  most  commonly  used  gene  delivery  vehicles  in 
clinical gene therapy trials. So far the progress of retroviral vectors have included; a) 
general  design  improvements,  b)  greater  insight  into  retroviral  stability  and 
production,  c)  safer  systems  to  ensure  that  replication-competent  virus  is  not 
produced, d) vectors based on lentiviruses. The latest generation of retroviral vectors 
are resistant to silencing and provide the strongest transcriptional activity particularly 
in haematopoietic cells. Therefore, retroviral vectors are ideal for gene delivery to T 
cells, and hence their use in this study.
The constructs  generated here  are  summarized  in Figure  3.1.  The  generated 
retroviral vector is a SFFV hybrid based on Mo-MuLV vector with several features as 
described in Chapter  1, which make it an attractive vehicle for T cell gene transfer. 
Moreover,  the  lentiviral  vector  constructed  here  is  a  third-generation  HIV-1  based 
vectors  with  self-inactivating  (SIN)  advantage  and  as  described  in  Chapter  1,  has 
different elements to improve its efficiency. The lentiviral vectors, unlike MLVs, are 
able to infect differentiated cells, and it was thought that they may give advantages to 
target EBV-specific T cells in our study without the need for a high number of cell 
division  cycles.  This  appears  to  be  due  to  the  presence  of  redundant  nuclear 
localisation signals both in the HIV MA protein as well as in the HIV accessory gene
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product Vpr associated with MA protein (Heinzinger et al,  1994).  The transduction 
efficiency on EBV- T cell lines of two vectors is studied in Chapter 4.
The cell surface markers eGFP and ALNGFR were designed to  enable us to 
select transduced cells. The SAP and marker protein expression were under a single 
SFFV promoter using the ERES element derived from the encephalomyocarditis virus 
(ECMV). It has been shown there is a direct linear correlation between the genes (Zhu 
etal,  1999).
To  generate retroviral  SFFV vector,  the  PG13  packaging cell  line was used 
and single cell high virus titre clones were selected. It has been reported that the two 
step  approach  to  the  production  of  retroviral  vector  from  infected  cell  clones 
containing a single provirus provide higher and more stable virus production (Coffin 
et  al,  1997).  The  clones  were  selected  with  a  virus  production  titre  higher  than 
106infectious particles/ml  for this  study.  The titration was measured by infecting  a 
fixed  number  of HeLa  cells  mediated  with  polybrene.  However,  because  the  viral 
envelope used here is GALV, the titration of virus particles on HeLa cells may not 
exactly represent the number of particles infecting T cells (further studied in Chapter 
4).
The  co-transfection  system  was  used  to  generate  lentiviral  vectors  because 
there were no packaging cell lines to produce lentiviral SIN vector at the time of our 
work.  The  transient  transfection  of 293  T  cells  with  different  constructs  shown  in 
Figure 3.8 produced a high number of viral particles with VSV envelope (G) known 
as  pseudotyping.  The  titration  of concentrated  virus  on  HeLa  cells  showed  a  titre 
higher than 108 infectious particles/ml.
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The risk of generation of the replication competent viruses for retroviral and 
lentiviral vectors is low in both systems. A GALV-pseudotyped retrovirus is incapable 
of infecting murine cells (PG13 cell lines) and so the chance of self-infection and re­
combination  of introduced  SFFV  retroviral  vector  with  PG13  endogenous  murine 
retroviral  sequences  is  near impossible.  Also  using  a  SIN  HIV-1  based  vector  and 
providing  the  trans-active  elements  and  envelope with  different  plasmid  constructs 
reduces significantly the chance of replication competent virus production.
Because  SAP  is  a  small  cytoplasmic  protein,  the  SAP  expression  in 
transduced  cells  with  retroviral  and  lentiviral  vectors  was  detected  using  immuno 
blotting. The results here shows that all steps of cloning human SAP into vectors and 
producing the viruses with above mentioned methods were successful and were able 
to express stable and detectable  SAP in the human cells under the  SFFV promoter. 
However,  although  the  40-50%  of  transduced  cells  were  negative  for  eGFP 
expression,  the  SAP band  was  very  strong  showing  a high  level  of expression.  It 
remains to be addressed whether the constructed vectors have the same capability to 
express SAP in T cells, and this is further investigated in Chapters 4 and 7.
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4.1  Introduction
The first ever approved clinical trial of gene therapy began in 1990 at the NIH, 
and involved repeated ex vivo transduction of autologous peripheral blood T cells with 
retroviral vector expressing human ADA, followed by expansion and reinfusion into 
two  patients  (Blaese  et  al,  1995).  Genetic  manipulation  of  T  lymphocytes  may 
significantly benefit patients with various genetic or acquired haematologic disorders. 
Although T cells present a mature blood cell population, they can be very long lived 
and  have  the  capacity  for  limited  clonal  activation  and  expansion.  In  the  switch 
between  the  resting  and  the  activated  status,  chromosomal  organisation  and 
transcription factor equipment is reordered. Thus, a stably integrating retroviral vector 
is  an excellent tool  for genetic  manipulation of T cells, but vector expression may 
vary depending on the cellular activation status.  At this time, the most widely used 
method for gene transfer into human T cells has involved Moloney murine leukemia 
virus  (MuLV)-based  vectors.  MuLV  based  vectors  allow  stable  and  efficient  gene 
transfer  but  efficiency  mainly  depends  on  cell  division.  In  recent  trials,  the  virus 
supernatant used along with co-localisation agents such as fibronectin has improved 
the  efficiency  of  transduction  of  haematopoietic  stem  cells  (HSC)  and  T  cell 
transduction  by  retroviral  vectors  (Moritz  et  al,  1996;  Stockschlader  et  al,  1999; 
Parsley et al, 2002). The fibronectin binds to the integrins VLA-4 (very late antigens) 
and  VLA-5  (expressed  on  T  cells)  through  its  active  CH-269  carboxy-terminal 
chymotryptic moiety, which is currently being used for clinical trials (Retronectin).
Furthermore,  most  protocols  for  primary  T  cell  transduction  are  based  on 
using mitogen (PHA),  anti-CD3  alone or in combination with anti-CD28,  and  IL-2 
with reliable results (Bonini et al,  1997; Pollok et al,  1999; Ferrand et al,  2000). In 
spite of this, gene transfer into antigen (Ag) specific T cells is difficult to achieve with
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current techniques and methodology. New lentiviral vectors based on HIV 1   may be 
appropriate  candidates  for targeting  T  cells without polyclonal  expansion  and  may 
target Ag stimulated T cells which have limited proliferation capacity in comparison 
with ordinary stimuli.
While this methodology holds promise, optimism has been moderated by the 
difficulties encountered in achieving high levels of gene transfer into T cells without 
affecting their TCR repertoire distribution and function (Sauce et al,  2002; Qasim et 
al,  2003). For instance the stimulation of T cells with anti-CD3 caused shifting of T 
cells from naive to the memory phenotype (Verhoeyen et al, 2003). In a recent report 
by Koehne et al, they succeeded in transducing purified EBV stimulated T cells with 
a dicistronic based MuLV vector which achieved 10% transduction but the efficiency 
was still very low (Koehne et al,  2000). Moreover, the third generation of lentiviral 
vectors based on HIV-1  as described in Chapter 1  may hold promise to improve gene 
delivery to Ag specific T cells without extra stimulation.
Since the well developed protocols for T cell targeting are mainly based on 
non-specific T cell activation and preparing patient material is a significant problem 
particularly in the rare diseases; developing a convenient practical system to target T 
cells without unwanted effects is a major aim. We have therefore tried to develop an 
efficient  transduction protocol  to  minimise  the  ex-vivo  manipulation  of primary T 
cells  and  preserve  the  high  efficiency  of transduction  using  retroviral  or  lentiviral 
vectors. It was also a major objective to target mainly primary EBV- specific T cells 
with higher transduction efficiency rather than the T cell general population. Finally, 
we have been able to show efficient transduction of EBV- T cells from XLP patients 
with a defined protocol.
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4.2  EBV T cells stimulation
To define conditions resulting in maximal transduction of antigen-reactive T 
cells,  we  initially  examined  different  stimulation  protocols  based  on  autologous 
BLCL  stimulation  to  achieve  proper  EBV  specific  T  cell  proliferation.  2  x  106 
PBMCs  from three normal  EBV  seropositive donors (Cl,  C2,  C3)  were  stimulated 
with irradiated autologous BLCL at a  1/40 cell ratio (BLCL/ PBMCs)  and cultured 
with  complete  RPMI medium  at  a concentration  of lxlO6  cells/ml  as  described  in 
Chapter  2.  To  prepare  cells  for  transduction,  different  stimulation  protocols  were 
tested (summarised in Table 4.1) and expanded EBV T cell polyclonal lines analyzed 
for cell proliferation, CD4/CD8 ratio or prepared for transduction.
Table  4.1  Stimulation  protocols  used  in  this  study  for  EBV-T  cell 
polyclonal lines 
P rotocol  F irst S tim ulation  Second Stim ulation
Protocol 1
Protocol 2
PBMCs stimulated with  On 4* day with PHA (5ug/ml) and
Autologous BLCL and rEL-2 for 3 days  rEL-2 (20 IU/ml) for 48 hours
PBMCs stimulated with 
Autologous BLCL for 7 days
On 7* day with PHA (5ug/ml) and 
rEL-2 (20IU/ml) for 48 hours
Protocol 3 PBMCs stimulated with 
Autologous BLCL for 7 days
On 7-8* day restimulated with 
Autologous BLCL (4/1) and rDL-2
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Following  stimulation  with  each  protocol,  proliferative  responses  were 
analysed using Trypan blue to count live cells. There was an average 3.5 fold increase 
in cell number using protocol No.2 (Figure 4.1).  However, using protocol No.l  and 
No.3,  there was  a 2  and  2.5  fold  increase  in cell number,  respectively.  In order to 
show  T  cell  percentage  and  CD4/CD8  ratio  upon  different  stimulation,  stimulated 
cells  were  analysed  by  flow  cytometry  for  CD3,  CD4  and  CD8  expression.  All 
stimulated cells  showed  up to  80-90%  CD3  positive phenotype with protocol No.l 
showing less CD3  expression than others around 80% (Figure 4.2).  In addition, the 
CD4/CD8  ratio  presented  considerable  diversity  using  the  different  stimulation 
methods.  Cells  stimulated  with  protocol  No.l  and  No.3  exhibited  2.5:1  to  1.7:1 
CD4/CD8 ratio whereas cells stimulated with protocol No.2 shifted to  1:1  CD4:CD8 
ratio. Thus although cells stimulated with protocol No.2 showed a greater increase in 
cell number, it had an unwanted effect on the CD4:8 ratio.
4.3  Optimising EBV T cells transduction with viral vectors
So  far  optimal  ex  vivo  conditions  for  T  cell  manipulations,  transduction 
protocols,  and  vector constructs  that  maintain  adequate  transgene  expression,  have 
been under refinement. We next investigated the optimal transduction of EBV T cell 
clones  with  retroviral  and  lentiviral  vectors  using  different  stimulation  and 
transduction protocols (Figure 4.3). Firstly, the transduction protocol was justified to 
prepare prestimulated T cells using fibronectin or polybrene to enhance gene delivery 
efficiency. In this study, retroviral SFFV vectors encoding SAP-eGFP or eGFP alone 
(a gift from Dr.W. Qasim, ICH) and SIN lentiviral (pHR’cPPT SFFV) vectors
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Figure  4.1  T  cell  proliferation  rate  in  response  to  stimulation 
protocols No 1-3
Prestimulation of PBMCs (Cl-3) with stimulation protocols No 1-3 (see Table 
4.1) induced T cell proliferation. The number of cells in culture were counted at the 
end of pre-activation (48 hours) using Trypan blue dye exclusion. Prestimulated cells 
(Cl-3) without additional stimulation were used as the control for analysis. Data from 
three experiments on three volunteer donors is presented. The mean value (± SD) for 
each condition was used for statistical analysis.  Significant differences are indicated 
by asterisks (no asterisk, no statistical significance; *, 0.05 >p  >0.001; **, 0.001>/?).
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Figure 4.2  The  effect of stimulation  with  protocols Nol-3  on  CD4/8 
ratio
CD4/CD8  T  cells  ratio  were  studied  in  response  to  different  types  of  stimuli 
combination  (protocol  stimulation  number  1-3)  in  three  normal  individuals.  The 
CD4/CD8  ratio  were  measured  48  hours  after  final  step  of stimulation  with  flow 
cytometric analysis respectively. The data is based on three experiments. The mean (± 
SD) for each condition was used for statistical analysis.
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encoding SAP-eGFP or eGFP were used (Figure 3.1). The viral vectors were prepared 
as explained previously.
4.4  EBV-T cells transduction with viral vectors
Stimulated  EBV  T  cells,  as  described  in  Chapter  2,  were  prepared  for 
transduction.  The  titre  of virus,  established  in  Chapter  3,  was  106 particles/ml  for 
retroviral  vectors  and  108 particles/ml  for  lentiviral  vectors.  Two  commonly used 
facilitation  agents,  polybrene  and  retronectin,  were  used  to  increase  transduction 
efficiency.  EBV-T  cells  were  exposed  to  two  rounds  of infection  with  virus.  The 
introduction of an additional step, whereby EBV-T cells and viral supernatant were 
centrifuged for 20 minutes, before the addition of fresh supernatant and rIL2. On the 
fourth day,  cells were  stained and analysed  for CD3,  CD4,  CD8,  eGFP  expression 
with flow cytometry or cultured further to generate EBV- T cell clones as described in 
Chapter 2 (Figure 4.3).
4.4.1  Transduction EBV T cells with retroviral vectors
EBV T cells were infected with retroviral SFFV vector containing SAP-eGFP 
or eGFP alone using recombinant Retronectin. Because activated T cells express very 
late antigens (VLA)-4, and VLA-5, which interact with fibronectin, this may improve 
transduction of T cells with retroviral vectors (Stockschlader et al,  1999). Following 
stimulation  with  protocol  No  2,  the  flow  cytometry  results  showed  transduction 
efficiencies were between 35-40%. Upon stimulation with protocol No.l,
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EBV-T cells Transduction Protocol
4 DAYS
Culture for 6-8 weeks\ 
And weekly stimulation 
with Auto-LCL & rlL -/
Stimulation
Protocol
PBMCs
isolation
Retronectin FCM
VIRUS
X-Vivo 10/10% Autologous serum/rIL-2
Figure 4.3 Protocol for the transduction of stimulated EBV-T cells
The following procedure was judged to achieve optimal levels of gene transfer into 
EBV- T cell polyclonal lines. Stimulated T cells from the stimulation protocols (1-3) 
were suspended  in X-Vivo  10 with  10% autologous  serum  and 20iu/ml of rIL-2  at 
0.5xl06/ml. The cells were transferred to fibronectin coated plates that had been pre- 
loaded with viral supernatant. Two rounds of 24 hours virus exposure were carried out 
and the cells were cultured for 48-72 hours before analysis by flow cytometry.  The 
cells stimulated with protocols 2 and 3 were cultured for 6-8 weeks to generate EBV- 
T cell lines.
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Figure 4.4 Transduction efficiency of retroviral vector in stimulated T 
cells with protocols No 1-3
Stimulated T cells from three normal individuals were transduced with retroviral vector 
encoding SAP-eGFP or eGFP following stimulation protocol  1-3. The eGFP expression 
was measured by flow cytometry after four days of transduction.  The mean (±SD)  for 
each condition based on three experiments was used for statistical analysis.
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efficiency was very low with  10-15%  (Figure 4.4).  However, prestimulated T cells 
with  protocol  No.3  in  which  there  was  only  stimulation  with  specific  antigens 
(autologous  BLCL)  exhibited  wide  range  of transduction  efficiency  with  10-50% 
efficiencies  (Figure 4.4).  The  comparison of MFI  for all  experiments was  constant 
with  200-250  mean  range  (data not  shown).  Analysis  of CD4,  CD8  expression on 
transduced cells with both vectors showed the same distribution of T cell populations 
as seen prior to infection with retroviral vectors (results not shown). Therefore, there 
was  not  preferential  transduction  of CD4  and  CD8  T  cell.  The  efficiency  of both 
retroviral  vector  constructs  suggests  that  SAP  expression  does  not  affect  the 
transduction efficiency by retroviral vectors.  In addition, the retroviral SFFV vector 
encoding SAP-ALNGFR was used to test whether the reporter gene has any effect on 
transduction efficiency.  Flow cytometric analysis results showed no difference with 
above results (data not shown).
4.4.2  Transduction EBV T cells with lentiviral vectors
To  investigate  whether  SIN  lentiviral  vectors  based  on  HIV  are  promising 
vehicles for gene delivery to prestimulated or unstimulated T cells, particularly EBV 
T cells,  transduction  efficiency with  lentiviral  vector was  examined using different 
stimulations  and  conditions.  A  modified  lentiviral  SIN backbone  vector was  used, 
which benefits  from cPPT and WPRE under the SFFVp U3  promoter.  Two vectors 
were  used  encoding  SAP-eGFP  or  eGFP  for  these  experiments.  Transduction  of 
prestimulated T cells with different quantities of viron particles demonstrated 10-20% 
efficiency. There was a positive correlation between MOI and transduction efficiency.
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Figure  4.5  Transduction  efficiency  of lentiviral  vector  in  stimulated  T 
cells with protocols No 1-3
T cells stimulated with different protocols (stimulation protocols No  1-3, see table 4.1) 
were  transduced  with  lentiviral  vectors  encoding  SAP-eGFP  or  only  eGFP  (data 
presented for vector encoding only eGFP). The MOI for all experiments presented in this 
figure  was  30.  On  the  fourth  day  of  transduction,  they  were  analysed  with  flow 
cytometry  for  eGFP  expression.  The  mean  (±SD)  for  each  condition  based  on  three 
experiments was used for analysis.
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However,  this  correlation  was  limited  to  MOI  under  50  and  the  best  efficiency 
achieved  in  MOI  of 20-40  (units)  (data  not  shown).  Moreover,  stimulation  with 
different protocols did not increase transduction efficiency (Figure 4.5) and quantities 
more than 50 MOI had toxic effects on T cells. Although other studies showed a high 
MOI does not have toxic effect in some type of cells, the toxicity of viral particles in 
primary T cells can be as the result of viral proteins such as VSV-G.  To  examine 
whether low efficiency was caused by specific EBV T cell line stimulation or caused 
by vector insufficiency, T cells were stimulated by co-localized OKT3 and CD28 for 
48  hours  and  then  cells  infected  with  lentivirus  particles.  The  results  showed  no 
improvement  in  transduction  efficiency  (data  not  shown).  However,  infection  of 
Jurkat  cells  or  non-stimulated  T  cells  did  not  change  expression  level  (results  not 
shown). Instead, retroviral vectors infected Jurkat cells with up 50-60% transduction 
efficiency.  In  addition  co-localization  of  lentiviral  vectors  and  target  cells  on 
fibronectin only increased eGFP expression by less than 5% and using polybrene did 
not  show  enhanced  eGFP  expression  (Figure  4.6).  The  results  from both  lentiviral 
vectors were consistent.
4.5  Transduction of EBV T cell lines of XLP patients
In  order  to  show  feasibility  of SAP  reconstitution  in  T  cells  by  retroviral 
vectors,  the  optimized  transduction  system  was  performed  on  EBV-T  cell  lines  of 
XLP  patients.  Considering  the  result  of transduction  efficiency  of retroviral  and 
lentiviral vectors in stimulated T cells with BLCL (protocols No 1-3), the stimulation 
protocols No 2, and No 3 were used with retroviral vectors. The prestimulated EBV-T 
cells from two EBV seropositive XLP patients were prepared with protocol No 2 and 
No 3. Then cells were transduced either with retroviral vector encoding SAP-eGFP or
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Protocol Nol Protocol No3 Protocol No2
Figure  4.6  The  effect  of  retronectin  and  polybrene  on  transduction 
efficiency of lentiviral vector in stimulated T cells with protocol Nol-3
The effect of Retronectin and Polybrene on the transduction percentage of stimulated T 
cells  (with  protocol  No 1-3)  with  lentivirus  vector  was  studied.  PBMCs  from  three 
normal  individuals  (Cl-3)  were  stimulated  with  protocol  No 1-3  and  transduced  with 
lentiviral vector (see figure 4.3) and transduction efficiency were measured with analysis 
of transduced cells  for eGFP  expression using flow cytometry.  The mean (±  SD) was 
estimated for each condition based on three experiments. The interindividual difference 
for each condition was not significant using stimulation protocols No 1-3.
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Figure  4.7  The  efficiency  of retroviral  vector  transduction  of EBV-T 
cell stimulated with protocol No 3 in XLP patients versus controls
Transduction  efficiency  of retroviral  SFFV  vector encoding  SAP  and  eGFP  or eGFP 
alone on EBV-T cells. EBV-T cells from XLP 1, 2 and C 1  (C2, 3 data not shown) were 
stimulated with protocol No 3.  Transduced cells were analysed by flow cytometry for 
eGFP  expression  on  the  fourth  day.  The  flow  cytometry  histograms  show  CD3-PE 
expression  of  T  cell  clones  and  eGFP  expression  (XLP1,  2  and  Cl).  The  eGFP 
expression was significantly variable in different individuals from 25% to 50%. The data 
was confirmed based on three or more experiments in all three normal individuals and 
two XLP patients.
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eGFP  alone.  Consequently,  the  result  from  protocol  No2  was  identical  with 
transduction  of  normal  T  cells.  XLP  1   showed  low  transduction  efficiency  of 
approximately  25%  with  protocol  No3  but  EBV  stimulated  T  cells  from  XLP2 
(stimulated with protocol No 3) were transduced up to 50% with both vectors (Figure 
4.7). The transduced cells from XLP patients and normal were prepared for generation 
of EBV-T cell lines in further experiments.
4.6  Discussion
Conditions  to  achieve  optimal  gene  transfer  into  EBV-T  cell  lines  were 
evaluated  using  PBMCs  from  three  healthy  EBV  seropositive  controls  (Cl-3). 
Exposure of PBMCs to EBV-LCLs is a well-known method to generate EBV- T cell 
lines (Moss et al,  1988; Papadopoulos et al,  1994; Heslop et al,  1997; Haque et al, 
2002).  Therefore,  we  hypothesised  that  if EBV-LCLs  were  used  for the  necessary 
stimulation  of T  cells  prepared  for  transduction  with  viral  vectors,  it  would  have 
advantages  for  generating  transduced  EBV-  specific  T  cell  lines  without  requiring 
excessive  non  specific  T  cell  prestimulation.  So,  three  types  of T  cell  stimulation 
developed here are based on EBV-LCL Ags challenge. The different pre-stimulation 
of primed EBV-T cells were tried in protocols 1, 2 and 3 to ensure active division at 
the time of retrovirus or lentiviral exposure. It has been shown that although PHA and 
anti-CD3/28  stimulation  increases  T  cell  transduction,  it  causes  CD4:CD8  ratio 
alteration  (Duarte  et  al,  2002).  Movassagh  et  al  also  reported  that  preferential 
expansion of CD8  T cells led to the CD4:CD8 ratio becoming inverted after T cell 
activation upon  anti-CD3  and rIL-2  (high  level  of rIL-2)  (Movassagh et al,  2000). 
Although there was  considerable  inter-individual  variation between healthy donors, 
comparing the average data among individuals was consistent. In support of previous
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work, the results showed that the activated cells were predominantly T cells at time of 
analysis with each different protocol. Moreover, the results presented here confirmed 
that only protocol No 2 demonstrated a reversed CD4:CD8 ratio. However, although 
PHA was used with protocol Nol, the change in CD4:CD8 ratio was nearly similar to 
protocol No3  in which only Ag stimulation and a very low level of rIL2 was used. 
The CD4 preference seen with protocol Nol may be explained by the early analysis of 
the  stimulated  T  cells  whereas  other  studies  have  shown  that  the  CD4:CD8  ratio 
changed after five days of ex vivo stimulation (Movassagh et al, 2000).
It has been reported recently that highly efficient primary T cell transduction 
with  MLV  based  retroviral  vectors  can  be  achieved  using  retronectin  and  CD3/28 
stimulation  (Qasim  et  al,  2002).  Also  it  has  been  shown  that  the  additional 
centrifugation of target cells and virus  (also referred to  as  spinoculation)  improved 
infection efficiency (Qasim et al,  2002; Kuhlcke et al,  2002). The same transduction 
method was used here in addition to using different stimulations. However, although 
protocol Nol  showed the highest increase in cell numbers  following stimulation of 
EBV-T  cells,  the transduction efficiency results were  lower (10-20%) than the two 
other protocols.  Whereas  the  results  of transduction with protocol  No2  were  more 
efficient  and  comparable with  other reports,  using  a non-specific  mitogen,  such  as 
PHA, would have an effect not only on the T cells function as reported by Duarte et al 
(2002), it also has an effect on EBV- T cell lines phenotype, as we describe later in 
this study (see Chapter 5). In contrast, the percentage of transduced cells stimulated 
with protocol No3 varied considerably amongst individuals (10-50%) but is still more 
efficient  than  previous  reports  (Koehne  et  al,  2000).  It  may  be  explained  by  the 
different  frequencies  of EBV-specific  CTLp  in  population.  The  achievement  of a 
reliable  transduction  efficiency  with  protocol  No3  enables  us  to  avoid  the  extra
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stimulation  such  as  PHA  which  has  a  striking  effect  on  depletion  of both  EBV- 
specific  and  allospecific  T  cells  as  previously  reported  (Koehne  et  al,  2000).  In 
addition,  the  percentage  of transduced  CD4  and  CD8  was  similar  using  different 
protocols.  This  is  in  support  of previous  studies  (Duarte  et al,  2002;  Qasim  et al, 
2002).  In  all  these  experiments,  the  two  retroviral  constructs  preserved  the  same 
transduction efficiency confirming that different transgenes do not interfere with gene 
transfer efficiency.
Furthermore, the lentiviral vectors are recognised for their ability to transduce 
the target cells without any extra stimulation. However, the reports on the efficiency 
of lentiviral vectors to transduce T cells showed that extra stimulation with IL-2 alone 
or with  PHA  enhance the  efficiency  from  around  2%  to  40-70%  (Manganni  et al,
2002)  although others reported lower efficiency (Verhoeyen et al,  2003).  However, 
these  stimulations  would  have  effects  on  T  cell  functionality  and  phenotype  as 
described before. In our results using lentiviral SIN vector taking advantage of trans­
active  elements  such  as  cPPT  and  under  SFFVp  as  explained  in  Chapter  1,  the 
efficacy of transduction  was  not  as  high  as  using retroviral  vectors.  The protocols 
Nol, 2, and 3  showed almost the same results and applying co-localising agents did 
not have significant effect on outcomes. Interestingly, using anti-CD3/28 stimulation 
did  not  improve  transduction  efficiency.  More  recently,  application  of  IL-7,  a 
cytokine  which  interacts  with  T  cells  through  its  receptors,  has  been  shown  to 
improve  the  lentiviral  transduction  without  any  impact  on  T  cell  phenotype 
(Verhoeyen et al,  2003).  It could be possible that using IL-7 may be beneficial  for 
transducing EBV-T cells with higher efficiency without affecting EBV-specific  and 
allospecific T cell subpopulations. However, these issues remain to be investigated in 
future studies.
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Therefore, in these studies retroviral vectors provide the ideal tool to transduce 
EBV-T cells.  The results presented here show that we have been able to transduced 
EBV-T  cell  from  XLP  patients  and  controls  (26%-50%)  with  our  constructs  using 
defined  stimulation  protocol  with  transduction  efficiencies  appropriate  for  further 
investigations.
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5.1  Introduction
During the primary response and again during secondary infection, the most 
important function of cytotoxic T  lymphocyte (CTLs)  is to eliminate noncytopathic 
viruses, which may otherwise cause significant immunopathology. EBV provides one 
of the most informative systems with which to study CTL responses in humans (see 
Chapter 1). EBV is well known for its growth-transforming function that is regulated 
by a specific subset of genes, the latent genes, which are expressed in latently infected 
lymphoblastoid cell lines (LCL) in a coordinated manner (Tatsumi,  1992). LCLs arise 
following viral infection of resting B cells in vitro and provide an in vitro model to 
investigate T cell responses to EBV latency Ags (Rickinson et al,  1997). The infected 
B cells have the ability to generate cytotoxic T cells by presenting the viral antigen 
(Ag) to TCRs. Moreover, memory CTLs in the blood of healthy virus carriers can be 
reactivated in vitro by stimulation with autologous LCL and expanded as polyclonal T 
cell lines or as CTL polyclones in interleukin 2 (IL2)- conditioned medium.
So  far EBV-specific cytotoxic CD8  lymphocytes in normal individuals have 
been  well  characterized  for  memory-effector  and  activation  immunophenotypes 
(Callan  et  al,  1996  &  1998;  Hislop  et  al,  2001;  Appay  et  al,  2002).  Also  their 
dominant reactivities  are well  documented to  one or more  latency antigens,  mainly 
EBNA  3A,  3B,  3C  (Rickinson  et  al,  1997).  However,  studies  of specific  T  cell 
immunity to EBV in XLP are contradictory (Chapter 1; Gaspar et al,  2002). In order 
to study XLP T cell responses to EBV, an in vitro autologous LCL system was used 
in the work presented here. Although XLP patients respond to EBV infection with T 
cell proliferation, those who survive from FIM maintain a dominant CD8 population 
and  a reverse  CD4/CD8  ratio  (see  Chapter  1).  However,  the  T  cell phenotype  and
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responses  such  as  HLA-restricted  EBV-specific  T  cell  memory  have  not  been 
investigated in detail or compared with normal EBV carriers. More recently, cytotoxic 
CD4 lymphocytes have been defined and in EBV infection, particularly in response to 
EBNA 1, play an important role in immunity (Munz et al, 2000; Nikiforow et al, 2001 
&  2003).  In  contrast  with  cytotoxic  CD8  cells,  these  have  not  yet  been  studied 
comprehensively  and  their  character  with  regard  to  effector  phenotype  remains 
undetermined.  In  order  to  compare  the  phenotype  of EBV-  T  cell  lines  in  XLP 
patients (with defined genetic lesions; see Table 5.1) with normal controls, two kinds 
EBV-T cell lines were generated following the stimulation protocols No.2 and No.3, 
which were explained in the previous chapter. Furthermore, they were evaluated for 
SAP-related  receptors  and  chemokines,  which  recently have  been  suggested  to  be 
important in immune response to viral infection.
Table 5.1 Details of XLP patients who were investigated in this study
XLP patient Age Mutation Phenotype EBV serotype
XLP1 (PI) 4 years G - T (nt500) EBV+HLH Seropositive
XLP2 (P2) 16 years N448-159 del EBV+B cell 
lymphoma
Seropositive
XLP3 (P3) 19 years IVS: '32—28 
Del A TTTT
CVED Seronegative
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5.2  Generating EBV-T cell lines and their proliferation 
response to autologous EBV-LCL
Generating CTL in vitro has been well described for almost two decades and 
has been used beneficially in different clinical applications (Papadopoulos et al,  1994; 
Mackinnon et al,  1995; Heslop et al,  1997; O’Reilly et al,  1997; Haque et al,  2002). 
Simply, peripheral T cells can be divided into two subsets: naive and memory cells. 
Memory cells have the capacity to proliferate and generate effector cells in response 
to specific Ags. Autologous BLCLs can be considered as effective antigen presenting 
cells. Although they are not as potent as dendritic cells and macrophages because of 
poor  B7.1  and  B7.2  ligand  expression,  they  have  been  used  in  many  studies  to 
generate EBV-specific T cells in response to most latency antigens. As XLP is a rare 
disease  and  considering  the  difficulties  of obtaining  material  from  XLP  patients, 
generating EBV-T cell lines using autologous BLCL as antigen presenting cells is an 
ideal system for this study.
To generate autologous BLCL lines from XLP patients (XLP 1, 2) and normal 
control donors (Cl,  2,  3),  2-3  million PBMCs were infected with EBV, which was 
prepared from the B95-8 cell line as described in Chapter 2. Autologous BLCL from 
XLP3  was  generated  from  bone  marrow  cells  because  the  patient  had  B  cell 
lymphopenia. The established transformed cells were analyzed using flow cytometry 
for CD 19 (a B cell marker) and CD 3 (T cell marker). All lines were over 95% CD 19 
positive and negative for CD3 (data not shown). These EBV-LCL lines were used to 
generate EBV- specific T cell lines.
Pre-stimulated EBV- T cells were generated using protocols No2 and No3 (see 
Table 4.1), and used to produce EBV-T cell lines, which were either transduced (with 
SAP-eGFP or only eGFP) or non-transduced (as described in Chapter 4).  The lines 
were stimulated with irradiated autologous BLCL and rIL-2 weekly and cultured in
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complete RPMI as shown in Figure 4.3. EBV- specific T cell lines were successfully 
generated from two XLP patients and two normal controls. All lines generated using 
protocol No2 were mainly CD4 positive (85-95%) and lines generated with protocol 
No3 were mainly CD8 (80-95%) positive (see Table 5.2 and Table 5.3).
As shown in Figure 5.1, the rate of EBV- specific T cell lines expansion obtained in 
XLP patients was comparable to the pattern observed with lines from healthy donors, 
with a mean of 4-4.5-  fold expansion after 4  stimulations.  In addition, non-specific 
polyclonal stimulation of XLP T cells with lectin substances such as PHA induced a 
2-  fold  expansion,  which  was  consistent  with  results  from  healthy  controls.  To 
summarise,  these  results  confirmed  that  T  cells  from  XLP  patients  show  normal 
proliferation  capacity  in  response  to  autologous  BLCL  or  a  polyclonal  stimulator 
demonstrating that lack of SAP expression does not affect this process.
5.3  EBV-T cell line immunophenotyping
The EBV-T cell lines generated were CD3 positive (95-99%) with more than 
90% of cells positive for the ap TCR and less than 5-10% of the lines expressing yS 
TCR (Figure 5.2). Natural killer cells (defined as cells expressing CD56 and /or CD 16 
antigen but lacking CD3 expression) represented less than 2-5% of the population in 
both CD4 and CD8 lines. In addition, the EBV -T cell lines were almost negative (less 
than  1-2%)  for  lymphokine  activated  killer  (LAK)  (CD3+/CD56+).  As  shown  in 
Table  5.2  and  5.3,  EBV-T  cell  lines  were  examined  for  other markers,  which  are 
explained in detail below.
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Figure 5.1 T cell proliferation in XLP patients and controls
EBV- T cell proliferation was measured by cell counting in two XLP patients and two 
controls under protocol  stimulation number 2 and  3  after four weeks.  The mean (± 
SD) data for each group (XLP and control groups) were calculated based on at least 
three occasions. As a control, PBMCs were stimulated with PHA and the increase in 
cell number was measured after 48 h.
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Figure 5.2 Surface expression of ap and y8 TCR by EBV-T cell lines
The surface expression of ap and y8 TCR EBV- T cell lines were examined by flow 
cytometric analysis. Plots from a representative experiment (XLP1) are displayed and 
were generated by gating on cells with a high forward and side scatter then on CD3 
positive population.  Quadrants were placed according to their isotype  controls  (not 
shown).  All the lines from control and XLP patients were mainly ap  TCR positive 
with a small percentage y8 TCR T cell population.
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Table  5.2  Cell  surface  phenotype  of  EBV-CD8  T  cells  from 
controls and XLP patients
Cell surface 
marker
% expression (MFI) % expression (MFI)
NORMAL 
Cl  C2
PATIENT 
XLP1  XLP2
CD3 95-95(136) 95-95(227) 95-98(183) 95-99(133)
CD4 5-15(19.6) 12-20(39.5) 7-8(26) 10-12(43)
CD8 80-95(283) 85-95(232) 90-95(185) 80-90(223)
CD16 3-10(1.6) 2-5(2.1) 7-13(1.3) 10-12(1.6)
CD56 5-15(3.4) 10-12(3) 8-10(2.8) 10-12(3.1)
CD45RA 2-5(3.5) 2-5(2.1) 3-6(2.5) 8-10(3.3)
CD45RO 90-95(70.6) 90-97(60.1) 94-97(40.3) 90-93(51.4)
CD28 0.5(2.5) 0 9(1.5) 1.05(2.7) 1(1-9)
CD25 1-2(12) 3-5(3.2) 2-3(11.2) 1-2(4.2)
CD27 30-50(1.2) 30-55(2.4) 25-55(2.1) 20-60(1.5)
CD69 20-70(41.9) 20-65(56) 20-55(61)
CCR5 50-55(10.4) 50-75(13.1) 3-8(6.1) 2-4(23)
CCR7 5-12(4.2) 5-7(3.9) 10-12(3.6) 7-10(5.6)
SLAM 1-4(1.8) 2-3(2.7) 1-4(8.4) 3-5(3.2)
2B4 40-90(27) 35-95(31) 40-95(38) 30-85(41)
CD95 10-13(1.6) 6-7(1.2) 7-9(1) 7-15(1.7)
The EBV-T cell lines (from two XLP patients 1, 2 and two healthy controls 1, 2) were 
stimulated with protocol No 3 and were analysed for different CTL and NK markers 
with  flow  cytometry.  The  lines  were  mainly  CD3/CD8  positive.  The  percentage 
expression  and  mean  fluorescence  intensity  (MFI)  were  estimated  on  at  least  two 
occasions.  The  CCR5  expression was  different  in the XLP  and  control  lines  (It  is 
highlighted with Bold font).
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Table 5.3 Cell surface phenotype of EBV-CD4 T cell lines from 
controls and XLP patients
Cell
surface
% expression (MFI) % expresssion (MFI)
marker
NORMAL PATIENT
C l C2 XLP1 XLP2
CD3 99-99.5(213) 98-99(234) 97-99(300) 98-99(330)
CD4 90-95(99) 85-95(102) 90-95(116) 90-97(93)
CD8 5-7(1.9) 10-15(3.4) 7-8(1.9) 5-8(1.7)
CD16 3-4(1.5) 4-5(1.2) 2-6(1.1) 5-7(1.6)
CD56 6-8(3.1) 3-4(2.8) 4-8(2.3) 5-7(2.7)
CD45RA i 1-3(5.8) 2~3(2.4) l-2(2.6) 1-5(2.8)
CD45RO 90-97(95.5) 95-98(69.3) 98-99(78.9) 94-99(70)
CD28 86-85(1.5) 70-86(1.6) 80-87(1.7) 57-75(1.5)
CD25 85-90(21) 87-92(24.6) 80-90(27.1) 85-94(21.3)
CD27 60-70(1.5) 65-73(1.7) 55-70(2.1) 47-73(1.7)
CD69 40-90(31) 35-85(28) 45-85(36) 40-80(33)
CCR5 <1 <1 <1 <1
CCR7 10-15(2.4) 8-17(3.2) 5-7(2.7) 10-12(3.3)
SLAM 1-4(2.2) 3-4(2.2) 2-5(2.6) 3-4(2.8)
2B4 85-99(22) 86-95(17) 80-95(23) 80-97(39)
CD95  W M   2-5<L2> 3-7(1.5) 6-7(1.3) 5-8(1.6)
The EBV T cell lines (from two XLP patients 1, 2 and two healthy controls 1, 2) were 
stimulated with protocol No 2 and were analysed for different CTL and NK markers 
with  flow  cytometry.  The  lines  were  mainly  CD3/CD4  positive.  The  percentage 
expression  and  mean  fluorescence  intensity  (MFI)  were  estimated  on  at  least  two 
occasions.
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5.3.1  Memory-effector EBV-T cell lines phenotype
In order to characterize EBV-T cell lines for memory and effector phenotype, 
they have been analysed by flow cytometry for surface expression of CD28, CD27, 
CD45RA  and  CD45RO.  CD28  and  CD27  are  costimulatory receptors  involved  in 
regulation  of  T  cell  activation  and  in  the  generation  of  antigen-primed  cells 
respectively (Hintzen et al,  1994;  Lenschow et al,  1996; Appay et al,  2002).  CD28 
interacts with CD80 (B7-1) and CD86 (B7-2), which are expressed on APCs and has 
a dual role as an adhesion and a signalling molecule (Mauri et al,  1995; Sansom et al,
2003).  On  the  other hand,  CD27  binds  to  CD70  and  plays  a role  in  TCR-induced 
expansion of both CD4 and CD8 T cells (Hendriks et al, 2000).
While CD28 is down regulated after TCR stimulation, CD27 is up regulated 
and the expression of CD28 and CD27 is particularly useful in distinguishing between 
subsets of differentiated effector/memory T cells (Hamann et al,  1997; Tomiyama et 
al,  2002).  It  has  been  reported  that  CD28-  CD27+  and  CD28-  CD27-  phenotypes 
define late and intermediate effector subset differentiation in humans (Tomiyama et 
al,  2002). The results of CD8 CTL lines were 25-60% positive for CD27 and almost 
negative for CD28 (less than 2%) in XLP patients and in normal controls. In contrast 
57-87% of CD4 CTL lines were positive for CD28 at a low fluorescent intensity and 
were 47-73 % positive for CD27. CD27 expression was slightly higher than that seen 
in the CD8 population.  The expression of CD27 and CD28 on CD4 CTL lines was 
similar between XLP patients and controls. Moreover, for both XLP and control CD4 
and CD8 CTL lines very low levels of CD45RA (1-10%) were expressed but more 
than  90%  of  each  population  was  positive  for  CD45RO.  Interestingly,  CD25 
expression on CD8 lines was very low (1-5%) instead of high expression (80-94%) on 
CD4  lines.  The  results  for  other  activation  marker  CD69  were  dependent  on  the
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stimulation  conditions  and  showed  similar  patterns  in  both  patients  and  healthy 
donors.  Together,  these  results  suggest  that while  CD4  and  CD8  EBV-T  cell  lines 
demonstrate a slightly different effector phenotype, which were the low expression of 
CD28 and CD25 (1-10%) on CD8 lines in comparison with high expression (60-90%) 
on CD4 lines.  However, there was no difference between XLP and normal lines for 
these markers.
5.3.2  SLAM-2B4 expression in EBV- specific T cell lines
To date, it has been shown that the CD2 Ig super family members SLAM and 
2B4  are  mainly  involved  in  the  pathogenesis  of the  XLP  syndrome  through  SAP, 
although  the  role  of other  members  of this  receptor  family  cluster  remains  to  be 
determined. It has been reported that SLAM is expressed on CD45ROhlgh peripheral- 
blood memory T cells in vivo and it is rapidly induced on naive CD45RO' T cells and 
enhanced  on  CD45ROh,gh  T  cells  after  activation  (Cocks  et  al,  1995).  It has  been 
speculated  that  during  EBV  infection,  SLAM-SLAM  interactions  at  the  interface 
between  EBV-infected B  cells and T cells may promote the development of EBV- 
specific  T  responses  but  this  has  not  been  studied  for  CTLs.  Moreover,  2B4  is 
expressed  mainly  in  NK  cells,  CD8y5  and  almost  half of CD8ap  cells,  but  the 
regulation  of its  expression  has  not  been  fully  investigated  in  CTLs  or  in  T  cells 
generally.  In  order  to  address  this,  EBV-T  cell  lines  were  examined  for  2B4  and 
SLAM  expression  by  flow  cytometric  analysis.  Interestingly  both  CD4  and  CD8 
EBV-T cell lines displayed very low or negative (1-5%) SLAM expression but high 
2B4 expression (40-95%) was seen (Figure 5.3). The level of 2B4 expression varied 
with different stimulation situations. The similarity of the phenotype of lines from
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Figure 5.3 SLAM and 2B4 surface expression of EBV-CD8 T cell 
lines
The surface expression of SLAM  and 2B4 on EBV-CD8 T cell  lines  from Cl  was 
examined  by  flow  cytometry  analysis.  Plots  from  a  representative  experiment  are 
displayed and were generated by gating on cells with a high forward and side scatter 
then on CD3  positive population.  Quadrants were placed according to their isotype 
controls (not shown).  EBV-CD8 T cell lines expressed a low level of SLAM and a 
high level of 2B4.  Flow cytometric analysis of CD4  and CD8  lines  show the same 
pattern for SLAM and 2B4 expression in XLP patients and healthy controls (see table 
5.2-3).
1.5%
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Figure 5.4 SLAM and 2B4 surface expression of CMV- T cell lines
The  surface  expression  of SLAM  and  2B4  by  CMV-  T  cell  line  from  a  healthy 
individual  was  examined  by  flow  cytometric  analysis.  Plots  from  a  representative 
experiment are displayed and generated by gating on cells with a high  forward and 
side  scatter then  on  CD3  positive population.  Quadrants  were  placed  according  to 
their isotype controls (not shown).  CMV- T cell  line expressed a high level of 2B4 
and negative for SLAM.
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XLP patients and healthy donors confirmed that SAP is not necessary for SLAM and 
2B4 expression. Furthermore, to detect whether this phenotype is EBV specific or is a 
general phenotype  for cytotoxic  T  cells,  CMV  specific  T  cell  lines were  generated 
using  DCs  pulsed  with  CMV  peptide  (kindly  gifted  by  Dr  S.  Mackinnon)  and 
investigated for SLAM and 2B4 expression.  Similar to EBV-T cell lines, the results 
from flow cytometric analysis showed 59- 69 % positivity for 2B4 and very low or 
negative SLAM expression (Figure 5.4).
This data demonstrates that 2B4 is a dominant marker an effector cells which 
might play a role in T cell response to EBV latency Ags. It remains to be investigated 
whether higher expression of 2B4 on CTL lines compared with SLAM expression is 
consistent during generating of CTLs.
In addition it remains unclear whether 2B4 is the main SAP related pathway. 
As  a  result,  it  is  crucial  to  answer  this  question  with  regard  to  the  SAP  related 
pathway for CTLs in XLP. These questions are investigated further in Chapter 6.
5.3.3  Chemokine and chemokine receptors characteristics of 
EBV- specific T cell lines
Chemokines play well-established roles as attractants of nai've and effector T 
cells (Cyster,  1999; Campbell et al,  2000; Sallusto et al,  2000). It has been recently 
reported that chemokine  families  also play important roles  in T cell  differentiation 
along with cytokines such as IFN-y (Luther et al, 2001). Moreover, studies of immune 
response  to  viruses  particularly  HIV  demonstrated  the  importance  of chemokines 
(Cocchi et al,  1995; Hadida et al,  1998; Littman,  1998). Therefore, chemokines may 
play a crucial role in the pathogenesis of XLP, which is well documented to be
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Figure 5.5 Surface CCR5 and CCR7 expression by EBV-CD8 T cell 
lines from Cl  and XLP patients
The surface expression of CCR5  (A) and CCR7 (B) by EBV-CD8 T cell line from 
Cl  and  XLP1,  2  was  examined  by  flow  cytometric  analysis.  Histograms  from  a 
representative experiment are displayed and were generated by gating on cells with a 
high  forward  and  side  scatter then  on  CD3  positive  population.  The  expression  of 
CCR5 and CCR7 shown as overlay histogram.
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Figure 5.6  Intracellular expression  of RANTES  by EBV-CD8  T cell 
lines
Intracellular RANTES  expression by EBV-CD8  T  cell  lines  (XLP1  and  Cl)  was 
examined  by  flow  cytometric  analysis.  Plots  from  a  representative  experiment  are 
displayed  and  were  generated  by  gating  on  cells  with  a  high  forward  scatter. 
Quadrants  were  placed  according  to  their  isotype  controls  (not  shown).  The 
expression of RANTES in XLP1 was very low in comparison with control (Cl).
EBV-T cell Line PI EBV-T cell Line Cl
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triggered by viral infections, especially EBV.  Thus, to investigate the significance of 
chemokines  in  XLP,  surface  expression  of  CCR5  and  CCR7  and  intracellular 
expression of RANTES (CCL5) were examined. It is known that CCR5 is upregulated 
by Thl  cytokines such as IL-2 and IL-12 on T cells (Bonecchi et al,  1998; Loetscher, 
1998; Sallusto et al,  1998). In EBV-T lines there was a significant difference in CCR5 
chemokine  receptor  expression  between  XLP  and  normal  EBV-CD8  T  cell  lines. 
XLP-CD8  lines  showed  very  low  CCR5  expression  (2-8%  of  total  population) 
compared with 50-75% positivity in normal donors (Figure 5.5 A). EBV- CD4 T cell 
lines showed  similar CCR5  expression  level  in XLP  and normal controls  (data not 
shown). In contrast, CCR7 a chemokine involved in homing memory of T cells was 
only expressed in 5-26% of the total population in both CD4 (data not shown) and 
CD8 lines from normal and XLP donors (Figure 5.5 B). Next, RANTES a ligand for 
CCR5  was investigated in CD8  CTL lines.  Interestingly,  intracellular expression of 
RANTES  in  XLP  CD8  CTL  lines  was  very low  (1%)  in  comparison  with  normal 
lines, which had a 70-75% expression level (Figure 5.6).
These results raise the possibility that SAP may be involved in the regulation 
of  chemokines  and  chemokine  receptors,  which  could  be  important  for  the 
pathogenesis of XLP.
5.4  Discussion
In  normal  individuals  the  immune  response  to  EBV  infection,  the  major 
pathological trigger in XLP, is dominated by the proliferation of CD8+ EBV-T cell 
lines and NK cells. The development of EBV driven lymphoma and fulminant IM in 
XLP  would  strongly  suggest  that  defects  exist  in  these  effector  populations  (See 
Chapter one).  In this study we show that it is possible to generate EBV-T cell lines
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from XLP patient blood. Using different culture conditions we were able to generate 
T cell lines of both CD8+ and CD4+ phenotype from both normal and XLP patients. 
It has been shown T cells are normally capable of proliferating under different stimuli 
in SAP deficient murine models (Howei et al, 2002). Our results demonstrated that T 
cells from XLP patients show a comparable proliferation response to mitogen (PHA) 
or EBV-LCL. Sanzone et al (2003) recently showed that non-transformed T cell lines 
from two XLP patients failed to proliferate upon CD3 or CD3/28 stimulation but not 
with  PHA,  suggesting  SAP  is  involved  in  early  T  cell  activation.  However,  our 
results  and  a recent report by Plunkett  et al (2005)  support the  idea that  the  early 
proliferation capacity of primary XLP T cells is intact. The different observations may 
be due to the investigational model (primary T cells versus established T cell lines) or 
the inter-individual differences between XLP  samples that may have experienced a 
variable time course or type of exposure to infection (such as EBV).
Furthermore,  although  most  cytotoxic  T  cell  lines  are  CD8+,  polyclonal 
expansion of T cells in response to viral antigens can result in CD4+ T cell lines and 
CD4+  cytotoxicity is well  documented  (Peggs  et al,  2001;  Sun  et al,  2002).  Cell 
surface marker expression profiles  and intensity of expression were  similar in both 
XLP  and control  groups.  Interestingly,  in both controls  and XLP  EBV-T  cell  lines 
there  was  very  little  SLAM  expression  observed  while  2B4  was  expressed  at 
significant levels. To date, SLAM has been cited as the main partner for SAP binding 
and  as  an  important  co-stimulatory  molecule  in  T  cell  responses  to  antigenic 
stimulation.  Much  of this  work  has  been  performed  on  murine  T  cells  and  the 
differential  expression  of  SLAM  and  2B4  in  human  effector  cells  has  not  been 
extensively studied. Our analysis shows abundant 2B4 expression in both control and 
XLP  EBV-T  cell  lines,  while  SLAM  expression was minimal.  Furthermore,  in our
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studies, stimulation of EBV-T cell lines and PBMCs from normal individuals shows 
no significant enhancement in SLAM expression at least in the early response period 
(Chapter  7).  Our  observations  would  suggest  that  2B4,  not  SLAM,  is  the  major 
partner  for  SAP  in  EBV-T  cell  lines  and,  as  previously  observed  in  NK  cells, 
signalling through 2B4 in XLP EBV-T cell lines may be defective.
Furthermore, all XLP lines showed a similar phenotype as compared to normal 
controls except for CCR5 expression in CD8 lines, which in XLP lines was minimal 
but expressed at high levels in normal  EBV-CD8  T cell  lines.  CCR5  is chemokine 
receptor, which is up regulated by Thl  cytokines such as IL-2 and IL-12 through the 
STAT4 pathway (Bleul et al,  1997). CCR5 is expressed mainly on T cells with a Thl 
phenotype (Loetscher, et al 1998) and recruits lymphocytes to sites of inflammation. 
As  CCR5  upregulation  is  important  in  response  to  MEFa  in  DC  and  T  cell 
interactions, this could play a role to initiate immune responses in APC process. More 
recently it has been reported that XLP patients  show an abnormality in chemokine 
expression (Malbran et al, 2004). This may be as the result of the cytokine imbalance 
reported in XLP patients. However, the possibility of CCR5 mutations has not been 
ruled out in these patients as reported in HIV patients (Liu et al,  1996; Samson et al, 
1996).  More  interestingly,  the  CD8  T  cell  lines  from  XLP  patients  showed  a 
significant defect in RANTES (CCL5) production. It has been reported that RANTES 
(CCL5) magnifies the cytokine polarity of the T cell response and therefore may play 
a  key  role  in  the  immune  response  to  viral  infection  (Luther  et  al,  2001).  In 
particular,  chemokines  are  likely to play important roles in the pathophysiology of 
disease associated with EBV (Nakayama et al,  2004). EBV infection induces B cells 
to  up  regulate their constitutive  expression of MIP-1<VCCL4,  and RANTES,  which 
are known to attract Thl cells and activated cytotoxic T cells via CCR5 (Yoshie et al,
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2001; Nishimura et al,  2002). Moreover, it has been demonstrated that T cells are a 
major source of RANTES production upon EBV infection in vitro (Jabs et al, 2002).
Together,  this might demonstrate that  due to  lack  of SAP  function,  or as  a 
result of the  reduction of IFN-y response,  there may be  a consequent reduction  of 
RANTES and CCR5 expression. This may play some role in the cellular pathogenesis 
or at least determine severity of IM in XLP patients. This result provides intriguing 
data regarding XLP pathogenesis and requires further investigation.
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6.1  Introduction
Immune  cells  are  activated  as  a  result  of productive  interactions  between 
ligands  and various receptors.  The result of this orchestrated response provides the 
balanced participation of several immune cell types. In immune cells, SAP is shown 
to associate with SLAM, 2B4, and NTB-A and other members of this group shown in 
transfected cell lines as mentioned previously. In this context, interaction of SAP with 
SLAM family members regulates activation of T and B cells, which may be important 
in the immune response to Ags such as EBV (Latour et al, 2004).
As discussed in section  1.6.2, SAP regulatory function seems to be complex. 
In  particular,  this  is  highlighted  by  its  interaction  with  heterogeneously  expressed 
SLAM family members in immune cells. Thus the pathogenesis of XLP may be more 
complex than previously thought. Investigation of SAP expression and its receptors in 
leading the dynamic processes of the immune response may shed some light on the 
pathogenesis of XLP and the role of the  SAP pathway signalling machinery.  It has 
been reported by several  groups that  SAP expression  in human T  and NK cells  is 
regulated differently to that in murine cells (see section 1.4.3). Moreover, it has been 
reported that in the murine model,  SLAM  is upregulated upon T cell  activation by 
non-specific stimulators but SAP at the mRNA level is down regulated (see section 
1.6.2). Therefore, considering the importance of SAP in balancing function in T and 
NK cells, it is fundamental to look at regulation of SAP expression and the expression 
of its ligands particularly SLAM and 2B4. Thus in the following chapter SLAM-2B4 
expression in different cell lineages in both the resting and activated condition will be 
discussed.
168Chapter 6  Expression of SLAM & 2B4 on Immune Cell Lineages
6.2  SLAM and 2B4 expression on immune cell lineages
SLAM and 2B4 expression on different immune cell lineages were described 
in  Chapter  1  (see Table  3.1).  However,  there  is  little known  about coexpression  of 
SLAM  family  receptors  on  immune  cells  in  the  resting  and  active  condition. 
Therefore,  in the  following  section  co-expression  of SLAM  and  2B4  pre  and  post 
stimulation is discussed.
6.2.1  SLAM and 2B4 expression on T cell subsets
SLAM and 2B4 expression on T cell subpopulations were investigated by flow 
cytometric analysis. As shown in Figure 6.1-2, SLAM expression on both resting CD4 
and CD8 populations was low (1.5%-3%).  However, 2B4 expression averaged 27% 
(15-30%) for CD8 cells and for CD4 cells an average of 9% (7-12%) expression was 
seen (Figure 6.1 and 6.2).
6.2.2  SLAM and 2B4 expression on B cells and BLCLs
EBV-BLCL lines showed double positive expression of both 2B4 and SLAM 
with  90-95%  expression  but  2B4  showed  relatively  low  fluorescence  intensity. 
Primary  B  cells  showed  very  low  SLAM  expression  and  were  negative  for  2B4 
(Figure 6.3).
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Figure 6.1 The surface coexpression of SLAM and 2B4 on CD4 T cells
The  surface  expression  of SLAM  and  2B4  by  peripheral  blood  CD4  T  cells  was 
examined  by  flow  cytometric  analysis.  Plots  from  a  representative  experiment  are 
displayed and were generated by gating on cells with a high forward and side scatter 
then on the CD3/4 double positive population. CD4 T cells expressed a low level of 
SLAM and a moderate level of 2B4 in unstimulated conditions.
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Figure 6.2 The surface coexpression of SLAM and 2B4 on CD8 T cells
The  surface  expression  of SLAM  and  2B4  by  peripheral  blood  CD8  T  cells  was 
examined  by  flow  cytometric  analysis.  Plots  from  a  representative  experiment  are 
displayed and were generated by gating on cells with a high forward and side scatter 
then on the CD3/8  double positive population.  Quadrants were placed according to 
their isotype controls (not shown). CD8 T cells expressed a very low level of SLAM 
but a higher level of 2B4 in unstimulated conditions.
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Figure 6.3 The surface coexpression of SLAM and 2B4 on B cells (A) 
and BLCL lines (B)
The surface expression of SLAM  and 2B4 by peripheral blood B  cells and BLCLs 
was examined by flow cytometric analysis. Plots from a representative experiment are 
displayed and were generated by gating on cells with a high forward and side scatter 
then on the CD19 positive population.  B cell expressed a very low level SLAM and 
2B4 in unstimulated condition (panels group A). BLCL expressed a very high level of 
SLAM and 2B4 (panels group B).
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6.2.3  SLAM  and  2B4  expression  on  primary NK cells  and
NK/LAK cell lines
It has been well documented that 2B4 is expressed on primary NK cells  (see
section  1.6.1).  In  support  of previous work,  we  have  found  that  non-activated NK
cells express 2B4  at 55-70% level (marker set up based on negative control) while 
they are negative for SLAM expression (Figure 6.4). Moreover, NK and LAK lines 
from three normal individuals tested and were positive for 2B4 on over 90% of cells 
and negative  for  SLAM  (data  shown  only  for  LAK  lines,  Figure  6.5).  The  results 
confirmed  that  SLAM  is  not  expressed  on NK cells  either in  the  resting  or active 
condition.
6.2.4  SLAM and 2B4 expression on DCs
Furthermore,  SLAM  and  2B4  expression  on  DCs  were  studied  with  flow 
cytometric analysis.  It has been reported that unlike monocytes, which are negative 
for SLAM  and show low expression of 2B4,  only mature DCs express SLAM  (see 
section 1.61). However, 2B4 expression on DCs has not yet been reported. In order to 
answer this question, harvested DCs were  analysed  for 2B4  and  SLAM.  Immature 
DCs based on a CDllc positive phenotype (100%) and very low expression of CD86 
(10.12%) a marker indicative of DC maturation, and mature DCs double positive for 
CDllc  (100%)  and CD86  (99%) were  analysed.  Interestingly,  immature  DCs were 
positive for 2B4 with 35-45% expression but were SLAM negative. After maturation 
over 48 hours,  mature DCs showed  10-12%  SLAM but were 75-76% 2B4 positive 
(Figure 6.6).
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Figure 6.4  The surface coexpression of SLAM and 2B4 by NK cells
The surface expression of SLAM and 2B4 by peripheral NK cells was examined by 
flow cytometric  analysis.  Plots  from  a representative experiment  are  displayed  and 
were generated by gating on cells with a high forward and side scatter then on CD3 
negative  and  CD56 positive population.  NK cells  expressed  a very high  level  2B4 
(55%)  (marker  was  based  on  negative  control)  and  no  expression  of  SLAM  in 
unstimulated conditions.
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Figure 6.5 SLAM and 2B4 expression by LAK cell lines (CD3/56/16)
The surface expression of SLAM and 2B4 by LAK cell lines (presenting the results 
from Cl) were examined by flow cytometry. Plots from a representative experiment 
are displayed  and  were  generated by gating  on  cells  with  a high  forward  and  side 
scatter.  Quadrants were placed according to their isotype controls (not  shown).  The 
cells were positive for CD3/CD56/CD16. LAK cell lines expressed a very high level 
of 2B4 and were negative for SLAM expression.
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Figure 6.6 The surface coexpression of SLAM and 2B4 by immature 
and mature DCs
The surface expression of SLAM and 2B4 by normal immature and LPS-matured DC 
was examined by flow cytometric analysis. Plots from a representative experiment are 
displayed and were generated by gating on cells with a high forward and side scatter. 
DCs were identified by expression of CDllc and absence of lineage markers:  CD3, 
CD 14, CD 16, CD 19, CD20, CD56. Quadrants were placed according to their isotype 
controls  (not  shown).  Maturation  upregulated  the  CD86  surface  marker.  Immature 
DCs expressed high levels of 2B4 and a very low level of SLAM. Surface expression 
of 2B4 further increased with maturation while SLAM expression increased slightly.
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6.3  SLAM and 2B4 expression upon specific stimuli
It has been shown in humans that  SLAM  is up regulated upon  CD3-CD28, 
Con  A  and  PHA  stimulation  on  T  cells.  Although  initial  reports  showed  that 
established CD4 Thl clones show high SLAM expression with low expression on Th2 
clones (Cocks et al,  1995), SLAM expression has not been comprehensively studied 
in primary T cells upon specific stimulation. To date, 2B4 expression has been mainly 
studied on NK cells but not on T cell populations. In this context there is little known 
about 2B4 expression in human T cells, although it has been suggested that 2B4 is up 
regulated  after stimulation in murine cells (Sayos et al,  2000).  The  combination of 
SLAM/2B4 dual expression has not been investigated in T and NK cells, particularly 
their dynamic coexpression over time upon specific stimulation.
Therefore,  after  observing  the  predominance  of 2B4  expression  on  EBV- 
specific  T  cell  lines  and  on  CD4  or CD8  T  cells,  we  considered  investigating  the 
expression of these two markers under specific stimuli on different populations of T 
cells and NK cells.
SLAM and 2B4 expression upon CD3-CD28, CD3-SLAM, CD3-2B4, and autologous 
BLCLs stimulation at differing time points were investigated using flow cytometric 
analysis. Equal number of PBMCs from three normal donors were stimulated either 
with co-localised antibody (Ab) combination CD3/CD28, CD3/SLAM,  CD3/2B4 or 
with autologous BLCL lines at a ratio of 10:1 cell (PBMCs/BLCL cells) were cultured 
in  complete  RPMI  medium  as  described  in  Chapter  2.  To  check  efficiency  of 
activation,  stimulated cells were analysed for CD69,  an activation marker on T and 
NK cells. As shown in Figure 6.7, upon different antibody stimuli, T and NK cells 
showed constant activation during the stimulation period, with 40-67% of populations
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positive for CD69 expression (data show expression after 12 hours). In contrast, cells 
when  stimulated  with  BLCL  showed  rising  CD69  expression  after  6-12  hours  of 
stimulation with over 95% CD69 positivity on both T and NK cells (data not shown). 
To consider the effect of the above stimuli on cell proliferation, stimulated cells were 
counted using Trypan blue to detect live cells. There was no significant difference in 
proliferation responses to specific stimuli (data not shown). Stimulated cells were then 
analysed with  four colour flow  cytometry for SLAM,  2B4,  CD3,  and  one of CD4, 
CD8, CD56 parameters at time 0,  12, 24, and 48 hours after stimulation (some were 
checked after 6 hours or in case of stimulation with BLCL, checked after 72 hours). 
Results are presented based on CD8, CD4, and NK cell analysis and are discussed as 
follows.
6.3.1  SLAM and 2B4 expression on CD8 T cells
As described above, CD8 T cells express 2B4 at greater levels than SLAM in 
the  resting  situation.  Interestingly,  2B4  upregulation  was  significantly  higher  and 
earlier than SLAM upregulation (Figure 6.8). However, SLAM was upregulated after 
CD3/28 stimulation reaching its highest level after 48 hours. Stimulation with BLCL 
induced no increasing of SLAM expression even after 72 hours, which correlates with 
our previous data from CTL lines. Double positive populations for SLAM and 2B4 on 
resting CD8 cells and upon different stimuli were very low except after CD3/CD28 
stimulation, where an increase in 2B4 and SLAM double positive cells were observed 
after  24  hours.  Significant  2B4  expression  was  observed  regardless  of  the  type 
stimulation,  and only its  expression upon CD3/2B4 stimulation at early time points 
was decreased but increased again after 12 hours. It may be due to internalization of
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Figure 6.7 Surface expression of CD69 by activated T cell
The surface expression of CD69 by T cell was examined by flow cytometric analysis. 
Plots from a representative experiment are displayed and were generated by gating on 
cells  with  a  high  forward  and  side  scatter  then  on  CD3  positive  population  (not 
shown).  Quadrants  were placed  according to  their isotype  controls  (not  shown).  T 
cells were negative  for CD69 expression at the time zero before  stimulation.  Upon 
different stimulation (CD3/28, SLAM, 2B4) CD69 expression upregulated between 6- 
12 hours (the results present the CD69 expression after 12 hours).
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this  receptor.  These  results  showed  early  and  sustained  up  regulation  of 2B4  in 
comparison to SLAM.
6.3.2  SLAM and 2B4 expression on CD4 T cells
It has been reported previously that SLAM is the dominant receptor on CD4 
cells. In contrast, it is believed that 2B4 is not significantly expressed on CD4 T cells. 
However, the data from CD4 CTL lines showed high levels of 2B4 expression. These 
results, together with our observation on resting CD4 T cells showing 2B4 expression 
made a strong case to investigate expression of these receptors on CD4 T cells. Upon 
CD3/CD28  stimulation,  SLAM  and 2B4  expression was  similar, but after 24 hours 
2B4 was more highly expressed, although SLAM expression remained high (Figure 
6.9).  In  contrast,  upon  other  stimuli  SLAM  upregulation was  not  significant.  Low 
SLAM expression after CD3/SLAM stimulation as observed on CD8 T cells might be 
related  to  SLAM  internalization.  Significant  2B4  expression  over  48  hours  of 
stimulation, strongly suggests an important role for 2B4 on CD4 T cells.
It remains to be addressed whether Thl  or Th2 specific CD4 T cells show the 
same characteristics.
6.3.3  SLAM and 2B4 expression on CD56 NK cells
It has been shown in murine cells that 2B4 is highly expressed on NK cells, 
and SLAM is only expressed at low levels on primary NK cells. Recently it has been 
reported  that  NTB-A  (SF2000)  and  CRACC  (CS-1)  are  expressed  on  NK  cells. 
However, although 2B4 is expressed on primary NK cells and up regulates upon IL-2
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Figure 6.8  SLAM  and  2B4  surface  expression  on  CD8  T cells  upon 
activation by different stimuli
SLAM and 2B4 expression on CD8 T cells was investigated after CD3-SLAM (A), 
CD3-2B4  (B),  CD3-CD28  (C),  and  autologous  BLCLs  (D)  stimulation  at differing 
time points using flow cytometric analysis. Three healthy different individuals were 
studied  twice  each.  The  values  for  each  experiment  were  derived  from  flow 
cytometric analysis of the data, and the average percentage (± SD) of expression for 
each individual and mean percentage for all three was calculated for each point. The 
percentage expression of SLAM, 2B4 and double positive (SALM+2B4) are shown in 
blue, red and green, respectively.
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Figure 6.9  SLAM  and  2B4  surface  expression  on  CD4  T  cells  upon 
activation by different stimuli
SLAM and 2B4 expression on CD4 T cells was investigated after CD3-SLAM (A), 
CD3-2B4  (B),  CD3-CD28  (C),  and  autologous  BLCLs  (D)  stimulation  at  differing 
time points using flow cytometric analysis. Three healthy different individuals were 
studied  twice  each.  The  values  for  each  experiment  were  derived  from  flow 
cytometric  analysis  data and the  average percentage  (±  SD) of expression  for each 
individual and mean percentage for three was calculated for each single time point. 
The  percentage  expression  of SLAM,  2B4  and  double  positive  (SLAM+2B4)  are 
shown in blue, red and green, respectively.
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Figure  6.10  SLAM  and  2B4  surface  expression  on  NK  cells  upon 
activation by different stimuli
SLAM and 2B4 expression on NK cells was investigated during PBMCs stimulation 
after CD3-SLAM  (A),  CD3-2B4  (B),  CD3-CD28  (C),  and  autologous  BLCLs  (D) 
stimulation  at  differing  time  points  using  flow  cytometric  analysis.  Three  healthy 
different individuals were studied twice each. The values for each experiment were 
derived  from  flow  cytometric  analysis  data  and  the  average  percentage  (±  SD)  of 
expression for each individual and mean percentage for three controls was calculated 
for each time point.  The percentage expression of SLAM,  2B4 and double positive 
(SLAM+2B4) are shown in blue, red and green, respectively.
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activation,  it remains to be determined if SLAM  and 2B4  are co-expressed on NK 
cells  after various  activations.  SLAM  was  detected on  0.5-1%  of resting NK cells 
with slight upregulation up to 3% on activated NK cells regardless of activation type. 
In  contrast,  2B4  was  up  regulated  upon  all  stimuli  and  highly  expressed  on 
CD56+/CD3-  cells  (Figure  6.10).  Analysing  CD56+/CD3+  cells  showed  the  same 
expression  for 2B4  and  SLAM  (data not  shown).  2B4  internalisation was  detected 
after  a-2B4  stimulation  on  NK  cells  as  observed  by  sudden  decrease  in  2B4 
expression.
6.4  Discussion
Studies on SLAM and 2B4 expression showed, in contrast to SLAM, which is 
expressed at low levels on unstimulated T cells and not on other immune cell lineages, 
2B4 has a high level of expression.  It has been reported that monocytes are positive 
for 2B4 expression (Nakajima et al,  1999). Interestingly, we have found that 2B4 was 
expressed in immature DCs and was upregulated on mature DCs.  In addition,  2B4 
was expressed on LAK cell lines and EBV-LCLs suggesting a wider 2B4 distribution 
than  thought  previously.  As  described  before  (Chapter  1),  2B4  functions  in 
cytotoxicity  and  T  cells  proliferation  are  well  documented.  However,  the  results 
shown here may suggest 2B4 plays a more diverse role in immune cell interaction.
Receptors  of  the  SLAM  family  regulate  immune  cell  function  including 
regulating  cytokine  production  and  cytotoxicity.  As  has  been  addressed  they  are 
expressed  heterogeneously  and  study  of  their  co-expression  under  physiological 
conditions  may be  critical  to  understand  the  pathogenesis  of the  XLR  The  results 
reported here on co-expression of 2B4 and SLAM upon specific stimuli suggest high
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expression of 2B4 receptors as an early response on T and NK cells.  It may suggest 
that SLAM probably is involved as part of an intermediate T cell response rather than 
in the very early response. However, the only condition where SLAM expression was 
higher than 2B4 was on CD4 T cells upon CD3/28 stimulation after 12 hours, which 
decreased  after  24  hours.  It  reveals  that  regulation  of  SLAM  family  receptors 
expression is more complex than has been thought and the combination of different 
stimuli determines the outcome of cellular responses.  In addition, there were double 
SALM/2B4 positive CD4 and CD8 T cell populations, whose percentage varied upon 
different  stimulation.  It  would  be  very  interesting  to  investigate  the  function  and 
phenotype of these populations.
Moreover, SLAM and 2B4 showed significant internalization upon stimulation 
with combinations of CD3/SLAM  and CD3/2B4 respectively.  More recently,  it has 
been  shown  that  CD229  (Ly9)  a  family  member  of  SLAM  family  is  rapidly 
internalized on T cells after antibody ligation. Although CD229 extracellular domains 
are  slightly  different  from  rest  of SLAM  family  (it  has  4  extra  cellular  domains 
instead of two  domains),  it is possible other members of this  family may mimic  a 
similar pattern (Del Valle et al, 2003). Internalisation may be crucial step in formation 
of signal synapse involving SLAM and 2B4 in immune cell lineages.
In brief,  the  results  presented here  require more  fundamental  investigations 
and reconsideration of the role of SAP and its receptors involvement in immune cell 
activation,  the results  of which may help  us to  understand the pathogenesis  of the 
XLP.
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7.1  Introduction
An  adequate  immune  response to  EBV  requires  a coordinated humoral  and 
cell  mediated  immune  response  including  Th,  Tc  and  NK  cells  to  eradicate  and 
control EBV infection. Although the exact pathogenesis of XLP is poorly understood, 
it has been suggested that the abnormalities of the immune system of XLP patients 
may be due to defects of Th cells, CTLs, and NK cells (see section 1.10). So far it has 
been  shown  that  the  hallmark  of XLP  is  a  dysregulated,  ineffective  host  response 
against EBV in the majority of cases with a formal demonstration that a T cell defect 
is  central  to  the  pathophysiology.  However,  the  most  supportive  data  of  this 
hypothesis  are based on  a murine model, which was  shown to  exhibit an Thl/Th2 
imbalance, particularly increased EFN-y production upon TCR and SLAM stimulation 
either in combination or alone. More recently, it has been shown in a murine system 
that SAP has an essential role in maintaining late B cell help and long term humoral 
immunity by effective CD4 T cell function.
In humans,  the T cell paradigm in the pathogenesis of XLP  is controversial 
and not well documented. It remains to be investigated further whether the Thl  and 
Th2  cytokine  profile  in  XLP  is  similar  to  that  observed  in  mice,  particularly  in 
response  to  specific  stimuli.  Furthermore,  as  shown  in  previous  chapters  SLAM 
expression is not necessarily dominant either on EBV-T cell lines nor on activated T 
cells and instead higher levels of 2B4 expression have been demonstrated. It remains 
to be addressed whether SLAM or 2B4 has the dominant role in controlling the Thl 
profile of XLP patients and in particular IFN-y secretion and how these functions are 
regulated by SAP.
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In  XLP  it  has  been  suggested  that  the  inability  of the  immune  system  to 
control EBV-infected B lymphocyte proliferation may be due to defects of cytotoxic 
activity by CTL and/or NK cells. Studies on NK cells from XLP patients show failure 
of 2B4  mediated  cytotoxic  killing of CD48  expressing target cells  and  EBV-LCLs 
(see  Chapter  1).  This  defect  is  thought  to  arise  from  the  delivery  of an  inhibitory 
signal through the 2B4/CD48 interaction since disruption of this association restores 
normal cytolytic function (Parolini et al,  2000). However, as discussed in Chapter 1, 
the  results  of studies  on  specific  T  cell  immunity  to  EBV  are  contradictory.  In 
particular  T  cell  cytotoxicity  against  EBV  remains  elusive.  In  these  studies 
cytotoxicity due  to  TCR  specific  EBV  antigen  recognition  has  not been  addressed 
comprehensively because  of technical  difficulties.  In S/lP-deficient murine  models, 
although  CTL  function  was  not  studied  specifically  it  was  shown  that  following 
challenge with LCMV (lymphocyte choriomeningitis virus) the numbers of tetramer- 
positive CD8 cells were three to fivefold higher in the spleens of SAP deficient mice 
in compared to wild type mice (Wu et al, 2001).  It was concluded that CD8 T cells 
were effective at eliminating the virus in SAP-deficient mice by measurement of virus 
load.  In  contrast,  XLP  patients  who  were  EBV  seropositive  were  shown  to  have 
persistent high numbers  of EBV-infected  B  cells  in the peripheral blood  and  other 
lymphoid tissues indicating a defective cell mediated immune response (Okano et al, 
1990). Together, current data from XLP patients and SAP deficient mice models are 
contradictory with regard to CTL function.
To  understand  the  cellular  defects  in  XLP,  we  investigated  the  Thl/Th2 
profiles of primary PBMCs by ELISPOT assay in response to TCR stimulation with 
SLAM,  2B4,  CD28,  CD3  or  combinations  thereof  and  specific  Ag  stimulation 
(BLCL).  To  determine  Thl  and  Th2  profiles,  IFN-y  and  IL-5,  IL-10  were
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investigated, respectively, whereas in XLP only IFN-y was studied because of lack of 
access to patient material.  We also used EBV  autologous specific  T cell  lines  from 
XLP patients and studied the functionality of these effector T cells with IFN-y profiles 
and  cytotoxic  activity.  Finally,  using  a  retrovirus  gene  delivery  system  encoding 
hSAP  cDNA,  we  demonstrated  reconstitution  of cytokine  secretion  and  cytotoxic 
function  in  patient  EBV-T  cell  lines,  thereby  confirming  SAP  dependent  cellular 
defects in XLP.
7.2  Cytokine  production  by  PBMCs  from  XLP  patients
and normal individuals
7.2.1  IFN-y production in PBMCs
Disturbances  in  cytokine  secretion  may  play  an  important  role  in  the 
pathogenesis of XLP and recent studies on SAP deficient murine strains demonstrated 
increased  secretion  of IFN-y  in  response  to  viral  infection  and  TCR  and  SLAM 
stimulation  (see  section  1.10.2).  IFN-y  release  in  patients  with  XLP  has  been 
previously studied but the existing data is controversial.
Therefore,  IFN-y production  in  cells  from  XLP  patients  in  comparison  to 
normal individuals was studied in response to a variety of different stimuli. In initial 
experiments responses in PBMCs from three XLP (PI, P2 and P3) individuals (with 
defined  genetic  lesions;  see  Table  5.1)  were  analyzed  by  ELISPOT  assays  and 
compared to responses seen in control samples (C). Following PMA stimulation, cells 
from XLP patients showed high levels of IFN- y production with profiles similar to 
these observed in normal individuals, suggesting an intact capacity to produce IFN- y 
(Figure  7.1).  Cells were then activated with more  specific  stimuli.  In these  specific 
receptor  stimulation  experiments  we  observed  significant  differences  in  IFN-  y
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production  between  controls  and  patient  responses.  After  stimulation  with  CD3, 
CD3/2B4 and 2B4, significantly less IFN- 7 secretion was observed in patient samples 
compared to controls (Fig 7.2 A and B). One exception to this was P3 (who was EBV 
seronegative  at  the  time  of  analysis),  who  showed  an  increased  IFN-7  response 
following CD3 stimulation (p>0.05). His responses to CD3/2B4 and 2B4 were similar 
to the other patients.  Cells were then stimulated with autologous EBV  immortalized 
LCLs  and  again  the  IFN- 7 was decreased  in  all patients,  although  in  P3  who  was 
EBV  seronegative  and where no  spots were observed, this may be expected due to 
lack  of  memory  to  EBV  (Fig  7.2  B).  Cells  were  also  stimulated  with  CD28, 
CD3/CD28, SLAM or CD3/SLAM but no differences were observed between control 
individuals and XLP patients (data not shown).
7.2.2  Th2 cytokines production in PBMCs
Th2  cells  induce  humoral  and  allergic  responses  and  downregulated 
inflammation through production of IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13 cytokines. 
It has been reported that in murine CD4 Ag-specific clones ligation of SLAM by anti- 
SLAM Abs redirected Th2 responses to a Thl or ThO phenotype. More recently, it has 
been  demonstrated  that  SAP  deficient  murine  T  cells  are  unable  to  produce  Th2 
responses  following  challenge  with  pathogens  or  upon  TCR  activation  (see 
section 1.10.2).  These  studies  may  suggest  that  SLAM  and  SAP  modulate  Th2 
responses. However, the role of SLAM family receptors and SAP in Th2 profiles has 
not been studied on primary human T cells, and in particular in response to specific 
stimuli. To investigate this matter, we studied IL-5 and IL-10 production in cells from
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Figure  7.1  IFN-y  expression  by  PBMCs  from  controls  and  XLP 
patients following stimulation with PMA
ELISPOT analysis was used to determine EFN-y expression following stimulation of 
PBMCs  from  controls  (C)  and  XLP  patients  (PI,  P2  and  P3)  with  PMA.  Control 
values  for  each  experiment were  derived  from  pooled  data on  a number of control 
individuals  so  that  each  experiment  has  a  single  control  value,  mean  and  standard 
deviation.  Three  different  control  individuals  were  studied  each  in  triplicate  and 
therefore the control mean is obtained from 9 data points. Each mean patient response 
and variance was then compared against the control response for each experiment.
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Figure  7.2  IFN-y  expression  by  PBMCs  from  controls  and  XLP 
patients following specific stimulation
ELISPOT analysis was used to determine IFN-y expression following stimulation of 
PBMCs from controls (C) and XLP patients (PI, P2 and P3) with CD3 or CD3/2B4
(A),  2B4  alone  or  autologous  LCL  stimulation  (B).  Control  values  for  each 
experiment were derived from pooled data on a number of control individuals so that 
each  experiment  has  a  single  control  value,  mean  and  standard  deviation.  Three 
different control individuals were studied each in triplicate and therefore the control 
mean is obtained from 9 data points.  Each mean patient response and variance was 
then  compared  against  the  control  response  for  each  experiment  and  analysed  for 
statistical  significance  using  a one  tail  unpaired  T-test  assuming,  unequal  variance 
between the two study groups.  Significant differences are indicated by asterisks (no 
asterisk, no statistical significance; *, p<0.05: **, p<0.01; ***, p<0.001).
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normal donors in response to a variety of different stimuli. IL-5 is often co-expressed 
with  IL-4  and  anti-CD3  induces  production  of both  cytokines  in  humans.  This 
cytokine  is responsible  for eosinophil  differentiation  and activation  and  is  involved 
with helping B cells in IgM, IgE production along with IL-4 (Coffman et al,  1998). In 
contrast to  IL-5,  IL-10 was identified as a Th2  cytokine synthesis inhibitory factor, 
which  has  cytokine  inhibitory  function  and  inhibits  Thl  cytokine  production 
particularly from T and NK cells. T and B cells are the sources of IL-10 production 
mainly.
In  this  study,  responses  in  PBMCs  from  two  normal  individuals  (C2,C3)  were 
analysed with ELISPOT assays. Responses to Ags or LPS were used respectively for 
IL-5 and IL-10 as positive control (see chapter 2). Stimulation with CD3 induced IL- 
5, which was equivalent responding to Ags. In contrast, IL-10 production upon CD3 
stimulation was less than response to LPS  (Figure 7.3  A, C).  Cells were stimulated 
with CD3 and combination of CD28, SLAM or 2B4 showed a slightly decrease in IL- 
5  and  no  any  change  in  IL-10  production  (Figure  7.3  B,  D).  Stimulation  with 
autologus BLCL only decreased IL-10 production and not IL-5. Upon CD28, SLAM 
and  2B4  stimulation  alone,  no  IL-5  and  IL-10  secretion  was  observed  (data  not 
shown). Put together, the results showed SLAM or 2B4 and TCR activation in human 
might modify some of Th2 cytokines response.
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Figure  7.3  IL-5  and  IL-10  expression  by  PBMCs  from  healthy 
controls following specific stimulation
ELISPOT  analysis  was  used  to  determine  IL-5  and  IL-10  expression  following 
stimulation  of PBMCs  from  controls  (C2,  3)  with  Ags,  LPS  or  CD3  (A,  C)  and 
CD3/28, CD3, SLAM, CD3/2B4 or BLCL (B, D). Two different control individuals 
were studied each in triplicate and three times.  Data from three experiments on two 
volunteer donors is presented. The mean value (± SD) for each condition was used for 
statistical analysis.
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7.3  EBV-T cell line function in XLP and reconstitution of 
defects following SAP gene transfer
It  has  been  postulated  that  the  cellular pathogenesis  of XLP  may reside  in 
abnormal function of EBV-T cell lines and in their inability to control EBV infection. 
Previous  reports,  performed  before  the  identification  of the  SAP  gene  defect,  are 
inconclusive with certain studies demonstrating that cytokine secretion and cytoxicity 
are abnormal and others suggesting that both functions are intact. We also examined 
whether  introducing  expression  of the  SAP  gene  into  EBV-T  cell  lines  from  XLP 
patients  (known  to  lack  SAP  expression)  could  restore  these  observed  functional 
defects. We transduced EBV-T cell lines from XLP patients PI  and P2 (CTLP1  and 
CTLP2)  with  a  retroviral  vector  encoding  the  SAP  cDNA  and  the  reporter  eGFP 
(transduced cells designated S+CTLP1  and S+CTLP2). Transduced EBV-T cell lines 
were analyzed and showed the same phenotypic characteristics as the parent cell lines 
(data not shown). The expression of eGFP and SAP in the transduced cell lines was 
confirmed by flow cytometric and immunoblot analysis, respectively (Figure 7.4A-B). 
The  percentage  of cells  transduced  was  approximately  45%  and  these  cells  were 
purified by FACS for use in the reconstitution experiments described below.Chapter 7 Immunocellular Function of XLP patients
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Figure  7.4  eGFP  and  SAP  expression  following  retroviral 
transduction of EBV-T cell lines from XLP patients
(A)  Flow  cytometric  analysis  of EBV-T  cell  lines  from  XLP  patient  PI  following 
transduction with eGFP/SAP encoding retroviral construct shows 42% expression of 
eGFP in the EBV-T cell line from patient 1  (S+CTLP1).
(B) Immunoblot analysis using an anti-SAP antibody shows a 15kD protein expressed 
in  EBV-T  cell  lines  from  a  control  (CTLC1)  and  in  cells  transduced  using  the 
eGFP/SAP  retroviral  vector  (S+CTLC1)  and  a  vector  encoding  eGFP  only 
(G+CTLC1). The 15kD protein is also seen in XLP EBV-T cell lines transduced with 
the eGFP/SAP retroviral vector (S+CTLP1) but not in EBV-T cell  lines transduced 
with the vector encoding eGFP only (G+CTLP1) or in untransduced EBV-T cell lines 
(CTLP1).
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7.3.1  IFNy production by CD8+EBV-T cell lines from XLP 
patients and controls
CD8+  EBV-T  cell  lines  from  normal  individuals  (C),  XLP  patients 
untransduced  (CTLP1,  CTLP2)  and  SAP  transduced  (S+CTLP1,  S+CTLP2)  were 
then activated with the same set of stimuli used in the PBMC experiments described 
above.  Following  PMA,  CD3,  CD28,  CD3/CD28,  SLAM  and  CD3/SLAM 
stimulation no difference in IFN- 7 secretion was observed between control  EBV-T 
cell lines and untransduced and transduced XLP EBV-T cell lines (data not shown). 
Cells were then stimulated with CD3/2B4, 2B4 or autologous LCLs using a range of 
target:effector cell  ratios.  Figure  7.5  shows that  in  comparison  to  the  control  CTL 
response,  there  is  significantly  decreased  IFN-y secretion observed  in  XLP  EBV-T 
cell lines from both patients following all three stimuli. However, SAP reconstituted 
lines,  S+CTLP1  and  S+CTLP2,  show  marked  increases  in  IFN-7  secretion  that, 
following 2B4 or autologous LCL stimulation are no different from the control EBV- 
T  cell  line  response.  The  most  dramatic  reduction  in  IFN-7  secretion  and 
reconstitution  of  function  is  seen  following  autologous  LCL  stimulation  (Figure 
7.5C).  As a further control, XLP EBV-T cell lines transduced with eGFP alone did 
not show any differences in IFN- 7 secretion suggesting that the process of retroviral 
transduction per se did not affect cytokine secretion (data not shown).
7.3.2  Cytotoxic activity of unreconstitute and reconstitute 
EBV-T cell lines from XLP patients and normal 
individuals
We next tested the ability of XLP EBV-T cell lines to kill autologous LCLs 
using a standard LDH release assay (Figure 7.6). EBV-T cell lines from both XLP
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Figure  7.5  IFN-y  expression  by  EBV-T  cell  lines  from  controls  and 
XLP patients following stimulation
ELISPOT analysis was used to determine IFN-y expression following stimulation of 
EBV-T cell lines from controls (C) and XLP patients (CTLP1  and CTLP2) and SAP 
transduced XLP patient EBV-T cell lines (S+CTLP1, S+CTLP2) with (A) CD3/2B4,
(B)  2B4  alone  or  (C)  autologous  LCL.  Control  values  for  each  experiment  were 
derived from pooled data on a number of control individuals so that each experiment 
has  a  single  control  value,  mean  and  standard  deviation.  Two  different  control 
individuals were studied each in triplicate and therefore the control mean is obtained 
from  6  data points.  Each  mean  patient  response  and  variance  was  then  compared 
against  the  control  response  for  each  experiment  and  analysed  for  statistical 
significance using a one tail unpaired T-test assuming, unequal variance between the 
two study groups.  Significant differences are indicated by asterisks (no  asterisk, no 
statistical significance; *, p<0.05: **, p<0.01; ***, p<0.001).
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Figure  7.6  EBV-T  cell  line  cytotoxicity  against  autologous  LCL  in 
controls and XLP patients
Cytoxicity of untransduced and transduced EBV-T cell lines  from controls and XLP 
patients  was  measured  using  LDH  release  assays.  (A)  EBV-T  cell  lines  from  Cl, 
untransduced  (CTLC1),  eGFP/SAP vector transduced  (S+CTLC1)  and  eGFP  alone 
vector (G+CTLC1), (B) as for (A) using CTLC2, (C) as for (A) using CTLP1, (D) as 
for (A) using CTLP2.
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patient  PI  and  P2  showed  markedly decreased  cytotoxic  activity  in  comparison  to 
EBV-T  cell  lines  from  two  normal  individuals  (Figure  7.6).  SAP  reconstitution 
experiments  were  then performed  to  see  if cytotoxic  function  could be  restored to 
XLP EBV-T cell lines. We demonstrate that cytotoxic function can be increased from 
30% to 60% cell  lysis  for CTLP1  (Figure 7.6C), and from 20% to 60%  for CTLP2 
(Figure 7.6D), at effectontarget cell ratios of 10:1. At similar effector:target cell ratios 
approximately 80% cell lysis was seen in EBV-T cell lines from normal individuals 
Cl  and C2 (Figure 7.6A-B). Normal EBV-T cell lines transduced with SAP or eGFP 
(S+CTL or G+CTL) or XLP EBV-T cell lines transduced with eGFP (G+CTLP) did 
not  show  any differences  in  cytotoxic  activity  from  untransduced  cell  lines,  again 
suggesting  that  retroviral  transduction per se  did  not  affect  cytotoxic  activity.  To 
confirm  MHC  class  I  specific  mediated  killing,  incubation  with  an  MHC  class  I 
antibody reduced cytotoxic activity to 20-30% cell lysis in both normal and S+CTLP 
lines (Figure 7.7).
7.4  Discussion
Following the identification of SAP as the defective gene in XLP, there has 
been  considerable  progress  in  the  understanding  of the  SAP  protein  structure,  its 
interaction  with  cell  surface  molecules  and  more  recently  with  proximal  tyrosine 
kinases such as Fyn T (Chan et al,  2003; Latour et al,  2003). However, the cellular 
pathogenesis  of XLP  in  humans  remains  poorly  understood,  especially  given  the 
different clinical phenotypes of the disease. Murine models of SAP deficiency suggest 
a tendency to a dysregulated Thl responses with T cell activation and increased IFN-7 
production, but it is clear from studies of other immunodeficiencies that abnormalities 
observed in murine models do not always accurately reflect human disease
206Chapter 7 Immunocellular Function of XLP patients
100
80
o C J J
I E
8  60 — S + C T L C 1
-^-S+C TLC 2
—A— S+CTLP1
— S+C TLP2
20
0
10:01 05:01 2.5:1 1.25:1
Effector:Target cell ratio
Figure  7.7  Blocking  EBV-T  cell  line  cytotoxicity  against  autologous 
LCL in controls and XLP patients
Incubation of eGFP/SAP vector transduced EBV-T cell lines from both controls and 
XLP  patients  (S+CTLC1,  S+CTLC2,  S+CTLP1,  S+CTLP2)  with  W6/32  antibody. 
Cytoxicity of untransduced and transduced EBV-T cell lines from controls and XLP 
patients was measured using LDH release assays.
(Khan et al,  1995). It is evident from a number of reports that human NK cell defects 
are present in this condition, but there is very little clear functional data on specific T 
cell populations (Nkajima et al, 2000; Parolini et al, 2000; Tangye et al, 2000). In this 
study  the  use  of EBV-T  cell  lines  from  XLP  patients  represents  a  physiological 
human  T  cell  effector  population.  The  lack  of cellular  transformation  or  species 
differences  provides  a  relevant  model  for  examining  defects  in  this  condition.In 
normal  individuals  the  immune  response  to  EBV  infection,  the  major pathological
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trigger in XLP, is dominated by the proliferation of CD8+ EBV-T cell lines and NK 
cells.  The development of EBV driven lymphoma and fulminant IM  in XLP would 
strongly suggest that defects exist in these effector populations. In this study we show 
that XLP patients are indeed capable of generating EBV-T cell lines.
Using different culture conditions we were able to generate T cell lines of both CD8+ 
and CD4+ phenotype from both normal and XLP patients (see Chapter 5).
A number of studies have reported cytokine abnormalities in XLP. However, 
in the majority of studies undertaken, the response to specific cell surface stimuli has 
not been addressed. In this analysis we stimulated both PBMCs and XLP EBV-T cell 
lines with specific T cell stimuli and assessed the IFN-y response. In both populations, 
differences were observed in response to CD3,  CD3/2B4, 2B4 or autologous  LCLs 
and not in response to PMA, CD28, CD3/CD28, SLAM or CD3/SLAM. The lack of 
response to CD3/SLAM or SLAM alone would be in keeping with the low levels of 
SLAM observed in these cell lines.
Following  CD3  stimulation  alone,  PI  and  P2,  who  are  EBV  experienced, 
demonstrated significant downregulation of IFN-y production. This is in keeping with 
observations  made  by  Sanzone  et  al.  where  EBV  experienced  XLP  patients  were 
analysed (Sanzone et al, 2003). However, P3 (who was EBV-seronegative at the time 
of analysis) shows an exaggerated EFN- y response that is significantly elevated from 
controls  and  is  similar  to  the  CD3  stimulation  T  cell  responses  observed  in  SAP 
deficient mice (Czar et al,  2001; Wu et al, 2001). Importantly stimulation via 2B4 or 
CD3/2B4 in P3 shows a downregulated response and is similar to PI  and P2. These 
observations  albeit  in  only  one  patient,  suggest  that  SAP  deficiency  in  the  EBV 
inexperienced  individual  augments  CD3  stimulation  which  after  EBV  infection  is 
downregulated.  The  role  of  SAP  downstream  of  CD3  triggering  without  co-
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stimulatory input is unclear but these data suggest a regulatory role for SAP, which 
needs further investigation in larger numbers of patients.
In addition, it is possible that combination of CD3 and 2B4/SLAM stimulation 
regulates  Th2  response  IL-5  and  IL-10  in  normal  individuals  as  we  showed  here. 
However, it remains unclear whether in human T cells it is a direct function of 2B4 or 
SLAM signalling in Th2 regulation as it has been recently shown in SAP and SLAM 
deficient murine models (Cannons et al, 2004; Wang et al, 2004).
In  our  study,  differences  in  XLP  and  normal  EBV-T  cell  lines  following 
CD3/2B4 or 2B4  activation suggest that activation through this  specific pathway is 
important in EBV-T cell  line  function and,  given the similarities in the cell  surface 
phenotype between the two T cell populations, point to defective SAP expression as 
being responsible for aberrant transduction of the 2B4 signal.  Similar findings after 
stimulation  by  autologous  LCLs  are  consistent  with  these  findings.  Cell  surface 
LCL/EBV-T  cell  line  interactions  include  homotypic  association  between  SLAM 
molecules (though in this study low SLAM expression negates this pathway) and also 
between  2B4  on  EBV-T  cell  lines  with  its  ligand  CD48  which  is  abundantly 
expressed on LCLs. Disruption of the signal arising from this interaction results from 
the lack of SAP expression in XLP EBV-T cell lines probably leading to decreased 
IFN- 7 expression and to the observed failure of cytotoxicity of autologous LCLs.
Our studies on human cells from EBV experienced individuals demonstrate a 
decrease in IFN- 7 production in response to specific stimuli and contrast significantly 
with murine data. A possible explanation for this discrepancy may be the fact that in 
murine  studies,  animals  were  examined  at  an  early  age  and  only  after  limited 
antigenic exposure. It would be interesting to repeat these studies on mice exposed to 
repeat  or  chronic  antigen  stimuli.  This  would  better  mimic  the  situation  in  XLP,
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which  was  initially  described  as  a  ‘progressive’  immunodeficiency  and  where 
repeated  immunological  insults  and  more  specifically  with  EBV  may  result  in  a 
gradual deterioration in immune function.
We  demonstrate  that  human  EBV-T  cell  lines  from  two  patients  with  a 
molecular diagnosis of XLP and lack of SAP expression show significant defects in 
direct killing of autologous LCLs. Previous studies have suggested this using indirect 
assays  such  as  LCL  growth  regression.  That  this  defect  occurs  via  the  2B4/CD48 
pathway is supported by the abundance of 2B4 rather than SLAM expression and also 
by  the  demonstration  of 2B4/CD48  abnormalities  in  NK  cell  cytotoxicity  in  XLP 
(Nakajima et al, 2000). The molecular detail of this pathway is unclear but it has been 
shown that 2B4 associates with the LAT (linker for activation of T cells) leading to 
tyrosine  phosphorylation  of  both  molecules.  Whether  this  interaction  is  SAP 
dependent has yet to be defined. It is also evident that other receptors are involved in 
mediating cytoxicity in T cells. NTB-A is a recently identified member of the SLAM 
family and can bind SAP following phosphorylation of its cytoplasmic tail (Bottino et 
al,  2001).  NTB-A behaves  in  an  analogous  manner to  2B4  in  NK  cells  triggering 
cytotoxicity but is also expressed in T cells  suggesting that the observed defects in 
XLP EBV-T cell lines may arise from abnormal signaling downstream of a number of 
different surface receptors. The final events in these pathways may be the inability to 
form the cytolytic machinery such as release of granzyme or perforin molecules and 
expression of such proteins in XLP EBV-T cell lines is currently being investigated. 
More recently it has been shown that the lytic effectors perforin and granzyme-B are 
normal in SAP-deficient CTL derived from XLP patients (Dupre et al, 2005).
The  cytokine  expression  and  cytotoxicity  defects  are  SAP  dependent  since 
introduction of SAP by gene transfer restored functionality. A marked increase was
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seen  in  both  patients  for  both  cytotoxicity  and  cytokine  assays.  Although  the 
restoration  of  function  was  not  entirely  equivalent  to  control  samples,  mock 
transfected cells did not show any reconstitution.
Retroviral transfer of the SAP gene into EBV-T cell lines was achieved during 
the repeated stimulation of T cells by autologous LCLs and makes CTLs an attractive 
target for gene transfer. Although the studies were principally conducted to show that 
the defects were SAP dependent, the restoration of function suggests that SAP gene 
transfer in XLP may hold some therapeutic value. In cases without a matched sibling 
donor, gene corrected CTLs could be generated and stored for future use if lymphoma 
or fulminant IM were to arise in XLP patients. However, much further work would be 
necessary to show that constitutive SAP expression under the control of a viral LTR 
does not lead to adverse effects. The possibility of SAP expression under the control 
of a T lineage restricted or endogenous SAP promoter could also be explored.
To  date  functional  cytotoxic  T  cell  defects  in XLP  have  not been carefully 
defined,  especially  in  response  to  EBV  infection.  Using  this  autologous  EBV- 
LCL/EBV-T cell line model we clearly demonstrate that both cytokine production and 
cytolytic activity are severely impaired as a result of SAP deficiency.  In combination 
with previously described NK cell defects this may explain the failure to control EBV 
infection and predisposition to B  cell  lymphoma which occurs in one third of XLP 
patients  and which indeed was the presenting  feature of XLP  patient P2.  One may 
also  speculate that the  tendency to  fulminant  IM  (as  in PI)  and  hemophagocytosis 
may  possibly  arise  from  the  initial  CTL  and  NK  cell  failure  leading  to  further 
dysregulated immune responses.
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8.1
SAP is  the  defective  gene  in  XLP,  a disease,  which  results  in  dysregulated 
immune responses. Many features of the disease are unexplained, including excessive 
susceptibility  to  EBV  infection,  cellular  and  humoral  immune  dysfunction,  late 
haematopoietic  malignancy  and  further  diverse  phenotypes.  However,  evidence 
unravelling the molecular defect responsible for XLP in recent years has led to critical 
new insights into the pathophysiology of this disease.  It has been demonstrated that 
SAP is involved in regulation of the immune response particularly in T and NK cells. 
In particular, SAP interacts with the SLAM family of immune cell receptors. Whereas 
the functions of these receptors are only beginning to be elucidated, they seem to play 
a major role  in  XLP pathogenesis  (see  Chapter  1).  More  recently,  development of 
XLP murine model has made it possible to investigate the immune function of SAP in 
vivo and in vitro following challenge with various pathogens. However, one limitation 
of the SAP deficient murine models is that mice are not susceptible to EBV infection 
and  therefore  are  unlikely  to  be  useful  in  explaining  the  molecular  and  cellular 
features of the SAP defect in humans. This is also debate particularly when CTL and 
NK cells function consider as major and crucial players in immune response to EBV 
infection in humans. Moreover, it is becoming clear that SLAM family receptors are 
widely involved in immune cell function and attributing all molecular features of XLP 
to the SLAM pathway is likely to be an oversimplification.
The  main  aim  of  this  thesis,  therefore,  was  to  investigate  the  cellular 
pathogenesis of XLP in humans in particular to explore the function of EBV-CTLs 
and  to  develop  an  ex  vivo  re-constitutional  model  using  a  retroviral  gene  transfer 
system. As a subsidiary aim, it was planned to characterise and profile the cytokine- 
phenotype of lymphocyte lineages in XLP patients in a more detailed manner.
213Chapter 8  Discussion
8.2  The role of SAP in immune cell functions
Appropriate  immune  responses  rely  on  the  functions  of  immune  cells 
controlled  by  the  signalling  of complex  and  heterogenous  receptor  families.  The 
balance  between  the  signalling  pathways  determines  the  specificity  of  immune 
response  and  regulates  its  intensity  and  duration.  Adaptors  play  crucial  roles  to 
maintain this balance and orchestrate the intracellular pathways. SAP is an example of 
a modulator protein, which is expressed predominantly in T and NK cells. Defective 
SAP  in  XLP  syndrome  highlights  the  important  function  of these  adaptors  in  the 
pathophysiology of immune responses (Latour et al, 2004).  The unique structure of 
SAP represents a family of adaptors, including EAT-2, that have the ability to interact 
with a variety of immune cells receptors from the SLAM family.
SLAM  family  receptors  conduct  a  variety  of  functions  including  the 
modulation of cytokine production and cytotoxicity (see Chapter 1). In addition, it has 
been reported that expression of human SLAM facilitates infection of lymphoid cells 
by measles virus infection (Hsu et al, 2001). While the roles of this family are only 
beginning to be understood, the clinical and pathology findings of XLP  suggest the 
functions of SAP-SLAM family receptors are vital in immune responses, in particular 
to EBV infection in humans.  EBV infection has several aspects, which are different 
from other viral pathogens, particularly modulation of cytokine production and B cell 
immortalization as described in Chapter 1. In this context, SAP function may provide 
an essential role in the immune surveillance against EBV. SAP enables SLAM family 
receptors  to  mediate  their  diverse  functions  through  facilitating  tyrosine 
phosphorylation of their cytoplasmic tails.  Depending on the tyrosine- based motifs 
present in their intra-cytoplasmic domain, SLAM family receptors can recruit distinct 
sets of SH-2  domain-containing effectors that  lead to different  signals with distinct
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biological  consequences  (Figure  8.1).  Typically,  SAP  makes  a  triple  complex  and 
promotes the recruitment and activation of Src-related tyrosine kinase (PTK) Fyn and 
its interaction with  SLAM  in murine T cells (Latour et al,  2001;  Chan et al,  2003; 
Latour et al,  2003; Davidson et al,  2004). These observations suggest that SAP acts 
like a modulator and differently from all signalling molecules such as ZAP70 and Btk 
described in Chapter 1. Moreover, the unique structure of SAP makes it different from 
other adaptors involved in signalling such as the SLP-76 adaptor family including B 
cell linker (BLNK) or Dok family. Although this adaptor family, like the SAP family, 
are  not  receptors  or kinase,  they  exhibit  more  complex  structure  and  bind  to  SH2 
domain-containg  partners.  For  instance,  upon  BLNK  interaction  with  Syk,  BLNK 
becomes rapidly phosphorylated on multiple N-terminal tyrosine residues, which act 
as binding sites to recruit the SH2 domain containing proteins PLC*y2, Btk, Vav, Grb2 
and  Nek  into  signalling  complex  (Goitsuka  et  al,  1998;  Kurosaki  et  al,  2000). 
Therefore BLNK acts as a molecular scaffold to link the pre-BCR (B cell receptor) 
activated  Syk  kinase  to  regulators  of  multiple  downstream  signalling  pathways 
(Schebesta et al, 2002).
Recent biochemical investigations suggested that SAP deficiency might cause 
an  abnormal  TCR  signalling  cascade  in  human  T  cells  (Nakamura  et  al,  2001; 
Sanzone et al,  2003). Studies on T cells from XLP patients showed that early TCR- 
induced signals such as tyrosine phosphorylation of PLC-7 and calcium fluxes were 
increased in SAP-deficent T cells, whereas T cells from a SAP deficient murine
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Figure 8.1 Regulation of SLAM family receptors by SAP
A model  of SLAM-related  receptor regulation by  SAP  is  presented.  SAP  binds  to 
tyrosines in the intra-cytoplasmic domain of SLAM family receptors (the consensus 
binding sites are boxed in red), thereby allowing recruitment and activation of FynT. 
This leads to tyrosine phosphorylation of the receptor, and recruitment and activation 
of downstream effectors that activate cellular responses (as specified in the figure). 
The presence of distinct sets on tyrosine-based motifs in the cytoplasmic domain of 
the  various  SLAM-related  receptors  enables  these  receptors  to  transduce  different 
signals and mediate unique functions. (Taken from Latour et al, 2004).
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model  showed  normal  calcium  mobilization  and  ERK  activation  upon  TCR 
activation, but  PKC-0  recruitment,  Bel-10 phosphorylation,  I/cB-a degradation,  and 
nuclear  NF-xBl/p50  levels  were  increased  (Sanzone  et  al,  2003;  Cannons  et  al, 
2004).  However,  it  is  not  clear  that  SAP  directly  regulates  the  TCR  downstream 
signals  or whether  it  is  part  of SAP’s  regulatory  function  interacting  with  SLAM 
family  receptors  pathways,  although  interaction  of SAP  with  cytoplasmic  proteins 
such as Dokl  reported by Sylla et al may be part of this regulatory axis (Sylla et al, 
2000).
The difference between human and mice TCR-induced signals may be caused 
by  excessive  challenge  of the  immune  system  in  affected  XLP  patients  by  EBV 
infection,  compared  to  the  naive  immune  system  in SAP deficient  murine  models. 
However, it cannot be excluded that the different phenotypes in human and mice may 
be  caused  by differences  in  signalling  pathways  controlled  by  SAP  function.  It  is 
notable that recent  data demonstrated  SAP  deficiency in murine  T  cells  appears  to 
selectively affect NF-k/3 members (Cannons et al,  2004). For example c-Rel required 
for IL-2 production is not affected by lack of SAP in T cells. Interestingly, this pattern 
has  been  reported  in  Fyn  7'T  cells,  supporting  the  assumption  that  SAP-Fyn 
interaction  is  necessary  for  the  PKC-0/NF-  k/3  pathway  (Cannons  et  al,  2004). 
Whereas, recruitment of Fyn by SAP has not been reported in humans and also given 
the preference of other PTK members such as Lck in human T cells,  it is therefore 
possible that SAP may play different roles in controlling T cell activation in humans 
and mice and deserves further exploration.
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8.3  Thl/Th2 profile in XLP human and mice
SAP  deficiency  causes  abnormalities  in  Thl/Th2  cytokine  profiles  as 
described in Chapter  1.  It has been demonstrated that there are different patterns of 
cytokine  production  in  human  and  SAP  deficient  mice.  Whereas  these  mice  were 
shown to exhibit an augmentation of Thl  responses (IFN-y production) and reduced 
Th2 responses (especially IL-4 production), human T cells from XLP patients failed 
to produce Thl  cytokines such as IFN-y and IL-2, although the Th2 profile has not 
been investigated in these patients (Nakamura et al,  2001; Sanzone et al,  2003). Our 
results presented in Chapter 7 not only reveal Thl response failure (IFN-y) in primary 
T cells and EBV- T cell lines in agreement with the previous reports (Yasuda et al, 
1991; Nakamura et al, 2001), but also we have been able to show this defect is partial 
as highlighted upon  stimulation through specific  receptors  (Sharifi  et al,  2004;  this 
thesis).  The fact that stimulation with PMA and ionomycin overcome the defects of 
SAP-deficient T cells observed upon TCR stimulation (with anti-CD3  Ab)  strongly 
suggests that SAP is involved in proximal T cell signalling. Moreover, in our patients 
IFN-y production was lower than normal levels upon TCR stimulation, except in an 
EBV  seronegative  XLP  case  that  had  showed  a  significant  increase  of  IFN-y 
production  in  comparison  to  normal  controls.  Whether  this  is  related  to  EBV 
seronegative  condition  or  cytokine  polymorphisms  is  not  clear  and  this  may 
emphasise the complexity of cytokine imbalance in humans affected with XLP when 
compared with SAP deficient murine models. More recently, it has been shown that 
TCR  stimulation  (with  anti  CD3/28  or  lectin)  of SAP-deficient  CD8  T  cell-lines 
(autologous and allogenic) from three XLP patients lead to normal production of IL-2, 
IL-4  and  IFN-y  (Dupre  et  al,  2005).  This  controversy  remains  to  be  addressed 
probably with a larger sample size and more well defined methods.
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Intriguingly,  the  studies  on  SAP deficient  murine  models  consistently  show 
aberrant TCR response conducting Thl/Th2 production (Czar et al,  2001; Wu et al, 
2001;  Latour  et  al,  2001).  The  precise  mechanism  by  which  the  SAP  signalling 
pathway  modulates  production  of cytokines  by  T  cells  is  not  well  documented. 
However,  it  seems  that  FynT,  SHIP-1,  Dok  family adaptors  and  or  RAS/GAP  are 
implicated in this effect. The most recent reports showed that CD4 T cells from non­
infected  SAP  Knock  out  mice  exhibiting  a  slightly  increased  IFN-7 production  in 
comparison  to  controls,  while  IL-2  production  was  normal  (Cannons  et  al,  2004; 
Davidson et al,  2004).  The Fyn T T cells presented the same phenotype as seen in 
SAP  T  T  cells.  Moreover,  the  profound  defect  in  Th2  cytokine  secretion  (IL-4 
production) in SAP-deficient T cells appears to be independent of the effects of IFN-7 
level. The defect in Th2 response has been shown in Fyn  T cells and also in T cells 
from 5^4PR78a Knockin mice (a mouse model in which the Fyn T binding site of SAP, 
R78,  was  replaced  by  an  alanine  in  the  germ  line)  suggesting  the  impaired  TCR- 
mediated signals are SAP-Fyn dependent (Cannons et al, 2004; Davidson et al, 2004). 
SAP-deficient CD4 T cells are able to polarize and secrete normal levels of both Thl 
and  Th2  cytokines  (Latour  et  al,  2001;  Wu  et  al,  2001;  Cannons  et  al,  2004). 
However, the affected CD4 T cells showed down-regulation of GATA-3  and not T- 
bet  expression  level  (GATA-3  and  T-bet  are  master  regulators  of Th2  and  Thl 
differentiation, respectively). Thus, murine SAP-deficient CD4 T cells have a specific 
defect in GATA-3 induction in response to TCR-mediated signals.
Furthermore,  the  recent  description  of  mice  lacking  SLAM  expression 
revealed that TCR-induced secretion of IFN-7 was only slightly increased by CD4 T 
cells whereas Th2 response (IL-4 production) was profoundly impaired (Wang et al, 
2004).  It questions the previous reports in mice showing that SLAM is important in
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Thl  cytokine  regulation  with  an  inhibitory  outcome.  This  along  with  the  recent 
reports  suggests that the triple complex  of SAP-Fyn-SLAM  is  a major regulator in 
Th2  response  and  not  Thl  response  (Cannons  et al,  2004;  Davidson  et al,  2004). 
These findings  suggest that  SLAM  is an activator of IL-4 production.  This  is most 
perplexing,  as  CD4  T  cells  upon  anti-SLAM  stimulation  did  not  produce  IL-4 
cytokine.  However,  an  explanation  for  these  models  could  be  co-localization  of 
SLAM with the TCR upon T cell activation (Howie et al, 2002).
It is notable that the additional SLAM-related receptors expressed in T cells, 
including 2B4, Ly-9 and NTBA, are candidates, which should be studied and could be 
incorporated  in this model.  It  should be pointed out that the recruitment of Fyn to 
SLAM  by  SAP  has  not  been  shown  with  other  SLAM  family  receptors.  These 
receptors may play different roles in T cell population function and homeostasis.
According  to  evidence  based  on  SAP  deficient  murine  models,  it  seems 
probable that the immunological abnormalities in XLP are caused by a defect in Th2 
response (IL-4) rather than Thl  responses.  However,  although Th2  response defect 
may explain dysgammagloubinemia phenotype of XLP, this Th2 paradigm is unlikely 
to address the uncontrolled FIM and late haematopoietic malignancy features of XLP. 
Firstly,  the  cytokine  IFN-y plays  a  central  role  in  resistance  of the  host  to  EBV 
infection via a direct  antiviral  effect as well  as through modulation of the  immune 
system response (Morrison et al,  2001).  Therefore, considering the essential role of 
the Thl  response  in pathophysiology of EBV  infection,  defects  in Thl  response as 
seen in XLP patients (Chapter 7) remain unexplained by data from murine  studies. 
Secondly,  we have been  able to  show that the  SLAM  responses  likely to be a late 
response, and also that its expression in comparison to 2B4, is relatively low on T cell 
populations (Chapter 6). This contradicts to the idea that the pathophysiology of SAP
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defect  is  predominantly  related  to  SAP-Fyn-SLAM  pathway,  which  assumes  that 
SLAM upregulation is the main receptor in signals regulated by SAP. Future work is 
needed  to  investigate  how  SAP  modulates  other  SLAM  family  receptors  such  as 
CD84/CS1/NTBA/2B4 that are expressed in T cells.  Lastly,  it is important to note 
that the defects in antibody production in response to viral infections observed in SAP 
V murine  model  were  a  late  defect  (Crotty et  al,  2003)  and  not  related  to  B  cell 
function. Therefore, severe Th2 impairment reported in the murine model is unlikely 
to explain the late defect of B cells function. SAP may have a role at least in some B 
cell population and homeostasis of Igs production, a role which is under estimated and 
not effectively addressed by Th2 imbalance theory.
It  has been  suggested  that  SLAM  family receptors,  particularly  SLAM,  are 
involved  in  Thl  cytokine  production  and  not  the  Th2  response  in  humans  (see 
Chapter 1). However, the Th2 cytokine profile has not been comprehensively studied 
in XLP patients particularly in response to various stimuli. As it has been shown in 
Chapter 7, SLAM and 2B4 may have an inhibitory effect on Th2 cytokine production 
(IL-5  and  IL-10  production)  by  human  primary  T  cells  and  this  requires  further 
investigation. Also it is important to investigate whether the lack of SAP affects the 
Th2 cytokine balance in XLP patients and if dysregulation of Th2 cytokine production 
contributes to XLP pathogenesis in humans.
8.4  C T L  fu n ctio n  in X L P  p atien ts
EBV infection triggers the pathological presentation in 90% of XLP cases. T 
and NK lymphocyte roles in cytotoxic function and cytokine homeostasis are crucial 
in the immune response to EBV infection (Rickinson et al,  1997). The Th2 response 
failure  theory  demonstrated  by  murine  models  may  not  completely  explain  the
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observed defects in these cell populations. The preliminary results reported by Wu et 
al indicated that NK and CTL function in SAP T mice are normal during acute phase 
of infection (Wu et al, 2001). However, the function of these lymphocyte populations 
in the murine model has not been investigated in detail.
The  results  reported  in  Chapter  7  demonstrate  SAP  dependent  defects  in  T 
cells  cytotoxicity  in  XLP  patients,  where  the  defect  was  corrected  by  SAP  gene 
transfer (Sharifi et al, 2004).  This is consistent with observations made by Sanzone et 
al  where  reconstitution  of  allogenic  T  cell  lines  from  two  XLP  patients  using 
retroviral vector encoding the SAP gene has completely restored abnormal signalling 
events  (Sanzone  et  al,  2003).  The  impaired  EBV-  T  cell  function,  including  Thl 
response  defects  suggest  that  these  abnomalities  may  participate  in  the 
pathophysiology of the  disease.  Firstly,  this  is  supported  with  evidence  from  XLP 
patients who are unable to eliminate the EBV virus from the blood and other organs. 
Secondly,  the  feature  of tumourgenesis  in  XLP  is  in  favour  of  T  and  NK  cell 
surveillance defects in these patients. Thirdly, the data presented on abnormalities of 
NK cell function in XLP patients (Sullivan et al,  1980; Harada et al,  1982; Nakajima 
et  al,  2000;  Parolini  et  al,  2000;  Tangye  et  al,  2000)  confirmed  that  the  cellular 
pathogenesis  of XLP  is  not only caused by Thl/Th2  imbalance,  but  that  impaired 
cytotoxicity  of NK  cells  along  with  CTLs  could  play  a major  role  in  the  clinical 
manifestations  of XLP  due  to  SAP  deficiency.  Although,  2Z?4-deficient mouse NK 
cells  were  found  to  exhibit  increased  NK  cell-  mediated  cytotoxicity  and  IFN-y 
production (Lee et al, 2004), this may highlight the differences in pathology between 
XLP patients and S^P-deficient murine models.
The failure of EBV-specific T cell  line cytotoxicity is unlikely to be SLAM 
dependent,  as  the  cytotoxic  T  cells  were  mainly  2B4 positive  (Sharifi  et al,  2004;
222Chapter 8  Discussion
Dupre et al, 2005). In T cells, triggering of 2B4 does not lead to T cell activation by 
itself, but it can augment antigen-specific T cell cytotoxicity (Nakajima et al,  1999; 
Lee et al, 2003). In addition, the CD48-2B4 interaction is important for the regulation 
of CD8  T  cell  proliferation  (Kambayashi  et  al,  2001).  SAP  is  essential  for  2B4 
signalling,  probably by preventing  SHP-2  and possibly SHP-1  binding to  2B4  and 
also by recruiting Fyn to 2B4 (Tangye et al,  1999; Eissmann et al, 2005). However, 
the  mechanism  of the  cytotoxicity defect of XLP  EBV-specific  T  cell  lines  in  our 
study remains elusive. A recent study has demonstrated that SAP-deficient CTLs from 
patients with  XLP  exhibit  a  specific  lytic  defect  against  autologous  and  allogeneic 
EBV-positive  B  cells;  the  defect  was  2B4  dependent  due  its  role  in  lytic  synapse 
formation (Dupre et al, 2005). It has been suggested that SAP regulates 2B4 activity 
by  controlling  lytic  synapse  formation  (Roda-Navaroo  et al,  2004).  Effective  lytic 
activity  requires  the  formation  of a  lytic  immunological  synapse  with  immediate 
central polarization of perforin-containing lytic granules at the effector T cell: target 
cell contact (Stinchcombe et al, 2001; McGavem et al, 2002).  The absence of SAP 
may cause a defect in the assembly of the lytic immunological synapse. Dupre et al 
have  been  able  to  show  that  CTLs  from  three  XLP  patients  exhibit  impaired 
polarization of both lytic granules and  lipid rafts at the contact point of CTLs with 
target  cells  (Dupre  et  al,  2005).  Interestingly,  the  defect  was  restricted  to  EBV- 
positive target cells with CD48  expression, whilst the polarization of lytic  granules 
(perforin and GM1) and lytic activity against the K562 targets were not affected in 
SAP-deficient CTL (Dupre et al, 2005). This supports previous studies on NK cells 
from XLP patients, which show failure of 2B4-mediated cytotoxic killing of CD48- 
expressing target cells and EBV-immortalized LCLs (Nakajima et al, 2000; Parolini 
et aly  2000; Tangye et al, 2000).
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In  most  viral  infections,  specific  CTL  activity  arises  within  3-4  days  after 
infection, peaks by 7-10 days, eliminating virions during this period (Ramshaw et al, 
1997). Since humoral immune response defects may be a late defect in XLP patients, 
the  function  of CTL  and  NK  in  elimination  of EBV  infected  B  cells  would  be 
essential in these patients.  It has been reported that the rapid elimination of B cells 
immediately  following  EBV  exposure  in  two  XLP  patients  using  the  anti-CD20 
antibody rituximab, provided recovery from viral  infection symptoms and reduction 
of EBV circulating viral load in addition to reduction of post EBV infection morbidity 
such as FIM or lymphoma (Milone et al, 2005).  Although these patients exhibit an 
increased numbers of CD8 T cells, the T cell dysfunction has not been investigated 
directly.  However,  the  effect  of eliminating  infected  B  cells  using  a  monoclonal 
antibody, demonstrates the importance of the CTL and NK cell eliminating function 
in XLP pathogenesis.
Although  there  is  substantial  evidence  supporting  CTL  dysfunction  as  a 
crucial role in XLP pathogenesis, the molecular aspects of XLP pathology in these 
cells remain uncertain, particularly the relationship of SAP to SLAM family receptors 
expressed in these cells such as 2B4, CS1, NTBA.
8.5  Feasibility of gene therapy for XLP
Although  rare,  primary immunodeficiencies  are  in many ways  ideally  suited to  the 
application  of  somatic  gene  therapy.  This  technology  has  delivered  promising 
outcomes in treatment of various types of immundeficienies disorders in recent years, 
mostly targeting haematopoietic stem cells (Bordignon et al,  1995; Cavazzana-Calvo 
et al, 2000; Hacein-Bey-Abina et al, 2002; Gaspar et al, 2004). The lack of success of 
conventional treatment for XLP makes the development of a gene therapy strategy for
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XLP an attractive proposition. The disease is monogenic and the coding sequence of 
SAP  cDNA  spans  only  400bp  and  is  readily  incorporated  into  retroviral  vector 
constructs.  In  addition the major cellular deficit  lies in T and NK cell populations, 
which  are easily accessible.  More recently it has been  shown that  SAP is  a crucial 
regulator on NKT cell ontogeny in humans and mice (Nichols et al, 2005). Therefore, 
other lymphocyte populations such as NKT and LAK cells may be potential targets 
for XLP gene therapy.
Advances in the genetic modification of T lymphocytes have led to the development 
of therapeutic  approaches  including  suicide  gene  therapy  after  allogeneic  HSCT 
(Heslop  et al,  1996;  Bonini  et al,  1997;  Qasim  et al,  2002),  and ADA-SCED  gene 
therapy (Blaese et al,  1995; Muul et al, 2003). It also has been used for rapid selection 
of antigen-specific T lymphocytes (Koehne et al,  2000). However, many issues have 
been raised such as the impact of T cell gene therapy on their functionality including 
cytotoxicity (Duarte et al,  2002; Sauce et al,  2002), T cell subpopulations and T cell 
receptor repertoire (Dietrich et al,  1997; Movassagh et al,  2000; Qasim et al,  2003). 
For  instance,  it  has  been  reported  that  the  transduction  protocol  using  anti-CD3 
antibody and IL-2 to activate T cells leads a significant reduction in EBV-reactive T 
cells (Sauce et al, 2002).
In this study we have tried to investigate the feasibility of an in vitro  gene 
therapy approach targeting EBV-specific T cells as a potential treatment for XLP. We 
have been able to develop a T cell transduction protocol using only Ags (autologous 
BLCLs)  stimulation  with  reliable  efficiency with  a retroviral  vector encoding  SAP 
(Chapter 4). Although both retroviral and lentiviral vectors showed good transduction 
efficiency  with  non-specific  stimulation  (PHA,  IL-2,  CD3/28),  the  transduction 
efficiency of lentiviral vectors was limited when we used a Ags stimulation protocol
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only  (Chapter  4).  Recent  data  suggests  that  lentiviral  vectors  cannot  efficiently 
transduce  primary  T  cells  without  prior  stimulation,  such  as  IL-7  pre-stimulation, 
despite their unique ability to transduce different cell types (Verhoeyen et al, 2003).
We  have been  able  to  demonstrate that  the transduction of EBV-specific  T 
cells with retroviral  vector constructs using Ags stimulation protocol, maintains the 
cytotoxicity and  EFN-7 production abilities of transduced T cells (Chapter 7).  Most 
importantly we have showed that the in vitro EBV-specific T cell model for XLP gene 
therapy  shows  promising  results  and  can  reconstitute  the  cytotoxicity  and  IFN-7 
production in EBV-specific T cell lines (Chapter 7; Sharifi et al, 2004). Other groups 
have  also  recently  shown  reconstitution  of  SAP  expression  by  retroviral  vectors 
encoding SAP led to significant restoration of TCR signalling defects in T cell lines 
derived from two XLP patients (Sanzone et al, 2003). In addition our retroviral vector 
constructs  encoding  SAP  have  been  used  by  Plunkett  et  al  in  a  study  on  the 
telomerase activity in primary CD8  T cells of XLP patients  and again have  shown 
stable SAP expression (Plunkett et al, 2005).
However, the next step to measure the feasibility of the EBV-specific T cell 
model  for XLP gene therapy is to develop an in vivo model.  The  SCID  (RAG-73) 
mouse  strain  model  is  an  ideal  model  to  study the  in  vivo  behaviour of engrafted 
human tumour cells and primary lymphocytes (Goldman et al,  1998). Intraperitoneal 
inoculation of EBV-LCLs and administration of autologous EBV-specific T cells to 
this type of mice results in the eradication of EBV driven lymphoproliferative disease 
(Lacerda et al,  1996). Therefore, this model provides a relevant physiological model 
to assay the ability of SAP reconstituted EBV-specific T cells.
The insertional mutagenesis has been reported subsequently of HSC retroviral 
transduction  in  mice  and  human  (Li  et  al,  2002;  Hacein-Bey-Abina  et  al,  2003).
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Retroviruses integrate essentially at random into the host genome which could induce 
malignancies  as  has  been  reported  in  mice  and  rhesus  monkeys  through  repeated 
infection that cause multiple synergizing mutations in the same cell (Nathwani et al, 
2004).  The  tumorgenesis  following  integration  is  known  to  arise  by  activation  of 
oncogene  sequences  occuring  as  a  result  of promoter/  enhancer  insertion,  and/  or 
tumour suppressor gene (TSG) inactivation (Neil et al,  1987). However, alteration of 
gene  expression  following  proviral  insertion  also  has  been  demonstrated  in  mice, 
which can lead to lethal ebmryonic outcomes (Jaenisch et al,  1983).
In the French gene therapy trial for SCID-XI, three boys have developed T cell 
leukaemia  (Hacein-Bey-Abina  et  al,  2003).  T  cells  originated  from  a  single 
transduced cell,  in which the oncoretroviral genome inserted in the vicinity of LIM 
domain only 2  (LMO-2)  locus,  in a manner that enabled the retroviral promoter to 
mediate  aberrant  expression of LMO-2  in these  cells.  The  LMO-2  gene  encodes  a 
transcription  factor  that  is  required  for  normal  haematopoiesis;  however,  when 
aberrantly expressed,  it is  associated with childhood  leukaemia (McCormack  et al,
2004).  However,  although  insertional  mutagenesis  is  a rare  incidence  (Kohn  et al, 
2003), with replication -incompetent retrovial vectors, it is not clear whether this is as 
a consequence of wild type promoter or combination with encoded transgene such as 
Tc.
Thus,  the  murine  model  also  could  provide  useful  information  regarding 
transgenic mutations in targeted cells and safety issues following introduction of new 
gene  by  retroviral  vectors.  Whether  the  promoter  in  retroviral  vector  affects  the 
chance of insertional mutagenesis  is not clear and replacement the  SFFV promoter 
with  a  tissues  specific  promoter  such  as  CD28  or  CD3  promoter  may  reduce  the 
chance of mutagenesis.
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8.6 Future work
8.6.1 SAP and SLAM & 2B4 expression
SAP  and the  SLAM  family are expressed heterogeneously in immune cells. 
The  results  presented  in  Chapter  6  add  further  information  on  SLAM  and  2B4 
expression  in  primary  immune  cell  lineages.  SAP  expression  in  LAK  cells  and 
recently in NKT shown by Nichols et al suggest a wider regulatory function for SAP 
(Chapter  1; Nichols et al, 2005). Moreover, there is uncertainty regarding regulation 
of SAP expression particularly in its promoter region and in signalling cascades both 
of which require further investigation.
We  have  been  able  to  study co-expression  of SLAM  and  2B4  on  different 
immune cell lineages. The expression of 2B4 on DCs and CD4 T cells may suggest a 
more  complex  function  of this  receptor  in  immune  cells  rather  than  controlling 
cytotoxicity  and  IFN-7  production  and  may  also  point  to  critical  roles  in  Ag 
presentation and B  cell help.  In addition,  stimulation studies of T (CD4/8)  and NK 
cells with a variety of stimuli showed 2B4 expression is more dominant than SLAM 
expression in the early response and SLAM is expressed as a late response upon TCR 
stimulation with combination of CD28, 2B4 and SLAM (Chapter 6). Although other 
groups  showed  that  SLAM  up  regulates  upon  lectin  stimulation  or  CD3  in 
combination with high level of IL-2 in CD4 T cells in vitro, the co-expression of these 
receptors and the effect of different methods has not been fully investigated.
8.6.2  Chemokines role in XLP
Chemokines  are  important  in  a  wide  range  of  physiological  functions 
including,  chemotaxis,  angiogenesis,  haematopoiesis,  embryonic  development,  and 
metastasis (Gerard et al,  2001; Oppermann, 2004). It has been well documented that
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they play crucial  roles in directing cell movements necessary for the initiation of T 
cell immune responses (Luther et al, 2001).  More recently, the chemokines profiles 
have been investigated in common variable immunodeficiency (CVED) showing a low 
CCR7  expression  profile  (Holm  et  al,  2004)  and  in  XLP  patients  demonstrating 
reduction of circulating CCR4 T cells (Malbran et al, 2004). With the results reported 
in Chapter 5, we have been able show low CCR5 and RANTES expression profiles in 
two XLP patients. Whether this phenotype is secondary to Thl/Th2 imbalance profile 
in  XLP patients  or is  due  to  direct  effect  of SAP  signalling  impairment  should be 
addressed in further studies.  The chemokine profile in XLP may also help to classify 
the XLP disorder as has been suggested in CVID (Holm et al, 2004).
8.6.3  New targets for gene therapy in XLP
NK cells  are a very attractive target  for immune cell  and  gene therapy.  The 
defect  in NK cells derived  from XLP patients is well  documented.  Therefore,  SAP 
reconstitution of NK cells with viral or non-viral vectors may provide an alternative 
treatment  in  those  patients  with  FIM  or malignant  lymphoma  clinical  phenotypes. 
However, the transduction of primary NK cells has not been  successful  so  far and 
developing  an  appropriate  vector  and  stimulation  protocol  would  be  crucial  steps 
towards this application.
Successes  in  targeting  X-linked  SCID  and ADA deficiency with  HSC  gene 
therapy suggest that similar approaches may be effective at least for other forms of 
primary immunodeficiency  (reviewed  by  Gaspar  et  al,  2003).  However,  the  major 
consideration in HSC gene therapy in XLP would be heterologous SAP expression in 
immune  cells.  SAP reconstitution  of HSC  using  a  gene  therapy  approach  in  SAP
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deficient  murine  models  and  also  of human  HSCs  from  normal  individuals  may 
provide valuable information to investigate efficiency of SAP reconstituted HSC  in 
correction of XLP phenotype, as well as SAP over expression effect on immune cell 
functions and phenotype. So far the HSC gene therapy model has not been used either 
in murine or human systems.
8.6.4  Application of new technologies in study of XLP
XLP  remains  a  difficult  disease  in  terms  of  its  molecular  and  cellular 
pathogenesis.  Although the T cell paradigm  suggested by Purtilo  still  holds true,  it 
may represent  an  oversimplification.  The recent  studies  into  the  XLP  pathogenesis 
mainly after developing the SAP deficient mice have been beneficial to give a clear 
understanding of the disease process and to  shed some light into the complexity of 
SAP  function in immune system.  With the advent of gene microarrays  and protein 
mass  spectrometry (proteomics)  it becomes possible to  examine  thousands  of gene 
and  proteins  involved  in  a particular  disease  in  comparison  with  normal  controls. 
Already  the  proteomics  approach  (SELDI-Ciphergen  Co)  has  been  used  in  many 
different areas including haematological disorders (Kummo et al,  2004; Hanna et al,
2005).  These technologies would be great tools to establish genomic and proteomic 
fingerprints in XLP patients with different clinical phenotypes as well as in different 
lymphocyte  subpopulations.  They  would  produce  high  output  data,  which  if 
effectively interpreted will help us in making a platform to develop better diagnostic 
assays and treatment procedures.
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